[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fBPuT9VXY-gNFjN4hLrE0aiY0fOoR1s6tj3uWT4dHYI8":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":36,"phaseBuckets":87,"rows":94},"University of California, San Diego",[4],955,false,245,39,433673,113,630,[14,17,20,23,25,28,31,34],{"name":15,"count":16},"Obesity",34,{"name":18,"count":19},"Obstructive Sleep Apnea",26,{"name":21,"count":22},"Schizophrenia",24,{"name":24,"count":22},"Depression",{"name":26,"count":27},"Breast Cancer",20,{"name":29,"count":30},"HIV",19,{"name":32,"count":33},"Contraception",18,{"name":35,"count":33},"Anorexia Nervosa",[37,42,47,52,57,62,67,72,77,82],{"nctId":38,"briefTitle":39,"date":40,"intervention":41},"NCT04002440","Directed Use of REmote Patient Management System AMia to Achieve Prescribed Dry Weight","2021-11-30","AMIA with SHARESOURCE Connectivity Platform",{"nctId":43,"briefTitle":44,"date":45,"intervention":46},"NCT04849455","Erector Spinae Plane Block Catheters and Intrathecal Morphine for Hepatic Resection","2023-05-01","0.2% ropivacaine local anesthetic continuous erector spinae plane block",{"nctId":48,"briefTitle":49,"date":50,"intervention":51},"NCT04716803","Bone Marrow Aspirate Concentrate (BMAC)Treatment for Knee Osteoarthritis","2023-12-31","Bone Marrow Aspirate Concentrate",{"nctId":53,"briefTitle":54,"date":55,"intervention":56},"NCT04616963","Emtricitabine\u002FTenofovir Alafenamide Switch Study for Transgender Individuals for HIV Pre-exposure Prophylaxis","2024-01-31","Emtricitabine \u002F Tenofovir Disoproxil Oral Tablet 200\u002F300 mg",{"nctId":58,"briefTitle":59,"date":60,"intervention":61},"NCT04721873","Pharmacologic Weight Loss as Adjunct Therapy for Ulcerative Colitis in Obese Patients","2024-06-30","Phentermine-Topiramate",{"nctId":63,"briefTitle":64,"date":65,"intervention":66},"NCT04779645","Effects of GRA in Patients With Type 1","2024-07-17","REMD-477",{"nctId":68,"briefTitle":69,"date":70,"intervention":71},"NCT02775500","Apremilast Pregnancy Exposure Registry","2024-12","apremilast",{"nctId":73,"briefTitle":74,"date":75,"intervention":76},"NCT05690282","Comparing Perioperative Outcomes in Pain Control","2024-12-31","Multimodal Pain Management",{"nctId":78,"briefTitle":79,"date":80,"intervention":81},"NCT06482268","Transplantation of Human iPS Cell-derived Dopaminergic Progenitors (CT1-DAP001) for Parkinson's Disease (Phase I\u002FII)","2025-02-28","Human induced pluripotent stem cell-derived dopaminergic progenitors",{"nctId":83,"briefTitle":84,"date":85,"intervention":86},"NCT04981912","Rituximab + High-Dose Methylprednisolone Debulking Prior to Venetoclax for CLL & SLL Patients","2025-07-22","HDMP + rituximab as a means of debulking prior to initiating venetoclax.",[88,89,90,91,92,93],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[95,143,170,188,217,246,264,292,322,349,367,393,415,441,459,477,505,523,548,570,588,615,644,662,680,698,716,734,759,782,809,827,855,873,950,988,1023,1075,1147,1198,1241,1280,1317,1343,1372,1390,1417,1435,1459,1485,1511,1529,1554,1572,1598,1616,1640,1658,1676,1700,1726,1751,1775,1800,1818,1843,1863,1890,1908,1933,1960,1978,1996,2020,2045,2063,2086,2104,2127,2147,2172,2190,2208,2234,2252,2275,2303,2324,2348,2372,2397,2421,2439,2472,2497,2522,2546,2571,2589,2622,2644,2679,2704,2736,2759,2779,2803,2825,2855,2873,2900,2921,2939,2957,3010,3062,3107,3142,3184,3217,3253,3280,3306,3332,3364,3386,3408,3433,3456,3474,3502,3529,3554,3578,3596,3622,3640,3663,3681,3706,3729,3747,3765,3783,3801,3827,3845,3870,3888,3906,3932,3950,3972,3997,4015,4041,4064,4088,4106,4130,4148,4174,4202,4220,4238,4256,4278,4303,4321,4346,4372,4399,4423,4441,4465,4483,4509,4534,4560,4588,4613,4637,4655,4680,4698,4716,4734,4757,4781,4806,4828,4850,4877,4901,4926,4951,5008,5035,5061,5095,5119,5150,5168,5191,5209,5234,5252,5278,5296,5320,5338,5363,5388,5406,5429,5453,5477,5499,5523,5566,5612,5639,5661,5708,5740,5779,5801,5823,5849,5867,5890,5908,5926,5944,5962,5986,6009,6032,6050,6075,6093,6115,6133,6151,6169,6187,6205,6223,6241,6259,6277,6295,6313,6331,6355,6373,6397,6421,6455,6481,6499,6524,6542,6564,6588,6614,6640,6658,6682,6704,6722,6749,6767,6790,6812,6842,6860,6878,6896,6914,6932,6950,6968,6992,7020,7038,7056,7074,7092,7110,7135,7157,7180,7202,7228,7246,7264,7289,7314,7332,7355,7378,7396,7421,7444,7462,7487,7512,7533,7556,7574,7597,7615,7633,7659,7677,7700,7727,7750,7774,7792,7816,7834,7858,7882,7900,7922,7948,7970,7993,8018,8045,8063,8081,8099,8124,8142,8163,8185,8206,8224,8247,8270,8301,8324,8346,8364,8387,8413,8437,8462,8480,8505,8523,8548,8573,8596,8642,8684,8714,8744,8776,8803,8828,8850,8882,8912,8935,8959,8982,9006,9029,9047,9071,9096,9114,9132,9156,9174,9197,9220,9238,9256,9279,9303,9326,9344,9366,9389,9407,9425,9448,9474,9492,9510,9528,9552,9576,9594,9615,9637,9655,9677,9701,9719,9737,9763,9781,9802,9829,9847,9869,9894,9923,9941,9959,9977,9995,10013,10036,10054,10076,10100,10124,10142,10165],{"intervention":96,"totalTrials":97,"cells":98},"vancomycin",2,{"EARLY_PHASE1":99,"PHASE1":102,"PHASE2":104,"PHASE3":106,"PHASE4":108,"NA":141},{"trials":100,"activeCount":101},[],0,{"trials":103,"activeCount":101},[],{"trials":105,"activeCount":101},[],{"trials":107,"activeCount":101},[],{"trials":109,"activeCount":140,"soonestReadout":132},[110,127],{"nctId":111,"briefTitle":112,"status":113,"phases":114,"primaryCompletion":115,"completion":116,"start":117,"enrollment":118,"conditions":119,"interventions":122},"NCT02384200","A Randomized Trial of Preoperative Prophylactic Antibiotics Prior to Kidney Stone Surgery (Percutaneous Nephrolithotomy [PCNL])","COMPLETED",[92],"2017-02-01","2019-06-01","2015-03",86,[120,121],"Nephrolithiasis","Urinary Tract Infections",[123,124,125,96,126],"nitrofurantoin monohydrate\u002Fmacrocrystalline","ampicillin","gentamicin","ceftriaxone",{"nctId":128,"briefTitle":129,"status":130,"phases":131,"primaryCompletion":132,"completion":133,"start":134,"enrollment":135,"conditions":136,"interventions":138},"NCT07282782","A Prospective, Randomized Parallel Group Study of the Efficacy of Vancomycin Administered Through Intraarticular Injection Versus Intraosseous Injection Versus Intravenous Infusion in Patients Undergoing Total Knee Arthroplasty","RECRUITING",[92],"2026-12-31","2028-12-31","2024-06-10",30,[137],"Total Knee Arthroplasty",[139],"Vancomycin",1,{"trials":142,"activeCount":101},[],{"intervention":144,"totalTrials":140,"cells":145},"Dupilumab",{"EARLY_PHASE1":146,"PHASE1":148,"PHASE2":150,"PHASE3":152,"PHASE4":154,"NA":168},{"trials":147,"activeCount":101},[],{"trials":149,"activeCount":101},[],{"trials":151,"activeCount":101},[],{"trials":153,"activeCount":101},[],{"trials":155,"activeCount":140,"soonestReadout":160},[156],{"nctId":157,"briefTitle":158,"status":130,"phases":159,"primaryCompletion":160,"completion":161,"start":162,"enrollment":163,"conditions":164,"interventions":166},"NCT06385236","Leveraging Pharmacogenomics in Asthma for Predication, Mechanism and Endotyping",[92],"2027-06-30","2028-01-31","2024-02-19",120,[165],"Moderate to Severe Asthma",[144,167],"Benralizumab",{"trials":169,"activeCount":101},[],{"intervention":167,"totalTrials":140,"cells":171},{"EARLY_PHASE1":172,"PHASE1":174,"PHASE2":176,"PHASE3":178,"PHASE4":180,"NA":186},{"trials":173,"activeCount":101},[],{"trials":175,"activeCount":101},[],{"trials":177,"activeCount":101},[],{"trials":179,"activeCount":101},[],{"trials":181,"activeCount":140,"soonestReadout":160},[182],{"nctId":157,"briefTitle":158,"status":130,"phases":183,"primaryCompletion":160,"completion":161,"start":162,"enrollment":163,"conditions":184,"interventions":185},[92],[165],[144,167],{"trials":187,"activeCount":101},[],{"intervention":189,"totalTrials":140,"cells":190},"Tranexamic Acid",{"EARLY_PHASE1":191,"PHASE1":193,"PHASE2":195,"PHASE3":197,"PHASE4":199,"NA":215},{"trials":192,"activeCount":101},[],{"trials":194,"activeCount":101},[],{"trials":196,"activeCount":101},[],{"trials":198,"activeCount":101},[],{"trials":200,"activeCount":140,"soonestReadout":205},[201],{"nctId":202,"briefTitle":203,"status":130,"phases":204,"primaryCompletion":205,"completion":205,"start":206,"enrollment":207,"conditions":208,"interventions":214},"NCT06820177","Tranexamic Acid for Second Trimester Dilation and Evacuation and Bleeding Outcomes",[92],"2026-05","2025-04-22",276,[209,210,211,212,213],"Abortion","Dilation and Evacuation","Hemorrhage","Prophylactic Tranexamic Acid Use","Blood Loss",[189],{"trials":216,"activeCount":101},[],{"intervention":218,"totalTrials":140,"cells":219},"Continuous Infusion of ropivacaine 0.2%",{"EARLY_PHASE1":220,"PHASE1":222,"PHASE2":224,"PHASE3":226,"PHASE4":228,"NA":244},{"trials":221,"activeCount":101},[],{"trials":223,"activeCount":101},[],{"trials":225,"activeCount":101},[],{"trials":227,"activeCount":101},[],{"trials":229,"activeCount":140,"soonestReadout":235},[230],{"nctId":231,"briefTitle":232,"status":233,"phases":234,"primaryCompletion":235,"completion":236,"start":237,"enrollment":238,"conditions":239,"interventions":242},"NCT05091905","Patient-Titrated Automated Intermittent Boluses of Local Anesthetic vs. a Continuous Infusion Via a Perineural Catheter for Postoperative Analgesia","ENROLLING_BY_INVITATION",[92],"2026-11","2026-12","2022-02-14",140,[240,241],"Pain, Acute Postoperative","Trauma Injury",[218,243],"Titratable Automated Intermittent Boluses of ropivacaine 0.2%",{"trials":245,"activeCount":101},[],{"intervention":243,"totalTrials":140,"cells":247},{"EARLY_PHASE1":248,"PHASE1":250,"PHASE2":252,"PHASE3":254,"PHASE4":256,"NA":262},{"trials":249,"activeCount":101},[],{"trials":251,"activeCount":101},[],{"trials":253,"activeCount":101},[],{"trials":255,"activeCount":101},[],{"trials":257,"activeCount":140,"soonestReadout":235},[258],{"nctId":231,"briefTitle":232,"status":233,"phases":259,"primaryCompletion":235,"completion":236,"start":237,"enrollment":238,"conditions":260,"interventions":261},[92],[240,241],[218,243],{"trials":263,"activeCount":101},[],{"intervention":265,"totalTrials":140,"cells":266},"Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL",{"EARLY_PHASE1":267,"PHASE1":269,"PHASE2":271,"PHASE3":273,"PHASE4":275,"NA":290},{"trials":268,"activeCount":101},[],{"trials":270,"activeCount":101},[],{"trials":272,"activeCount":101},[],{"trials":274,"activeCount":101},[],{"trials":276,"activeCount":140,"soonestReadout":281},[277],{"nctId":278,"briefTitle":279,"status":130,"phases":280,"primaryCompletion":281,"completion":132,"start":282,"enrollment":283,"conditions":284,"interventions":289},"NCT06865885","LDL-C Optimization Using Inclisiran in Patients in Which Drug-Drug Interactions Limit LDL Lowering",[92],"2026-09-30","2025-04-03",100,[285,286,287,288],"Drug Interactions","Primary Prevention","Cardiometabolic Syndrome","LDL-Cholersterol Lowering",[265],{"trials":291,"activeCount":101},[],{"intervention":293,"totalTrials":140,"cells":294},"Omeprazole 40 MG",{"EARLY_PHASE1":295,"PHASE1":297,"PHASE2":299,"PHASE3":301,"PHASE4":303,"NA":320},{"trials":296,"activeCount":101},[],{"trials":298,"activeCount":101},[],{"trials":300,"activeCount":101},[],{"trials":302,"activeCount":101},[],{"trials":304,"activeCount":140,"soonestReadout":309},[305],{"nctId":306,"briefTitle":307,"status":130,"phases":308,"primaryCompletion":309,"completion":310,"start":311,"enrollment":312,"conditions":313,"interventions":319},"NCT06999577","The Mechanism Versus PPI Trial",[92],"2029-05-01","2029-07-01","2025-06-04",160,[314,315,316,317,318],"Laryngopharyngeal Reflux","Cough","Throat Clearing","Dysphonia","Reflux",[293],{"trials":321,"activeCount":101},[],{"intervention":323,"totalTrials":140,"cells":324},"Clevidipine",{"EARLY_PHASE1":325,"PHASE1":327,"PHASE2":329,"PHASE3":331,"PHASE4":333,"NA":347},{"trials":326,"activeCount":101},[],{"trials":328,"activeCount":101},[],{"trials":330,"activeCount":101},[],{"trials":332,"activeCount":101},[],{"trials":334,"activeCount":140,"soonestReadout":340},[335],{"nctId":336,"briefTitle":337,"status":338,"phases":339,"primaryCompletion":340,"completion":340,"start":341,"enrollment":342,"conditions":343,"interventions":345},"NCT06063772","Effect of Treatment of Pre-induction Hypertension on Hemodynamic Stability During Induction of General Anesthesia","NOT_YET_RECRUITING",[92],"2025-12","2025-01",64,[344],"Hypertension",[323,346],"Lactated Ringers, Intravenous",{"trials":348,"activeCount":101},[],{"intervention":346,"totalTrials":140,"cells":350},{"EARLY_PHASE1":351,"PHASE1":353,"PHASE2":355,"PHASE3":357,"PHASE4":359,"NA":365},{"trials":352,"activeCount":101},[],{"trials":354,"activeCount":101},[],{"trials":356,"activeCount":101},[],{"trials":358,"activeCount":101},[],{"trials":360,"activeCount":140,"soonestReadout":340},[361],{"nctId":336,"briefTitle":337,"status":338,"phases":362,"primaryCompletion":340,"completion":340,"start":341,"enrollment":342,"conditions":363,"interventions":364},[92],[344],[323,346],{"trials":366,"activeCount":101},[],{"intervention":368,"totalTrials":140,"cells":369},"single injection nerve block",{"EARLY_PHASE1":370,"PHASE1":372,"PHASE2":374,"PHASE3":376,"PHASE4":378,"NA":391},{"trials":371,"activeCount":101},[],{"trials":373,"activeCount":101},[],{"trials":375,"activeCount":101},[],{"trials":377,"activeCount":101},[],{"trials":379,"activeCount":140,"soonestReadout":384},[380],{"nctId":381,"briefTitle":382,"status":130,"phases":383,"primaryCompletion":384,"completion":384,"start":385,"enrollment":386,"conditions":387,"interventions":390},"NCT06784882","Continuous Versus Single Injection Adductor Canal Blocks for Outpatient Total Knee Arthroplasty",[92],"2025-12-01","2025-06-01",40,[388,389],"Acute Postoperative Pain","Surgery",[368],{"trials":392,"activeCount":101},[],{"intervention":76,"totalTrials":140,"cells":394},{"EARLY_PHASE1":395,"PHASE1":397,"PHASE2":399,"PHASE3":401,"PHASE4":403,"NA":413},{"trials":396,"activeCount":101},[],{"trials":398,"activeCount":101},[],{"trials":400,"activeCount":101},[],{"trials":402,"activeCount":101},[],{"trials":404,"activeCount":140,"soonestReadout":75},[405],{"nctId":73,"briefTitle":74,"status":406,"phases":407,"primaryCompletion":75,"completion":408,"start":409,"enrollment":283,"conditions":410,"interventions":412},"ACTIVE_NOT_RECRUITING",[92],"2026-05-17","2021-05-17",[411],"Post-operative Pain",[76],{"trials":414,"activeCount":101},[],{"intervention":46,"totalTrials":140,"cells":416},{"EARLY_PHASE1":417,"PHASE1":419,"PHASE2":421,"PHASE3":423,"PHASE4":425,"NA":439},{"trials":418,"activeCount":101},[],{"trials":420,"activeCount":101},[],{"trials":422,"activeCount":101},[],{"trials":424,"activeCount":101},[],{"trials":426,"activeCount":140,"soonestReadout":45},[427],{"nctId":43,"briefTitle":44,"status":130,"phases":428,"primaryCompletion":45,"completion":45,"start":429,"enrollment":430,"conditions":431,"interventions":436},[92],"2021-05-24",70,[432,433,434,435],"Hepatic Resection","Acute Pain","Anesthesia","Anesthesia, Local",[46,437,438],"0.2% ropivacaine local anesthetic superficially taped continuous erector spinae plane block","Spinal Morphine",{"trials":440,"activeCount":101},[],{"intervention":437,"totalTrials":140,"cells":442},{"EARLY_PHASE1":443,"PHASE1":445,"PHASE2":447,"PHASE3":449,"PHASE4":451,"NA":457},{"trials":444,"activeCount":101},[],{"trials":446,"activeCount":101},[],{"trials":448,"activeCount":101},[],{"trials":450,"activeCount":101},[],{"trials":452,"activeCount":140,"soonestReadout":45},[453],{"nctId":43,"briefTitle":44,"status":130,"phases":454,"primaryCompletion":45,"completion":45,"start":429,"enrollment":430,"conditions":455,"interventions":456},[92],[432,433,434,435],[46,437,438],{"trials":458,"activeCount":101},[],{"intervention":438,"totalTrials":140,"cells":460},{"EARLY_PHASE1":461,"PHASE1":463,"PHASE2":465,"PHASE3":467,"PHASE4":469,"NA":475},{"trials":462,"activeCount":101},[],{"trials":464,"activeCount":101},[],{"trials":466,"activeCount":101},[],{"trials":468,"activeCount":101},[],{"trials":470,"activeCount":140,"soonestReadout":45},[471],{"nctId":43,"briefTitle":44,"status":130,"phases":472,"primaryCompletion":45,"completion":45,"start":429,"enrollment":430,"conditions":473,"interventions":474},[92],[432,433,434,435],[46,437,438],{"trials":476,"activeCount":101},[],{"intervention":478,"totalTrials":140,"cells":479},"Experimental continuous peripheral nerve blocks",{"EARLY_PHASE1":480,"PHASE1":482,"PHASE2":484,"PHASE3":486,"PHASE4":488,"NA":503},{"trials":481,"activeCount":101},[],{"trials":483,"activeCount":101},[],{"trials":485,"activeCount":101},[],{"trials":487,"activeCount":101},[],{"trials":489,"activeCount":140,"soonestReadout":494},[490],{"nctId":491,"briefTitle":492,"status":406,"phases":493,"primaryCompletion":494,"completion":495,"start":496,"enrollment":497,"conditions":498,"interventions":501},"NCT03461120","Improving Postamputation Functioning by Decreasing Phantom Pain With Perioperative Continuous Peripheral Nerve Blocks: A Department of Defense Funded Multicenter Study",[92],"2026-08-18","2026-11-18","2018-03-23",203,[499,500],"Lower Extremity Surgical Amputation","Post-amputation Phantom Limb Pain",[478,502],"Control continuous peripheral nerve blocks",{"trials":504,"activeCount":101},[],{"intervention":502,"totalTrials":140,"cells":506},{"EARLY_PHASE1":507,"PHASE1":509,"PHASE2":511,"PHASE3":513,"PHASE4":515,"NA":521},{"trials":508,"activeCount":101},[],{"trials":510,"activeCount":101},[],{"trials":512,"activeCount":101},[],{"trials":514,"activeCount":101},[],{"trials":516,"activeCount":140,"soonestReadout":494},[517],{"nctId":491,"briefTitle":492,"status":406,"phases":518,"primaryCompletion":494,"completion":495,"start":496,"enrollment":497,"conditions":519,"interventions":520},[92],[499,500],[478,502],{"trials":522,"activeCount":101},[],{"intervention":524,"totalTrials":140,"cells":525},"suzetrigine",{"EARLY_PHASE1":526,"PHASE1":528,"PHASE2":530,"PHASE3":532,"PHASE4":534,"NA":546},{"trials":527,"activeCount":101},[],{"trials":529,"activeCount":101},[],{"trials":531,"activeCount":101},[],{"trials":533,"activeCount":101},[],{"trials":535,"activeCount":140,"soonestReadout":540},[536],{"nctId":537,"briefTitle":538,"status":233,"phases":539,"primaryCompletion":540,"completion":541,"start":542,"enrollment":163,"conditions":543,"interventions":545},"NCT07463430","Suzetrigine for Non-Mastectomy Breast Surgery",[92],"2027-12-28","2027-12-31","2026-04-14",[240,544],"Breast Disease",[524],{"trials":547,"activeCount":101},[],{"intervention":56,"totalTrials":140,"cells":549},{"EARLY_PHASE1":550,"PHASE1":552,"PHASE2":554,"PHASE3":556,"PHASE4":558,"NA":568},{"trials":551,"activeCount":101},[],{"trials":553,"activeCount":101},[],{"trials":555,"activeCount":101},[],{"trials":557,"activeCount":101},[],{"trials":559,"activeCount":140,"soonestReadout":55},[560],{"nctId":53,"briefTitle":54,"status":406,"phases":561,"primaryCompletion":55,"completion":55,"start":562,"enrollment":342,"conditions":563,"interventions":566},[92],"2019-10-24",[564,565],"Hiv","Hormone Therapy",[56,567],"Emtricitabine Tenofovir Alafenamide 200\u002F25 mg",{"trials":569,"activeCount":101},[],{"intervention":567,"totalTrials":140,"cells":571},{"EARLY_PHASE1":572,"PHASE1":574,"PHASE2":576,"PHASE3":578,"PHASE4":580,"NA":586},{"trials":573,"activeCount":101},[],{"trials":575,"activeCount":101},[],{"trials":577,"activeCount":101},[],{"trials":579,"activeCount":101},[],{"trials":581,"activeCount":140,"soonestReadout":55},[582],{"nctId":53,"briefTitle":54,"status":406,"phases":583,"primaryCompletion":55,"completion":55,"start":562,"enrollment":342,"conditions":584,"interventions":585},[92],[564,565],[56,567],{"trials":587,"activeCount":101},[],{"intervention":589,"totalTrials":140,"cells":590},"Testosterone Cypionate 50 milligrams per millileter (mg\u002FmL) Injectable Solution",{"EARLY_PHASE1":591,"PHASE1":593,"PHASE2":595,"PHASE3":597,"PHASE4":599,"NA":613},{"trials":592,"activeCount":101},[],{"trials":594,"activeCount":101},[],{"trials":596,"activeCount":101},[],{"trials":598,"activeCount":101},[],{"trials":600,"activeCount":140,"soonestReadout":605},[601],{"nctId":602,"briefTitle":603,"status":130,"phases":604,"primaryCompletion":605,"completion":606,"start":607,"enrollment":608,"conditions":609,"interventions":612},"NCT07092527","Androgen Effects on the Reproductive Neuroendocrine Axis, 2025 Version",[92],"2028-11-15","2028-11-30","2025-12-05",80,[610,611],"Transgenderism","Reproductive Issues",[589],{"trials":614,"activeCount":101},[],{"intervention":616,"totalTrials":140,"cells":617},"Popliteal nerve block including liposomal bupivacaine",{"EARLY_PHASE1":618,"PHASE1":620,"PHASE2":622,"PHASE3":624,"PHASE4":626,"NA":642},{"trials":619,"activeCount":101},[],{"trials":621,"activeCount":101},[],{"trials":623,"activeCount":101},[],{"trials":625,"activeCount":101},[],{"trials":627,"activeCount":140,"soonestReadout":632},[628],{"nctId":629,"briefTitle":630,"status":233,"phases":631,"primaryCompletion":632,"completion":632,"start":633,"enrollment":238,"conditions":634,"interventions":636},"NCT06995352","Liposomal Bupivacaine Versus Continuous Peripheral Nerve Blocks for Analgesia Following Ankle Surgery",[92],"2027-06-22","2025-06-23",[635],"Moderate-to-severely Painful Ankle Surgery",[616,637,638,639,640,641],"Adductor canal nerve block including liposomal bupivacaine","Continuous popliteal nerve block with normal saline","Popliteal nerve block with exclusively unencapsulated bupivacaine","Adductor canal nerve block with exclusively unencapsulated bupivacaine","Continuous popliteal nerve block with unencapsulated bupivacaine",{"trials":643,"activeCount":101},[],{"intervention":637,"totalTrials":140,"cells":645},{"EARLY_PHASE1":646,"PHASE1":648,"PHASE2":650,"PHASE3":652,"PHASE4":654,"NA":660},{"trials":647,"activeCount":101},[],{"trials":649,"activeCount":101},[],{"trials":651,"activeCount":101},[],{"trials":653,"activeCount":101},[],{"trials":655,"activeCount":140,"soonestReadout":632},[656],{"nctId":629,"briefTitle":630,"status":233,"phases":657,"primaryCompletion":632,"completion":632,"start":633,"enrollment":238,"conditions":658,"interventions":659},[92],[635],[616,637,638,639,640,641],{"trials":661,"activeCount":101},[],{"intervention":638,"totalTrials":140,"cells":663},{"EARLY_PHASE1":664,"PHASE1":666,"PHASE2":668,"PHASE3":670,"PHASE4":672,"NA":678},{"trials":665,"activeCount":101},[],{"trials":667,"activeCount":101},[],{"trials":669,"activeCount":101},[],{"trials":671,"activeCount":101},[],{"trials":673,"activeCount":140,"soonestReadout":632},[674],{"nctId":629,"briefTitle":630,"status":233,"phases":675,"primaryCompletion":632,"completion":632,"start":633,"enrollment":238,"conditions":676,"interventions":677},[92],[635],[616,637,638,639,640,641],{"trials":679,"activeCount":101},[],{"intervention":639,"totalTrials":140,"cells":681},{"EARLY_PHASE1":682,"PHASE1":684,"PHASE2":686,"PHASE3":688,"PHASE4":690,"NA":696},{"trials":683,"activeCount":101},[],{"trials":685,"activeCount":101},[],{"trials":687,"activeCount":101},[],{"trials":689,"activeCount":101},[],{"trials":691,"activeCount":140,"soonestReadout":632},[692],{"nctId":629,"briefTitle":630,"status":233,"phases":693,"primaryCompletion":632,"completion":632,"start":633,"enrollment":238,"conditions":694,"interventions":695},[92],[635],[616,637,638,639,640,641],{"trials":697,"activeCount":101},[],{"intervention":640,"totalTrials":140,"cells":699},{"EARLY_PHASE1":700,"PHASE1":702,"PHASE2":704,"PHASE3":706,"PHASE4":708,"NA":714},{"trials":701,"activeCount":101},[],{"trials":703,"activeCount":101},[],{"trials":705,"activeCount":101},[],{"trials":707,"activeCount":101},[],{"trials":709,"activeCount":140,"soonestReadout":632},[710],{"nctId":629,"briefTitle":630,"status":233,"phases":711,"primaryCompletion":632,"completion":632,"start":633,"enrollment":238,"conditions":712,"interventions":713},[92],[635],[616,637,638,639,640,641],{"trials":715,"activeCount":101},[],{"intervention":641,"totalTrials":140,"cells":717},{"EARLY_PHASE1":718,"PHASE1":720,"PHASE2":722,"PHASE3":724,"PHASE4":726,"NA":732},{"trials":719,"activeCount":101},[],{"trials":721,"activeCount":101},[],{"trials":723,"activeCount":101},[],{"trials":725,"activeCount":101},[],{"trials":727,"activeCount":140,"soonestReadout":632},[728],{"nctId":629,"briefTitle":630,"status":233,"phases":729,"primaryCompletion":632,"completion":632,"start":633,"enrollment":238,"conditions":730,"interventions":731},[92],[635],[616,637,638,639,640,641],{"trials":733,"activeCount":101},[],{"intervention":735,"totalTrials":140,"cells":736},"Dupilumab 300 MG\u002F2 ML Subcutaneous Solution [DUPIXENT]",{"EARLY_PHASE1":737,"PHASE1":739,"PHASE2":741,"PHASE3":743,"PHASE4":745,"NA":757},{"trials":738,"activeCount":101},[],{"trials":740,"activeCount":101},[],{"trials":742,"activeCount":101},[],{"trials":744,"activeCount":101},[],{"trials":746,"activeCount":140,"soonestReadout":751},[747],{"nctId":748,"briefTitle":749,"status":130,"phases":750,"primaryCompletion":751,"completion":752,"start":753,"enrollment":135,"conditions":754,"interventions":756},"NCT06665971","Effect of Dupilumab on the Muscle Function of the Esophagus (food Pipe) in Participants with Eosinophilic Esophagitis (EoE)",[92],"2026-09-15","2026-11-14","2024-11-10",[755],"Eosinophilic Esophagitis (EoE)",[735],{"trials":758,"activeCount":101},[],{"intervention":760,"totalTrials":140,"cells":761},"Cannabidiol oral solution",{"EARLY_PHASE1":762,"PHASE1":764,"PHASE2":766,"PHASE3":768,"PHASE4":778,"NA":780},{"trials":763,"activeCount":101},[],{"trials":765,"activeCount":101},[],{"trials":767,"activeCount":101},[],{"trials":769,"activeCount":140,"soonestReadout":236},[770],{"nctId":771,"briefTitle":772,"status":130,"phases":773,"primaryCompletion":236,"completion":236,"start":774,"enrollment":163,"conditions":775,"interventions":777},"NCT04411225","Effects of Cannabidiol (CBD) Versus Placebo as an Adjunct to Treatment in Early Psychosis",[91],"2022-06-01",[776],"Early Psychosis",[760],{"trials":779,"activeCount":101},[],{"trials":781,"activeCount":101},[],{"intervention":783,"totalTrials":140,"cells":784},"Sotagliflozin Low Dose",{"EARLY_PHASE1":785,"PHASE1":787,"PHASE2":789,"PHASE3":791,"PHASE4":805,"NA":807},{"trials":786,"activeCount":101},[],{"trials":788,"activeCount":101},[],{"trials":790,"activeCount":101},[],{"trials":792,"activeCount":140,"soonestReadout":797},[793],{"nctId":794,"briefTitle":795,"status":338,"phases":796,"primaryCompletion":797,"completion":798,"start":799,"enrollment":800,"conditions":801,"interventions":803},"NCT07211802","CKM For Safe Use of SGLT2i in Type 1 Diabetes",[91],"2030-07-31","2030-12-31","2026-07-01",52,[802],"Type 1 Diabetes (T1D)",[783,804],"Sotagliflozin High Dose",{"trials":806,"activeCount":101},[],{"trials":808,"activeCount":101},[],{"intervention":804,"totalTrials":140,"cells":810},{"EARLY_PHASE1":811,"PHASE1":813,"PHASE2":815,"PHASE3":817,"PHASE4":823,"NA":825},{"trials":812,"activeCount":101},[],{"trials":814,"activeCount":101},[],{"trials":816,"activeCount":101},[],{"trials":818,"activeCount":140,"soonestReadout":797},[819],{"nctId":794,"briefTitle":795,"status":338,"phases":820,"primaryCompletion":797,"completion":798,"start":799,"enrollment":800,"conditions":821,"interventions":822},[91],[802],[783,804],{"trials":824,"activeCount":101},[],{"trials":826,"activeCount":101},[],{"intervention":828,"totalTrials":140,"cells":829},"PharmaNord Bio-Quinone Active CoQ10 Gold 100mg",{"EARLY_PHASE1":830,"PHASE1":832,"PHASE2":834,"PHASE3":836,"PHASE4":851,"NA":853},{"trials":831,"activeCount":101},[],{"trials":833,"activeCount":101},[],{"trials":835,"activeCount":101},[],{"trials":837,"activeCount":140,"soonestReadout":842},[838],{"nctId":839,"briefTitle":840,"status":130,"phases":841,"primaryCompletion":842,"completion":842,"start":843,"enrollment":844,"conditions":845,"interventions":849},"NCT06515184","Coenzyme Q10 for Gulf War Illness: A Replication Study",[91],"2027-12","2024-09-13",192,[846,847,848],"Gulf War Syndrome","Persian Gulf Syndrome","Mitochondrial Disorder, Respiratory Chain",[828,850,828],"PharmaNord Placebo",{"trials":852,"activeCount":101},[],{"trials":854,"activeCount":101},[],{"intervention":850,"totalTrials":140,"cells":856},{"EARLY_PHASE1":857,"PHASE1":859,"PHASE2":861,"PHASE3":863,"PHASE4":869,"NA":871},{"trials":858,"activeCount":101},[],{"trials":860,"activeCount":101},[],{"trials":862,"activeCount":101},[],{"trials":864,"activeCount":140,"soonestReadout":842},[865],{"nctId":839,"briefTitle":840,"status":130,"phases":866,"primaryCompletion":842,"completion":842,"start":843,"enrollment":844,"conditions":867,"interventions":868},[91],[846,847,848],[828,850,828],{"trials":870,"activeCount":101},[],{"trials":872,"activeCount":101},[],{"intervention":874,"totalTrials":875,"cells":876},"Acetazolamide",6,{"EARLY_PHASE1":877,"PHASE1":879,"PHASE2":881,"PHASE3":944,"PHASE4":946,"NA":948},{"trials":878,"activeCount":101},[],{"trials":880,"activeCount":101},[],{"trials":882,"activeCount":97,"soonestReadout":899},[883,895,904,914,925,935],{"nctId":884,"briefTitle":885,"status":113,"phases":886,"primaryCompletion":887,"completion":887,"start":888,"enrollment":9,"conditions":889,"interventions":894},"NCT06043830","Managing Opioid Related Sleep Apnea With Acetazolamide",[90],"2025-12-23","2023-10-18",[890,18,891,892,893],"Sleep-Disordered Breathing","Central Sleep Apnea","Chronic Pain","Opioid Use",[874],{"nctId":896,"briefTitle":897,"status":130,"phases":898,"primaryCompletion":899,"completion":899,"start":900,"enrollment":901,"conditions":902,"interventions":903},"NCT05804084","Patient-centered and Neurocognitive Outcomes With Acetazolamide for Sleep Apnea",[90],"2026-10-31","2023-05-16",60,[18],[874],{"nctId":905,"briefTitle":906,"status":130,"phases":907,"primaryCompletion":236,"completion":908,"start":909,"enrollment":910,"conditions":911,"interventions":913},"NCT06981234","Acetazolamide in Persons With Type 1 Diabetes - Crossover Trial",[90],"2027-06","2024-08-14",25,[912],"Type 1 Diabetes",[874],{"nctId":915,"briefTitle":916,"status":113,"phases":917,"primaryCompletion":918,"completion":918,"start":919,"enrollment":27,"conditions":920,"interventions":922},"NCT04639193","Combination Drug-Therapy for Patients With Untreated Obstructive Sleep Apnea",[90],"2022-01-27","2020-12-01",[921,18],"OSA",[874,923,924],"Eszopiclone","Venlafaxine",{"nctId":926,"briefTitle":927,"status":113,"phases":928,"primaryCompletion":929,"completion":930,"start":931,"enrollment":932,"conditions":933,"interventions":934},"NCT05473364","Acetazolamide in Persons With Type 1 Diabetes - Dose Finding",[89,90],"2024-02-23","2024-07-31","2023-03-20",12,[912],[874],{"nctId":936,"briefTitle":937,"status":113,"phases":938,"primaryCompletion":939,"completion":939,"start":940,"enrollment":941,"conditions":942,"interventions":943},"NCT05616260","Acetazolamide for Obstructive Sleep Apnea to Improve Heart Health",[90],"2025-05-13","2022-12-02",54,[18],[874],{"trials":945,"activeCount":101},[],{"trials":947,"activeCount":101},[],{"trials":949,"activeCount":101},[],{"intervention":951,"totalTrials":97,"cells":952},"THC",{"EARLY_PHASE1":953,"PHASE1":955,"PHASE2":966,"PHASE3":982,"PHASE4":984,"NA":986},{"trials":954,"activeCount":101},[],{"trials":956,"activeCount":140,"soonestReadout":842},[957],{"nctId":958,"briefTitle":959,"status":130,"phases":960,"primaryCompletion":842,"completion":961,"start":962,"enrollment":135,"conditions":963,"interventions":965},"NCT05322213","THC Effects on Glucose in Type 2 Diabetes",[89],"2028-06","2024-08-22",[964],"Type 2 Diabetes",[951],{"trials":967,"activeCount":140,"soonestReadout":972},[968],{"nctId":969,"briefTitle":970,"status":130,"phases":971,"primaryCompletion":972,"completion":972,"start":973,"enrollment":974,"conditions":975,"interventions":980},"NCT05514899","Effects of Cannabidiol and Tetrahydrocannabinol on Microbiome and Neuroinflammation in HIV",[90],"2027-10-31","2023-09-01",90,[29,976,951,977,978,979],"Cannabis","Neuroinflammatory Disease","Neuroinflammatory Response","Microbiome",[951,981],"CBD",{"trials":983,"activeCount":101},[],{"trials":985,"activeCount":101},[],{"trials":987,"activeCount":101},[],{"intervention":989,"totalTrials":97,"cells":990},"Medi-TBS",{"EARLY_PHASE1":991,"PHASE1":993,"PHASE2":995,"PHASE3":1017,"PHASE4":1019,"NA":1021},{"trials":992,"activeCount":101},[],{"trials":994,"activeCount":101},[],{"trials":996,"activeCount":97,"soonestReadout":1013},[997,1009],{"nctId":998,"briefTitle":999,"status":130,"phases":1000,"primaryCompletion":1001,"completion":1001,"start":1002,"enrollment":163,"conditions":1003,"interventions":1008},"NCT07512284","Mindfulness Engaged Neurostimulation for Depression (MEND II)",[90],"2029-04-30","2026-05-01",[24,1004,1005,1006,1007],"Treatment Resistant Depression","Major Depressive Disorder","Depressive Disorder","Depressive Symptoms",[989],{"nctId":1010,"briefTitle":1011,"status":406,"phases":1012,"primaryCompletion":1013,"completion":1013,"start":1014,"enrollment":430,"conditions":1015,"interventions":1016},"NCT06399406","Mindfulness Engaged Neurostimulation for Depression",[90],"2026-04-30","2024-05-15",[24,1004,1005,1006],[989],{"trials":1018,"activeCount":101},[],{"trials":1020,"activeCount":101},[],{"trials":1022,"activeCount":101},[],{"intervention":923,"totalTrials":1024,"cells":1025},4,{"EARLY_PHASE1":1026,"PHASE1":1028,"PHASE2":1030,"PHASE3":1049,"PHASE4":1051,"NA":1073},{"trials":1027,"activeCount":101},[],{"trials":1029,"activeCount":101},[],{"trials":1031,"activeCount":140,"soonestReadout":1036},[1032,1045],{"nctId":1033,"briefTitle":1034,"status":130,"phases":1035,"primaryCompletion":1036,"completion":1036,"start":1037,"enrollment":1038,"conditions":1039,"interventions":1044},"NCT04875364","Do Endotypes Predict Response and Sequelae in OSA Patients",[90],"2027-01-01","2020-08-01",200,[18,1040,1041,1042,1043],"Sleep Apnea","Sleep Apnea, Obstructive","Sleep","Sleep Disorder",[923],{"nctId":915,"briefTitle":916,"status":113,"phases":1046,"primaryCompletion":918,"completion":918,"start":919,"enrollment":27,"conditions":1047,"interventions":1048},[90],[921,18],[874,923,924],{"trials":1050,"activeCount":101},[],{"trials":1052,"activeCount":101},[1053,1063],{"nctId":1054,"briefTitle":1055,"status":113,"phases":1056,"primaryCompletion":1057,"completion":1057,"start":1058,"enrollment":1059,"conditions":1060,"interventions":1062},"NCT00365261","Effect of Eszopiclone on Sleep Disturbance and Pain in Cancer",[92],"2009-12","2006-09",45,[1061],"Sleep Initiation and Maintenance Disorders",[923],{"nctId":1064,"briefTitle":1065,"status":1066,"phases":1067,"primaryCompletion":1068,"completion":1068,"start":1069,"enrollment":386,"conditions":1070,"interventions":1072},"NCT00414037","How do Sleeping Pills Affect Pain in the Brain?","TERMINATED",[92],"2008-12","2006-12",[1071],"Primary Insomnia",[923],{"trials":1074,"activeCount":101},[],{"intervention":1076,"totalTrials":1024,"cells":1077},"Rituximab",{"EARLY_PHASE1":1078,"PHASE1":1080,"PHASE2":1082,"PHASE3":1141,"PHASE4":1143,"NA":1145},{"trials":1079,"activeCount":101},[],{"trials":1081,"activeCount":101},[],{"trials":1083,"activeCount":140,"soonestReadout":1120},[1084,1107,1116,1129],{"nctId":1085,"briefTitle":1086,"status":1066,"phases":1087,"primaryCompletion":1088,"completion":1088,"start":1089,"enrollment":1090,"conditions":1091,"interventions":1094},"NCT02043587","Chemotherapy With Liposomal Cytarabine CNS Prophylaxis for Adult Acute Lymphoblastic Leukemia & Lymphoblastic Lymphoma",[90],"2022-04-14","2014-01",31,[1092,1093],"Acute Lymphocytic Leukemia","Adult Lymphoblastic Lymphoma",[1095,1096,1097,1098,1099,1100,1101,1102,1103,1104,1105,1076,1106],"DNR","VCR","PEG-asp","CTX","Prednisone","Liposomal AraC","MTX","LCV","AraC","Etoposide","Dasatinib","Hydrocortisone",{"nctId":1108,"briefTitle":1109,"status":113,"phases":1110,"primaryCompletion":1057,"completion":1057,"start":1111,"enrollment":22,"conditions":1112,"interventions":1114},"NCT00147966","Assessment of Rituximab's Immunomodulatory Synovial Effects (The ARISE Study)",[90],"2008-06",[1113],"Rheumatoid Arthritis",[1115],"rituximab",{"nctId":1117,"briefTitle":1118,"status":130,"phases":1119,"primaryCompletion":1120,"completion":1121,"start":1122,"enrollment":1123,"conditions":1124,"interventions":1127},"NCT07222631","SB-4826 in Adult Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphomas",[89,90],"2031-02","2033-02","2026-02-18",48,[1125,1126],"Non Hodgkin Lymphoma","Solid Tumor",[1128,1076],"SB-4826",{"nctId":1130,"briefTitle":1131,"status":113,"phases":1132,"primaryCompletion":1133,"completion":1134,"start":1135,"enrollment":135,"conditions":1136,"interventions":1139},"NCT01199575","Phase II Trial of Revlimid® and Rituximab for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)",[90],"2015-01","2022-07-19","2010-08",[1137,1138],"Chronic Lymphocytic Leukemia","CLL",[1140,1076],"Revlimid",{"trials":1142,"activeCount":101},[],{"trials":1144,"activeCount":101},[],{"trials":1146,"activeCount":101},[],{"intervention":1148,"totalTrials":1149,"cells":1150},"Nivolumab",3,{"EARLY_PHASE1":1151,"PHASE1":1153,"PHASE2":1155,"PHASE3":1192,"PHASE4":1194,"NA":1196},{"trials":1152,"activeCount":101},[],{"trials":1154,"activeCount":101},[],{"trials":1156,"activeCount":140,"soonestReadout":1186},[1157,1168,1182],{"nctId":1158,"briefTitle":1159,"status":1160,"phases":1161,"primaryCompletion":1162,"completion":908,"start":1163,"enrollment":101,"conditions":1164,"interventions":1166},"NCT05153304","Personalized Immunotherapy in Adults With Upper Gastrointestinal Tract Cancers","WITHDRAWN",[89,90],"2026-06","2024-06",[1165],"Cancer of Gastrointestinal Tract",[1167,1148],"personalized vaccine",{"nctId":1169,"briefTitle":1170,"status":1066,"phases":1171,"primaryCompletion":1172,"completion":1173,"start":1174,"enrollment":1175,"conditions":1176,"interventions":1179},"NCT03646461","Trial of Ibrutinib Combined With Nivolumab or Cetuximab to Treat Recurrent\u002FMetastatic HNSCC",[90],"2020-08-15","2021-05-13","2018-10-17",5,[1177,1178],"Head and Neck Cancer","Squamous Cell Carcinoma of the Head and Neck",[1180,1181,1148],"Ibrutinib 560mg PO daily","Cetuximab",{"nctId":1183,"briefTitle":1184,"status":130,"phases":1185,"primaryCompletion":1186,"completion":1186,"start":1187,"enrollment":135,"conditions":1188,"interventions":1190},"NCT06624475","Neoadjuvant Nivolumab + Relatlimab (Opdualag) Versus Nivolumab for Resectable High-Risk Basal Cell Carcinoma",[90],"2028-05","2025-08-21",[1189],"Basal Cell Carcinoma",[1148,1191],"Relatlimab plus Nivolumab",{"trials":1193,"activeCount":101},[],{"trials":1195,"activeCount":101},[],{"trials":1197,"activeCount":101},[],{"intervention":1199,"totalTrials":1149,"cells":1200},"Cirmtuzumab",{"EARLY_PHASE1":1201,"PHASE1":1203,"PHASE2":1224,"PHASE3":1235,"PHASE4":1237,"NA":1239},{"trials":1202,"activeCount":101},[],{"trials":1204,"activeCount":101},[1205,1215],{"nctId":1206,"briefTitle":1207,"status":113,"phases":1208,"primaryCompletion":1209,"completion":1210,"start":1211,"enrollment":1149,"conditions":1212,"interventions":1213},"NCT02860676","Extension Study of UC-961 (Cirmtuzumab) for Patients With Chronic Lymphocytic Leukemia Treated Previously With UC-961",[89],"2018-02-27","2018-05-22","2016-11-03",[1137],[1214],"cirmtuzumab",{"nctId":1216,"briefTitle":1217,"status":1066,"phases":1218,"primaryCompletion":1219,"completion":1219,"start":1220,"enrollment":875,"conditions":1221,"interventions":1223},"NCT05156905","Study of Docetaxel Combined with Cirmtuzumab in Metastatic Castration Resistant Prostate Cancer",[89],"2024-10-01","2022-06-16",[1222],"Metastatic Castration-resistant Prostate Cancer",[1199],{"trials":1225,"activeCount":140,"soonestReadout":1230},[1226],{"nctId":1227,"briefTitle":1228,"status":406,"phases":1229,"primaryCompletion":1230,"completion":1230,"start":1231,"enrollment":1175,"conditions":1232,"interventions":1233},"NCT04501939","Cirmtuzumab Consolidation for Treatment of Patients With Detectable CLL on Venetoclax",[90],"2026-07-22","2020-08-06",[1137],[1199,1234],"Venetoclax",{"trials":1236,"activeCount":101},[],{"trials":1238,"activeCount":101},[],{"trials":1240,"activeCount":101},[],{"intervention":66,"totalTrials":1149,"cells":1242},{"EARLY_PHASE1":1243,"PHASE1":1245,"PHASE2":1247,"PHASE3":1274,"PHASE4":1276,"NA":1278},{"trials":1244,"activeCount":101},[],{"trials":1246,"activeCount":101},[],{"trials":1248,"activeCount":140,"soonestReadout":65},[1249,1259,1269],{"nctId":1250,"briefTitle":1251,"status":113,"phases":1252,"primaryCompletion":1253,"completion":1254,"start":1255,"enrollment":932,"conditions":1256,"interventions":1257},"NCT04545411","Combination GRA and SGLT-2i Treatment in Type 1 Diabetes",[89,90],"2022-02-28","2022-10-31","2021-02-22",[912],[1258,66],"Dapagliflozin 10 MG [Farxiga]",{"nctId":1260,"briefTitle":1261,"status":113,"phases":1262,"primaryCompletion":1263,"completion":1264,"start":1265,"enrollment":1024,"conditions":1266,"interventions":1268},"NCT03919617","Metabolic Pathways of GRA in Patients With Type 1 Diabetes",[89,90],"2021-07-31","2022-05-31","2019-07-01",[1267],"Type 1 Diabetes Mellitus",[66],{"nctId":63,"briefTitle":64,"status":406,"phases":1270,"primaryCompletion":65,"completion":1271,"start":1263,"enrollment":135,"conditions":1272,"interventions":1273},[90],"2025-12-31",[912],[66],{"trials":1275,"activeCount":101},[],{"trials":1277,"activeCount":101},[],{"trials":1279,"activeCount":101},[],{"intervention":1281,"totalTrials":97,"cells":1282},"Epidiolex",{"EARLY_PHASE1":1283,"PHASE1":1296,"PHASE2":1298,"PHASE3":1311,"PHASE4":1313,"NA":1315},{"trials":1284,"activeCount":101},[1285],{"nctId":1286,"briefTitle":1287,"status":1066,"phases":1288,"primaryCompletion":1289,"completion":1289,"start":1290,"enrollment":30,"conditions":1291,"interventions":1293},"NCT04231643","Effects of Cannabis on Cognition and Endocannabinoid Levels in Bipolar Disorder Patients and Healthy Volunteers",[88],"2023-11-28","2021-09-01",[1292],"Bipolar Disorder",[1294,1281,1295],"Dronabinol","Placebos",{"trials":1297,"activeCount":101},[],{"trials":1299,"activeCount":140,"soonestReadout":1304},[1300],{"nctId":1301,"briefTitle":1302,"status":406,"phases":1303,"primaryCompletion":1304,"completion":1271,"start":1305,"enrollment":1306,"conditions":1307,"interventions":1310},"NCT04517799","Trial of Cannabidiol to Treat Severe Behavior Problems in Children With Autism",[90],"2025-08-30","2020-06-01",42,[1308,1309],"Autism","Autism Spectrum Disorder",[1281],{"trials":1312,"activeCount":101},[],{"trials":1314,"activeCount":101},[],{"trials":1316,"activeCount":101},[],{"intervention":1318,"totalTrials":140,"cells":1319},"Evorpacept",{"EARLY_PHASE1":1320,"PHASE1":1322,"PHASE2":1324,"PHASE3":1337,"PHASE4":1339,"NA":1341},{"trials":1321,"activeCount":101},[],{"trials":1323,"activeCount":101},[],{"trials":1325,"activeCount":140,"soonestReadout":1330},[1326],{"nctId":1327,"briefTitle":1328,"status":406,"phases":1329,"primaryCompletion":1330,"completion":1331,"start":1332,"enrollment":1333,"conditions":1334,"interventions":1336},"NCT05787639","Neoadjuvant Immunoradiotherapy With Evorpacept and Pembrolizumab in HPVOPC (Human Papilloma Virus Oropharynx Cancer)",[90],"2026-08-20","2028-05-30","2024-02-20",29,[1335],"Oropharynx Cancer",[1318],{"trials":1338,"activeCount":101},[],{"trials":1340,"activeCount":101},[],{"trials":1342,"activeCount":101},[],{"intervention":1344,"totalTrials":140,"cells":1345},"Levetiracetam",{"EARLY_PHASE1":1346,"PHASE1":1348,"PHASE2":1350,"PHASE3":1366,"PHASE4":1368,"NA":1370},{"trials":1347,"activeCount":101},[],{"trials":1349,"activeCount":101},[],{"trials":1351,"activeCount":140,"soonestReadout":1356},[1352],{"nctId":1353,"briefTitle":1354,"status":130,"phases":1355,"primaryCompletion":1356,"completion":541,"start":1357,"enrollment":1358,"conditions":1359,"interventions":1364},"NCT05610085","A Dose Escalation Study of Levetiracetam in the Treatment of Neonatal Seizures",[90],"2027-07-01","2023-03-24",133,[1360,1361,1362,1363],"Neonatal Seizure","Neonatal Encephalopathy","Hypoxic-Ischemic Encephalopathy","Seizure Newborn",[1344,1365],"Phenobarbital Sodium",{"trials":1367,"activeCount":101},[],{"trials":1369,"activeCount":101},[],{"trials":1371,"activeCount":101},[],{"intervention":1365,"totalTrials":140,"cells":1373},{"EARLY_PHASE1":1374,"PHASE1":1376,"PHASE2":1378,"PHASE3":1384,"PHASE4":1386,"NA":1388},{"trials":1375,"activeCount":101},[],{"trials":1377,"activeCount":101},[],{"trials":1379,"activeCount":140,"soonestReadout":1356},[1380],{"nctId":1353,"briefTitle":1354,"status":130,"phases":1381,"primaryCompletion":1356,"completion":541,"start":1357,"enrollment":1358,"conditions":1382,"interventions":1383},[90],[1360,1361,1362,1363],[1344,1365],{"trials":1385,"activeCount":101},[],{"trials":1387,"activeCount":101},[],{"trials":1389,"activeCount":101},[],{"intervention":1391,"totalTrials":140,"cells":1392},"Molecularly matched therapy",{"EARLY_PHASE1":1393,"PHASE1":1395,"PHASE2":1397,"PHASE3":1411,"PHASE4":1413,"NA":1415},{"trials":1394,"activeCount":101},[],{"trials":1396,"activeCount":101},[],{"trials":1398,"activeCount":140,"soonestReadout":1403},[1399],{"nctId":1400,"briefTitle":1401,"status":338,"phases":1402,"primaryCompletion":1403,"completion":1404,"start":1162,"enrollment":1405,"conditions":1406,"interventions":1409},"NCT07346209","Real-world Trial of Individualized Precision Oncology",[90],"2031-03","2031-09",280,[1407,1408],"Metastatic Cancer","Unresectable Carcinoma",[1391,1410],"Standard of care",{"trials":1412,"activeCount":101},[],{"trials":1414,"activeCount":101},[],{"trials":1416,"activeCount":101},[],{"intervention":1410,"totalTrials":140,"cells":1418},{"EARLY_PHASE1":1419,"PHASE1":1421,"PHASE2":1423,"PHASE3":1429,"PHASE4":1431,"NA":1433},{"trials":1420,"activeCount":101},[],{"trials":1422,"activeCount":101},[],{"trials":1424,"activeCount":140,"soonestReadout":1403},[1425],{"nctId":1400,"briefTitle":1401,"status":338,"phases":1426,"primaryCompletion":1403,"completion":1404,"start":1162,"enrollment":1405,"conditions":1427,"interventions":1428},[90],[1407,1408],[1391,1410],{"trials":1430,"activeCount":101},[],{"trials":1432,"activeCount":101},[],{"trials":1434,"activeCount":101},[],{"intervention":1436,"totalTrials":140,"cells":1437},"nL-SCN2A-002",{"EARLY_PHASE1":1438,"PHASE1":1440,"PHASE2":1442,"PHASE3":1453,"PHASE4":1455,"NA":1457},{"trials":1439,"activeCount":101},[],{"trials":1441,"activeCount":101},[],{"trials":1443,"activeCount":140,"soonestReadout":1448},[1444],{"nctId":1445,"briefTitle":1446,"status":406,"phases":1447,"primaryCompletion":1448,"completion":1448,"start":1449,"enrollment":140,"conditions":1450,"interventions":1452},"NCT06314490","Personalized Antisense Oligonucleotide Therapy for Rare Pediatric Genetic Disease: SCN2A",[89,90],"2026-02-16","2024-02-16",[1451],"Genetic Disease",[1436],{"trials":1454,"activeCount":101},[],{"trials":1456,"activeCount":101},[],{"trials":1458,"activeCount":101},[],{"intervention":1460,"totalTrials":140,"cells":1461},"Elranatamab",{"EARLY_PHASE1":1462,"PHASE1":1464,"PHASE2":1466,"PHASE3":1479,"PHASE4":1481,"NA":1483},{"trials":1463,"activeCount":101},[],{"trials":1465,"activeCount":101},[],{"trials":1467,"activeCount":140,"soonestReadout":1472},[1468],{"nctId":1469,"briefTitle":1470,"status":130,"phases":1471,"primaryCompletion":1472,"completion":1473,"start":1474,"enrollment":1475,"conditions":1476,"interventions":1478},"NCT06711705","Elranatamab in Relapsed\u002FRefractory Multiple Myeloma",[90],"2029-12","2030-12","2024-12-18",33,[1477],"Multiple Myeloma",[1460],{"trials":1480,"activeCount":101},[],{"trials":1482,"activeCount":101},[],{"trials":1484,"activeCount":101},[],{"intervention":1486,"totalTrials":140,"cells":1487},"Ketamine",{"EARLY_PHASE1":1488,"PHASE1":1490,"PHASE2":1492,"PHASE3":1505,"PHASE4":1507,"NA":1509},{"trials":1489,"activeCount":101},[],{"trials":1491,"activeCount":101},[],{"trials":1493,"activeCount":140,"soonestReadout":1498},[1494],{"nctId":1495,"briefTitle":1496,"status":338,"phases":1497,"primaryCompletion":1498,"completion":1499,"start":1500,"enrollment":1501,"conditions":1502,"interventions":1504},"NCT07369089","Targeting Treatment-Resistant OUD With Ketamine-Assisted Mindfulness Oriented Recovery Enhancement",[90],"2028-01","2028-04","2026-02",88,[1503],"Opioid Use Disorder",[1486],{"trials":1506,"activeCount":101},[],{"trials":1508,"activeCount":101},[],{"trials":1510,"activeCount":101},[],{"intervention":1234,"totalTrials":140,"cells":1512},{"EARLY_PHASE1":1513,"PHASE1":1515,"PHASE2":1517,"PHASE3":1523,"PHASE4":1525,"NA":1527},{"trials":1514,"activeCount":101},[],{"trials":1516,"activeCount":101},[],{"trials":1518,"activeCount":140,"soonestReadout":1230},[1519],{"nctId":1227,"briefTitle":1228,"status":406,"phases":1520,"primaryCompletion":1230,"completion":1230,"start":1231,"enrollment":1175,"conditions":1521,"interventions":1522},[90],[1137],[1199,1234],{"trials":1524,"activeCount":101},[],{"trials":1526,"activeCount":101},[],{"trials":1528,"activeCount":101},[],{"intervention":1530,"totalTrials":140,"cells":1531},"Ruxolitinib",{"EARLY_PHASE1":1532,"PHASE1":1534,"PHASE2":1536,"PHASE3":1548,"PHASE4":1550,"NA":1552},{"trials":1533,"activeCount":101},[],{"trials":1535,"activeCount":101},[],{"trials":1537,"activeCount":140,"soonestReadout":842},[1538],{"nctId":1539,"briefTitle":1540,"status":130,"phases":1541,"primaryCompletion":842,"completion":1472,"start":1542,"enrollment":386,"conditions":1543,"interventions":1546},"NCT07219576","Retifanlimab and Ruxolitinib In Solid Malignancies",[89,90],"2026-01-08",[1544,1545],"Non Small Cell Lung Carcinoma","Renal Cell Carcinoma",[1530,1547],"Retifanlimab",{"trials":1549,"activeCount":101},[],{"trials":1551,"activeCount":101},[],{"trials":1553,"activeCount":101},[],{"intervention":1547,"totalTrials":140,"cells":1555},{"EARLY_PHASE1":1556,"PHASE1":1558,"PHASE2":1560,"PHASE3":1566,"PHASE4":1568,"NA":1570},{"trials":1557,"activeCount":101},[],{"trials":1559,"activeCount":101},[],{"trials":1561,"activeCount":140,"soonestReadout":842},[1562],{"nctId":1539,"briefTitle":1540,"status":130,"phases":1563,"primaryCompletion":842,"completion":1472,"start":1542,"enrollment":386,"conditions":1564,"interventions":1565},[89,90],[1544,1545],[1530,1547],{"trials":1567,"activeCount":101},[],{"trials":1569,"activeCount":101},[],{"trials":1571,"activeCount":101},[],{"intervention":1573,"totalTrials":140,"cells":1574},"Tricalm Hydrogel",{"EARLY_PHASE1":1575,"PHASE1":1577,"PHASE2":1579,"PHASE3":1592,"PHASE4":1594,"NA":1596},{"trials":1576,"activeCount":101},[],{"trials":1578,"activeCount":101},[],{"trials":1580,"activeCount":140,"soonestReadout":842},[1581],{"nctId":1582,"briefTitle":1583,"status":130,"phases":1584,"primaryCompletion":842,"completion":1585,"start":1586,"enrollment":1587,"conditions":1588,"interventions":1590},"NCT06748404","TriCalm Hydrogel® in the Treatment of Immunotherapy-Related Pruritus",[90],"2028-12","2025-01-31",28,[1589],"Immunotherapy-related Pruritus",[1573,1591],"Triamcinolone acetonide 0.1% cream",{"trials":1593,"activeCount":101},[],{"trials":1595,"activeCount":101},[],{"trials":1597,"activeCount":101},[],{"intervention":1591,"totalTrials":140,"cells":1599},{"EARLY_PHASE1":1600,"PHASE1":1602,"PHASE2":1604,"PHASE3":1610,"PHASE4":1612,"NA":1614},{"trials":1601,"activeCount":101},[],{"trials":1603,"activeCount":101},[],{"trials":1605,"activeCount":140,"soonestReadout":842},[1606],{"nctId":1582,"briefTitle":1583,"status":130,"phases":1607,"primaryCompletion":842,"completion":1585,"start":1586,"enrollment":1587,"conditions":1608,"interventions":1609},[90],[1589],[1573,1591],{"trials":1611,"activeCount":101},[],{"trials":1613,"activeCount":101},[],{"trials":1615,"activeCount":101},[],{"intervention":1617,"totalTrials":140,"cells":1618},"A CDK4\u002F6 inhibitor different from the first that the participant had received, plus fulvestrant.",{"EARLY_PHASE1":1619,"PHASE1":1621,"PHASE2":1623,"PHASE3":1634,"PHASE4":1636,"NA":1638},{"trials":1620,"activeCount":101},[],{"trials":1622,"activeCount":101},[],{"trials":1624,"activeCount":140,"soonestReadout":842},[1625],{"nctId":1626,"briefTitle":1627,"status":130,"phases":1628,"primaryCompletion":842,"completion":1585,"start":1629,"enrollment":1630,"conditions":1631,"interventions":1632},"NCT07227233","Artificial Intelligence and Machine Learning to Guide CDK4\u002F6 Inhibitor Rechallenge in Breast Cancer.",[90],"2026-03-31",105,[26],[1617,1633],"Treatment of physician's choice",{"trials":1635,"activeCount":101},[],{"trials":1637,"activeCount":101},[],{"trials":1639,"activeCount":101},[],{"intervention":1633,"totalTrials":140,"cells":1641},{"EARLY_PHASE1":1642,"PHASE1":1644,"PHASE2":1646,"PHASE3":1652,"PHASE4":1654,"NA":1656},{"trials":1643,"activeCount":101},[],{"trials":1645,"activeCount":101},[],{"trials":1647,"activeCount":140,"soonestReadout":842},[1648],{"nctId":1626,"briefTitle":1627,"status":130,"phases":1649,"primaryCompletion":842,"completion":1585,"start":1629,"enrollment":1630,"conditions":1650,"interventions":1651},[90],[26],[1617,1633],{"trials":1653,"activeCount":101},[],{"trials":1655,"activeCount":101},[],{"trials":1657,"activeCount":101},[],{"intervention":981,"totalTrials":140,"cells":1659},{"EARLY_PHASE1":1660,"PHASE1":1662,"PHASE2":1664,"PHASE3":1670,"PHASE4":1672,"NA":1674},{"trials":1661,"activeCount":101},[],{"trials":1663,"activeCount":101},[],{"trials":1665,"activeCount":140,"soonestReadout":972},[1666],{"nctId":969,"briefTitle":970,"status":130,"phases":1667,"primaryCompletion":972,"completion":972,"start":973,"enrollment":974,"conditions":1668,"interventions":1669},[90],[29,976,951,977,978,979],[951,981],{"trials":1671,"activeCount":101},[],{"trials":1673,"activeCount":101},[],{"trials":1675,"activeCount":101},[],{"intervention":1677,"totalTrials":140,"cells":1678},"nL-TUBB4-001",{"EARLY_PHASE1":1679,"PHASE1":1681,"PHASE2":1683,"PHASE3":1694,"PHASE4":1696,"NA":1698},{"trials":1680,"activeCount":101},[],{"trials":1682,"activeCount":101},[],{"trials":1684,"activeCount":140,"soonestReadout":1689},[1685],{"nctId":1686,"briefTitle":1687,"status":406,"phases":1688,"primaryCompletion":1689,"completion":1689,"start":1690,"enrollment":140,"conditions":1691,"interventions":1693},"NCT07222371","An Open-label, Single Center, Single Participant Study of an Experimental Antisense Oligonucleotide Treatment for TUBB4A-related Leukodystrophy",[89,90],"2027-09","2025-09-19",[1451,1692],"TUBB4A-Related Leukodystrophy",[1677],{"trials":1695,"activeCount":101},[],{"trials":1697,"activeCount":101},[],{"trials":1699,"activeCount":101},[],{"intervention":1701,"totalTrials":140,"cells":1702},"Oxygen gas",{"EARLY_PHASE1":1703,"PHASE1":1705,"PHASE2":1707,"PHASE3":1720,"PHASE4":1722,"NA":1724},{"trials":1704,"activeCount":101},[],{"trials":1706,"activeCount":101},[],{"trials":1708,"activeCount":140,"soonestReadout":1713},[1709],{"nctId":1710,"briefTitle":1711,"status":130,"phases":1712,"primaryCompletion":1713,"completion":1713,"start":1714,"enrollment":1715,"conditions":1716,"interventions":1719},"NCT05237505","The Cardiovascular Consequences of Sleep Apnea Plus COPD (Overlap Syndrome)",[90],"2028-08-31","2024-02-13",240,[18,1717,1718],"Chronic Obstructive Pulmonary Disease","Overlap Syndrome",[1701],{"trials":1721,"activeCount":101},[],{"trials":1723,"activeCount":101},[],{"trials":1725,"activeCount":101},[],{"intervention":1727,"totalTrials":140,"cells":1728},"Cemiplimab Plus Gemcitabine",{"EARLY_PHASE1":1729,"PHASE1":1731,"PHASE2":1733,"PHASE3":1745,"PHASE4":1747,"NA":1749},{"trials":1730,"activeCount":101},[],{"trials":1732,"activeCount":101},[],{"trials":1734,"activeCount":140,"soonestReadout":1739},[1735],{"nctId":1736,"briefTitle":1737,"status":130,"phases":1738,"primaryCompletion":1739,"completion":1472,"start":1740,"enrollment":1741,"conditions":1742,"interventions":1744},"NCT06790602","Cemiplimab Plus Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma",[90],"2028-07","2026-04",43,[1743],"Pancreatic Ductal Adenocarcinoma (mPDAC)",[1727],{"trials":1746,"activeCount":101},[],{"trials":1748,"activeCount":101},[],{"trials":1750,"activeCount":101},[],{"intervention":1752,"totalTrials":140,"cells":1753},"Seladelpar",{"EARLY_PHASE1":1754,"PHASE1":1756,"PHASE2":1758,"PHASE3":1769,"PHASE4":1771,"NA":1773},{"trials":1755,"activeCount":101},[],{"trials":1757,"activeCount":101},[],{"trials":1759,"activeCount":140,"soonestReadout":1689},[1760],{"nctId":1761,"briefTitle":1762,"status":338,"phases":1763,"primaryCompletion":1689,"completion":842,"start":205,"enrollment":1764,"conditions":1765,"interventions":1768},"NCT07305363","Seladelpar in Adult Liver Transplant Recipients With Ischemic Cholangiopathy (SELIC).",[90],10,[1766,1767],"Liver Transplant; Complications","Ischemic Cholangiopathy",[1752],{"trials":1770,"activeCount":101},[],{"trials":1772,"activeCount":101},[],{"trials":1774,"activeCount":101},[],{"intervention":1776,"totalTrials":140,"cells":1777},"Abemaciclib",{"EARLY_PHASE1":1778,"PHASE1":1780,"PHASE2":1782,"PHASE3":1794,"PHASE4":1796,"NA":1798},{"trials":1779,"activeCount":101},[],{"trials":1781,"activeCount":101},[],{"trials":1783,"activeCount":140,"soonestReadout":384},[1784],{"nctId":1785,"briefTitle":1786,"status":406,"phases":1787,"primaryCompletion":384,"completion":1788,"start":1789,"enrollment":33,"conditions":1790,"interventions":1792},"NCT04545710","Osimertinib and Abemaciclib in EGFR Mutant Non-Small Cell Lung Cancer After Osimertinib Resistance",[90],"2026-12-01","2020-11-21",[1791],"Lung Cancer",[1776,1793],"Osimertinib",{"trials":1795,"activeCount":101},[],{"trials":1797,"activeCount":101},[],{"trials":1799,"activeCount":101},[],{"intervention":1793,"totalTrials":140,"cells":1801},{"EARLY_PHASE1":1802,"PHASE1":1804,"PHASE2":1806,"PHASE3":1812,"PHASE4":1814,"NA":1816},{"trials":1803,"activeCount":101},[],{"trials":1805,"activeCount":101},[],{"trials":1807,"activeCount":140,"soonestReadout":384},[1808],{"nctId":1785,"briefTitle":1786,"status":406,"phases":1809,"primaryCompletion":384,"completion":1788,"start":1789,"enrollment":33,"conditions":1810,"interventions":1811},[90],[1791],[1776,1793],{"trials":1813,"activeCount":101},[],{"trials":1815,"activeCount":101},[],{"trials":1817,"activeCount":101},[],{"intervention":1819,"totalTrials":140,"cells":1820},"Psilocybin, [3-[2-(dimethylamino)ethyl]-1H-indol-4-yl] dihydrogen phosphate",{"EARLY_PHASE1":1821,"PHASE1":1823,"PHASE2":1825,"PHASE3":1837,"PHASE4":1839,"NA":1841},{"trials":1822,"activeCount":101},[],{"trials":1824,"activeCount":101},[],{"trials":1826,"activeCount":140,"soonestReadout":1162},[1827],{"nctId":1828,"briefTitle":1829,"status":130,"phases":1830,"primaryCompletion":1162,"completion":1831,"start":1832,"enrollment":1764,"conditions":1833,"interventions":1836},"NCT06814522","Psilocybin-Assisted Therapy for Physician Well-Being and Burnout",[89,90],"2026-07","2025-01-13",[1834,1835],"Burnout","Burnout, Healthcare Workers",[1819],{"trials":1838,"activeCount":101},[],{"trials":1840,"activeCount":101},[],{"trials":1842,"activeCount":101},[],{"intervention":61,"totalTrials":140,"cells":1844},{"EARLY_PHASE1":1845,"PHASE1":1847,"PHASE2":1849,"PHASE3":1857,"PHASE4":1859,"NA":1861},{"trials":1846,"activeCount":101},[],{"trials":1848,"activeCount":101},[],{"trials":1850,"activeCount":140,"soonestReadout":60},[1851],{"nctId":58,"briefTitle":59,"status":130,"phases":1852,"primaryCompletion":60,"completion":60,"start":1853,"enrollment":386,"conditions":1854,"interventions":1856},[90],"2020-12-18",[1855,15],"Colitis, Ulcerative",[61],{"trials":1858,"activeCount":101},[],{"trials":1860,"activeCount":101},[],{"trials":1862,"activeCount":101},[],{"intervention":1864,"totalTrials":140,"cells":1865},"phage therapy",{"EARLY_PHASE1":1866,"PHASE1":1868,"PHASE2":1870,"PHASE3":1884,"PHASE4":1886,"NA":1888},{"trials":1867,"activeCount":101},[],{"trials":1869,"activeCount":101},[],{"trials":1871,"activeCount":140,"soonestReadout":1876},[1872],{"nctId":1873,"briefTitle":1874,"status":130,"phases":1875,"primaryCompletion":1876,"completion":1877,"start":1878,"enrollment":1879,"conditions":1880,"interventions":1882},"NCT06409819","Phage Therapy for Recurrent UTIs in Kidney Transplant Recipients",[89,90],"2026-10-01","2027-03-01","2025-06-15",32,[1881],"Urinary Tract Infection, Recurrent",[1864,1883],"control",{"trials":1885,"activeCount":101},[],{"trials":1887,"activeCount":101},[],{"trials":1889,"activeCount":101},[],{"intervention":1883,"totalTrials":140,"cells":1891},{"EARLY_PHASE1":1892,"PHASE1":1894,"PHASE2":1896,"PHASE3":1902,"PHASE4":1904,"NA":1906},{"trials":1893,"activeCount":101},[],{"trials":1895,"activeCount":101},[],{"trials":1897,"activeCount":140,"soonestReadout":1876},[1898],{"nctId":1873,"briefTitle":1874,"status":130,"phases":1899,"primaryCompletion":1876,"completion":1877,"start":1878,"enrollment":1879,"conditions":1900,"interventions":1901},[89,90],[1881],[1864,1883],{"trials":1903,"activeCount":101},[],{"trials":1905,"activeCount":101},[],{"trials":1907,"activeCount":101},[],{"intervention":1909,"totalTrials":140,"cells":1910},"Axitinib Oral Tablet [Inlyta]",{"EARLY_PHASE1":1911,"PHASE1":1913,"PHASE2":1915,"PHASE3":1927,"PHASE4":1929,"NA":1931},{"trials":1912,"activeCount":101},[],{"trials":1914,"activeCount":101},[],{"trials":1916,"activeCount":140,"soonestReadout":1921},[1917],{"nctId":1918,"briefTitle":1919,"status":406,"phases":1920,"primaryCompletion":1921,"completion":1921,"start":1922,"enrollment":1923,"conditions":1924,"interventions":1926},"NCT03438708","Prior Axitinib as a Determinant of Outcome of Renal Surgery",[90],"2026-03-04","2018-03-05",22,[1925],"Clear Cell Renal Cell Carcinoma",[1909],{"trials":1928,"activeCount":101},[],{"trials":1930,"activeCount":101},[],{"trials":1932,"activeCount":101},[],{"intervention":1934,"totalTrials":140,"cells":1935},"Pramipexole Pill",{"EARLY_PHASE1":1936,"PHASE1":1938,"PHASE2":1940,"PHASE3":1954,"PHASE4":1956,"NA":1958},{"trials":1937,"activeCount":101},[],{"trials":1939,"activeCount":101},[],{"trials":1941,"activeCount":140,"soonestReadout":1946},[1942],{"nctId":1943,"briefTitle":1944,"status":130,"phases":1945,"primaryCompletion":1946,"completion":1946,"start":1947,"enrollment":1948,"conditions":1949,"interventions":1953},"NCT06269146","Pramipexole to Enhance Social Connections",[90],"2026-03","2024-05-13",108,[1950,1951,24,1952],"Anxiety Disorders","Anxiety","Social Disconnection",[1934],{"trials":1955,"activeCount":101},[],{"trials":1957,"activeCount":101},[],{"trials":1959,"activeCount":101},[],{"intervention":1128,"totalTrials":140,"cells":1961},{"EARLY_PHASE1":1962,"PHASE1":1964,"PHASE2":1966,"PHASE3":1972,"PHASE4":1974,"NA":1976},{"trials":1963,"activeCount":101},[],{"trials":1965,"activeCount":101},[],{"trials":1967,"activeCount":140,"soonestReadout":1120},[1968],{"nctId":1117,"briefTitle":1118,"status":130,"phases":1969,"primaryCompletion":1120,"completion":1121,"start":1122,"enrollment":1123,"conditions":1970,"interventions":1971},[89,90],[1125,1126],[1128,1076],{"trials":1973,"activeCount":101},[],{"trials":1975,"activeCount":101},[],{"trials":1977,"activeCount":101},[],{"intervention":1191,"totalTrials":140,"cells":1979},{"EARLY_PHASE1":1980,"PHASE1":1982,"PHASE2":1984,"PHASE3":1990,"PHASE4":1992,"NA":1994},{"trials":1981,"activeCount":101},[],{"trials":1983,"activeCount":101},[],{"trials":1985,"activeCount":140,"soonestReadout":1186},[1986],{"nctId":1183,"briefTitle":1184,"status":130,"phases":1987,"primaryCompletion":1186,"completion":1186,"start":1187,"enrollment":135,"conditions":1988,"interventions":1989},[90],[1189],[1148,1191],{"trials":1991,"activeCount":101},[],{"trials":1993,"activeCount":101},[],{"trials":1995,"activeCount":101},[],{"intervention":1997,"totalTrials":140,"cells":1998},"Ubiquinone 100 mg Oral Soft Gel",{"EARLY_PHASE1":1999,"PHASE1":2001,"PHASE2":2003,"PHASE3":2014,"PHASE4":2016,"NA":2018},{"trials":2000,"activeCount":101},[],{"trials":2002,"activeCount":101},[],{"trials":2004,"activeCount":140,"soonestReadout":2009},[2005],{"nctId":2006,"briefTitle":2007,"status":338,"phases":2008,"primaryCompletion":2009,"completion":2009,"start":2010,"enrollment":27,"conditions":2011,"interventions":2013},"NCT06962657","Mitigating Toxic Impact: The Role of Coenzyme Q10 in Post-Exposure Protection",[90],"2028-10-01","2026-05-15",[2012],"Toxicant Induced Chronic Multisymptom Illness and Associated Symptoms and Comorbidities",[1997],{"trials":2015,"activeCount":101},[],{"trials":2017,"activeCount":101},[],{"trials":2019,"activeCount":101},[],{"intervention":2021,"totalTrials":140,"cells":2022},"THC Cannabis",{"EARLY_PHASE1":2023,"PHASE1":2025,"PHASE2":2027,"PHASE3":2039,"PHASE4":2041,"NA":2043},{"trials":2024,"activeCount":101},[],{"trials":2026,"activeCount":101},[],{"trials":2028,"activeCount":140,"soonestReadout":2033},[2029],{"nctId":2030,"briefTitle":2031,"status":406,"phases":2032,"primaryCompletion":2033,"completion":1013,"start":2034,"enrollment":386,"conditions":2035,"interventions":2037},"NCT04800159","Cannabis Effects on Antiretroviral Therapy Pharmacokinetics and Neurotoxicity",[90],"2025-10-30","2021-02-19",[29,2036],"Cannabis Use",[2021,2038],"CBD Cannabis",{"trials":2040,"activeCount":101},[],{"trials":2042,"activeCount":101},[],{"trials":2044,"activeCount":101},[],{"intervention":2038,"totalTrials":140,"cells":2046},{"EARLY_PHASE1":2047,"PHASE1":2049,"PHASE2":2051,"PHASE3":2057,"PHASE4":2059,"NA":2061},{"trials":2048,"activeCount":101},[],{"trials":2050,"activeCount":101},[],{"trials":2052,"activeCount":140,"soonestReadout":2033},[2053],{"nctId":2030,"briefTitle":2031,"status":406,"phases":2054,"primaryCompletion":2033,"completion":1013,"start":2034,"enrollment":386,"conditions":2055,"interventions":2056},[90],[29,2036],[2021,2038],{"trials":2058,"activeCount":101},[],{"trials":2060,"activeCount":101},[],{"trials":2062,"activeCount":101},[],{"intervention":2064,"totalTrials":140,"cells":2065},"Sotagliflozin",{"EARLY_PHASE1":2066,"PHASE1":2068,"PHASE2":2070,"PHASE3":2080,"PHASE4":2082,"NA":2084},{"trials":2067,"activeCount":101},[],{"trials":2069,"activeCount":101},[],{"trials":2071,"activeCount":140,"soonestReadout":1498},[2072],{"nctId":2073,"briefTitle":2074,"status":130,"phases":2075,"primaryCompletion":1498,"completion":1498,"start":2076,"enrollment":22,"conditions":2077,"interventions":2078},"NCT05696366","Combination Adjunctive Therapy to Address Multiple Metabolic Imbalances in Type 1 Diabetes",[89,90],"2024-09-09",[912],[2064,2079],"Volagidemab",{"trials":2081,"activeCount":101},[],{"trials":2083,"activeCount":101},[],{"trials":2085,"activeCount":101},[],{"intervention":2079,"totalTrials":140,"cells":2087},{"EARLY_PHASE1":2088,"PHASE1":2090,"PHASE2":2092,"PHASE3":2098,"PHASE4":2100,"NA":2102},{"trials":2089,"activeCount":101},[],{"trials":2091,"activeCount":101},[],{"trials":2093,"activeCount":140,"soonestReadout":1498},[2094],{"nctId":2073,"briefTitle":2074,"status":130,"phases":2095,"primaryCompletion":1498,"completion":1498,"start":2076,"enrollment":22,"conditions":2096,"interventions":2097},[89,90],[912],[2064,2079],{"trials":2099,"activeCount":101},[],{"trials":2101,"activeCount":101},[],{"trials":2103,"activeCount":101},[],{"intervention":2105,"totalTrials":140,"cells":2106},"Trimethoprim",{"EARLY_PHASE1":2107,"PHASE1":2109,"PHASE2":2111,"PHASE3":2121,"PHASE4":2123,"NA":2125},{"trials":2108,"activeCount":101},[],{"trials":2110,"activeCount":101},[],{"trials":2112,"activeCount":140,"soonestReadout":842},[2113],{"nctId":2114,"briefTitle":2115,"status":338,"phases":2116,"primaryCompletion":842,"completion":842,"start":1162,"enrollment":2117,"conditions":2118,"interventions":2120},"NCT06536374","Folate Study in Men With Advanced Prostate Cancer",[90],50,[2119],"Prostate Cancer",[2105],{"trials":2122,"activeCount":101},[],{"trials":2124,"activeCount":101},[],{"trials":2126,"activeCount":101},[],{"intervention":86,"totalTrials":140,"cells":2128},{"EARLY_PHASE1":2129,"PHASE1":2131,"PHASE2":2139,"PHASE3":2141,"PHASE4":2143,"NA":2145},{"trials":2130,"activeCount":101},[],{"trials":2132,"activeCount":140,"soonestReadout":85},[2133],{"nctId":83,"briefTitle":84,"status":406,"phases":2134,"primaryCompletion":85,"completion":1230,"start":2135,"enrollment":1024,"conditions":2136,"interventions":2138},[89],"2021-09-02",[2137],"Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma",[86],{"trials":2140,"activeCount":101},[],{"trials":2142,"activeCount":101},[],{"trials":2144,"activeCount":101},[],{"trials":2146,"activeCount":101},[],{"intervention":2148,"totalTrials":140,"cells":2149},"SD-101",{"EARLY_PHASE1":2150,"PHASE1":2152,"PHASE2":2164,"PHASE3":2166,"PHASE4":2168,"NA":2170},{"trials":2151,"activeCount":101},[],{"trials":2153,"activeCount":140,"soonestReadout":908},[2154],{"nctId":2155,"briefTitle":2156,"status":130,"phases":2157,"primaryCompletion":908,"completion":908,"start":2158,"enrollment":27,"conditions":2159,"interventions":2161},"NCT06710223","Cryoablation and Arterial Infusion of SD-101 in Combination With Durvalumab and Tremelimumab",[89],"2025-01-03",[2160],"Hepatocellular Carcinoma",[2148,2162,2163],"Tremelimumab","Durvalumab",{"trials":2165,"activeCount":101},[],{"trials":2167,"activeCount":101},[],{"trials":2169,"activeCount":101},[],{"trials":2171,"activeCount":101},[],{"intervention":2162,"totalTrials":140,"cells":2173},{"EARLY_PHASE1":2174,"PHASE1":2176,"PHASE2":2182,"PHASE3":2184,"PHASE4":2186,"NA":2188},{"trials":2175,"activeCount":101},[],{"trials":2177,"activeCount":140,"soonestReadout":908},[2178],{"nctId":2155,"briefTitle":2156,"status":130,"phases":2179,"primaryCompletion":908,"completion":908,"start":2158,"enrollment":27,"conditions":2180,"interventions":2181},[89],[2160],[2148,2162,2163],{"trials":2183,"activeCount":101},[],{"trials":2185,"activeCount":101},[],{"trials":2187,"activeCount":101},[],{"trials":2189,"activeCount":101},[],{"intervention":2163,"totalTrials":140,"cells":2191},{"EARLY_PHASE1":2192,"PHASE1":2194,"PHASE2":2200,"PHASE3":2202,"PHASE4":2204,"NA":2206},{"trials":2193,"activeCount":101},[],{"trials":2195,"activeCount":140,"soonestReadout":908},[2196],{"nctId":2155,"briefTitle":2156,"status":130,"phases":2197,"primaryCompletion":908,"completion":908,"start":2158,"enrollment":27,"conditions":2198,"interventions":2199},[89],[2160],[2148,2162,2163],{"trials":2201,"activeCount":101},[],{"trials":2203,"activeCount":101},[],{"trials":2205,"activeCount":101},[],{"trials":2207,"activeCount":101},[],{"intervention":2209,"totalTrials":140,"cells":2210},"Imatinib",{"EARLY_PHASE1":2211,"PHASE1":2213,"PHASE2":2226,"PHASE3":2228,"PHASE4":2230,"NA":2232},{"trials":2212,"activeCount":101},[],{"trials":2214,"activeCount":140,"soonestReadout":2219},[2215],{"nctId":2216,"briefTitle":2217,"status":130,"phases":2218,"primaryCompletion":2219,"completion":2220,"start":2221,"enrollment":33,"conditions":2222,"interventions":2224},"NCT07171203","Preoperative Imatinib and Fampridine in KIT Mutant Gastrointestinal Stromal Tumor",[89],"2030-07","2031-07","2026-05-13",[2223],"Gastrointestinal Stromal Tumors",[2209,2225],"Fampridine",{"trials":2227,"activeCount":101},[],{"trials":2229,"activeCount":101},[],{"trials":2231,"activeCount":101},[],{"trials":2233,"activeCount":101},[],{"intervention":2225,"totalTrials":140,"cells":2235},{"EARLY_PHASE1":2236,"PHASE1":2238,"PHASE2":2244,"PHASE3":2246,"PHASE4":2248,"NA":2250},{"trials":2237,"activeCount":101},[],{"trials":2239,"activeCount":140,"soonestReadout":2219},[2240],{"nctId":2216,"briefTitle":2217,"status":130,"phases":2241,"primaryCompletion":2219,"completion":2220,"start":2221,"enrollment":33,"conditions":2242,"interventions":2243},[89],[2223],[2209,2225],{"trials":2245,"activeCount":101},[],{"trials":2247,"activeCount":101},[],{"trials":2249,"activeCount":101},[],{"trials":2251,"activeCount":101},[],{"intervention":2253,"totalTrials":140,"cells":2254},"HDV-Insulin Lispro",{"EARLY_PHASE1":2255,"PHASE1":2257,"PHASE2":2267,"PHASE3":2269,"PHASE4":2271,"NA":2273},{"trials":2256,"activeCount":101},[],{"trials":2258,"activeCount":140,"soonestReadout":2263},[2259],{"nctId":2260,"briefTitle":2261,"status":338,"phases":2262,"primaryCompletion":2263,"completion":2263,"start":2264,"enrollment":33,"conditions":2265,"interventions":2266},"NCT05689424","Suppression of Endogenous Glucose Production by Injectable HDV-Insulin Lispro: A Dose Response Study in Human Subjects With Type 1 Diabetes",[89],"2026-06-30","2025-02-01",[912],[2253],{"trials":2268,"activeCount":101},[],{"trials":2270,"activeCount":101},[],{"trials":2272,"activeCount":101},[],{"trials":2274,"activeCount":101},[],{"intervention":2276,"totalTrials":140,"cells":2277},"Intravenous Bacteriophage Cocktail plus Standard IV Antibiotics",{"EARLY_PHASE1":2278,"PHASE1":2280,"PHASE2":2295,"PHASE3":2297,"PHASE4":2299,"NA":2301},{"trials":2279,"activeCount":101},[],{"trials":2281,"activeCount":140,"soonestReadout":132},[2282],{"nctId":2283,"briefTitle":2284,"status":338,"phases":2285,"primaryCompletion":132,"completion":2286,"start":1271,"enrollment":135,"conditions":2287,"interventions":2294},"NCT07280598","Safety of Combined Intravenous Antibiotic and Bacteriophage Therapy in Adults With Cystic Fibrosis and Antibiotic-Resistant Lung Infections",[89],"2027-01-30",[2288,2289,2290,2291,2292,2293],"CF - Cystic Fibrosis","Klebsiella Pneumoniae Infection","E Coli Infections","Staphylococcus Aureus Infection","Achromobacter","Stenotrophomonas Maltophilia Infection",[2276],{"trials":2296,"activeCount":101},[],{"trials":2298,"activeCount":101},[],{"trials":2300,"activeCount":101},[],{"trials":2302,"activeCount":101},[],{"intervention":81,"totalTrials":140,"cells":2304},{"EARLY_PHASE1":2305,"PHASE1":2307,"PHASE2":2316,"PHASE3":2318,"PHASE4":2320,"NA":2322},{"trials":2306,"activeCount":101},[],{"trials":2308,"activeCount":140,"soonestReadout":80},[2309],{"nctId":78,"briefTitle":79,"status":130,"phases":2310,"primaryCompletion":80,"completion":1186,"start":2311,"enrollment":2312,"conditions":2313,"interventions":2315},[89],"2024-06-01",7,[2314],"PD - Parkinson's Disease",[81],{"trials":2317,"activeCount":101},[],{"trials":2319,"activeCount":101},[],{"trials":2321,"activeCount":101},[],{"trials":2323,"activeCount":101},[],{"intervention":2325,"totalTrials":140,"cells":2326},"Mirabegron",{"EARLY_PHASE1":2327,"PHASE1":2329,"PHASE2":2340,"PHASE3":2342,"PHASE4":2344,"NA":2346},{"trials":2328,"activeCount":101},[],{"trials":2330,"activeCount":140,"soonestReadout":2335},[2331],{"nctId":2332,"briefTitle":2333,"status":406,"phases":2334,"primaryCompletion":2335,"completion":1271,"start":2336,"enrollment":386,"conditions":2337,"interventions":2339},"NCT05634174","ADRB3 Signaling Pathway in Human Adipose Tissue",[89],"2025-09-30","2023-08-01",[2338],"Obesity, Prediabetes",[2325],{"trials":2341,"activeCount":101},[],{"trials":2343,"activeCount":101},[],{"trials":2345,"activeCount":101},[],{"trials":2347,"activeCount":101},[],{"intervention":2349,"totalTrials":140,"cells":2350},"Fostamatinib in combination with chemotherapy",{"EARLY_PHASE1":2351,"PHASE1":2353,"PHASE2":2364,"PHASE3":2366,"PHASE4":2368,"NA":2370},{"trials":2352,"activeCount":101},[],{"trials":2354,"activeCount":140,"soonestReadout":842},[2355],{"nctId":2356,"briefTitle":2357,"status":130,"phases":2358,"primaryCompletion":842,"completion":1585,"start":2359,"enrollment":2360,"conditions":2361,"interventions":2363},"NCT06639724","Perioperative Fostamatinib With Gemcitabine and Nab-paclitaxel in Resectable Pancreatic Cancer",[89],"2024-12-05",36,[2362],"Pancreatic Ductal Adenocarcinoma (PDAC)",[2349],{"trials":2365,"activeCount":101},[],{"trials":2367,"activeCount":101},[],{"trials":2369,"activeCount":101},[],{"trials":2371,"activeCount":101},[],{"intervention":2373,"totalTrials":140,"cells":2374},"IRE + intratumoral mitazalimab (CD40 antibody)",{"EARLY_PHASE1":2375,"PHASE1":2377,"PHASE2":2389,"PHASE3":2391,"PHASE4":2393,"NA":2395},{"trials":2376,"activeCount":101},[],{"trials":2378,"activeCount":140,"soonestReadout":2383},[2379],{"nctId":2380,"briefTitle":2381,"status":130,"phases":2382,"primaryCompletion":2383,"completion":2384,"start":2385,"enrollment":33,"conditions":2386,"interventions":2388},"NCT06205849","Intra-tumoral Mitazalimab (CD40 Antibody) With Irreversible Electroporation (IRE) in Locally Advanced Pancreas Cancer",[89],"2027-08","2029-08","2024-06-25",[2387],"Pancreatic Cancer",[2373],{"trials":2390,"activeCount":101},[],{"trials":2392,"activeCount":101},[],{"trials":2394,"activeCount":101},[],{"trials":2396,"activeCount":101},[],{"intervention":2398,"totalTrials":140,"cells":2399},"BRC-002",{"EARLY_PHASE1":2400,"PHASE1":2402,"PHASE2":2413,"PHASE3":2415,"PHASE4":2417,"NA":2419},{"trials":2401,"activeCount":101},[],{"trials":2403,"activeCount":140,"soonestReadout":2408},[2404],{"nctId":2405,"briefTitle":2406,"status":130,"phases":2407,"primaryCompletion":2408,"completion":2408,"start":2311,"enrollment":800,"conditions":2409,"interventions":2411},"NCT06393101","The Effects and Mechanisms of a High CBD Cannabis Extract (BRC-002) for the Treatment of Pain and Health in Complex Regional Pain Syndrome",[89],"2029-06-01",[2410],"Complex Regional Pain Syndrome",[2398,2412],"BRC-002 Placebo",{"trials":2414,"activeCount":101},[],{"trials":2416,"activeCount":101},[],{"trials":2418,"activeCount":101},[],{"trials":2420,"activeCount":101},[],{"intervention":2412,"totalTrials":140,"cells":2422},{"EARLY_PHASE1":2423,"PHASE1":2425,"PHASE2":2431,"PHASE3":2433,"PHASE4":2435,"NA":2437},{"trials":2424,"activeCount":101},[],{"trials":2426,"activeCount":140,"soonestReadout":2408},[2427],{"nctId":2405,"briefTitle":2406,"status":130,"phases":2428,"primaryCompletion":2408,"completion":2408,"start":2311,"enrollment":800,"conditions":2429,"interventions":2430},[89],[2410],[2398,2412],{"trials":2432,"activeCount":101},[],{"trials":2434,"activeCount":101},[],{"trials":2436,"activeCount":101},[],{"trials":2438,"activeCount":101},[],{"intervention":2440,"totalTrials":97,"cells":2441},"Cannabidiol",{"EARLY_PHASE1":2442,"PHASE1":2451,"PHASE2":2453,"PHASE3":2466,"PHASE4":2468,"NA":2470},{"trials":2443,"activeCount":140,"soonestReadout":1162},[2444],{"nctId":2445,"briefTitle":2446,"status":406,"phases":2447,"primaryCompletion":1162,"completion":1162,"start":2448,"enrollment":386,"conditions":2449,"interventions":2450},"NCT04878627","Role of CBD in Regulating Meal Time Anxiety in Anorexia Nervosa",[88],"2022-01-20",[35],[2440],{"trials":2452,"activeCount":101},[],{"trials":2454,"activeCount":101},[2455],{"nctId":2456,"briefTitle":2457,"status":113,"phases":2458,"primaryCompletion":2459,"completion":2459,"start":2460,"enrollment":2461,"conditions":2462,"interventions":2465},"NCT05823753","Cannabidiol to Reduce Anxiety Reactivity",[90],"2024-08-20","2023-04-19",63,[2463,2464],"Social Anxiety","Social Anxiety Disorder",[2440],{"trials":2467,"activeCount":101},[],{"trials":2469,"activeCount":101},[],{"trials":2471,"activeCount":101},[],{"intervention":2473,"totalTrials":140,"cells":2474},"Varenicline Tartrate",{"EARLY_PHASE1":2475,"PHASE1":2487,"PHASE2":2489,"PHASE3":2491,"PHASE4":2493,"NA":2495},{"trials":2476,"activeCount":140,"soonestReadout":2481},[2477],{"nctId":2478,"briefTitle":2479,"status":130,"phases":2480,"primaryCompletion":2481,"completion":2481,"start":2482,"enrollment":1038,"conditions":2483,"interventions":2486},"NCT06582888","Advancing VR-based Attentional Bias as a Biomarker for Tobacco Use Disorder",[88],"2028-08-15","2024-11-19",[2484,2485],"Nicotine Addiction","Craving",[2473],{"trials":2488,"activeCount":101},[],{"trials":2490,"activeCount":101},[],{"trials":2492,"activeCount":101},[],{"trials":2494,"activeCount":101},[],{"trials":2496,"activeCount":101},[],{"intervention":2498,"totalTrials":140,"cells":2499},"Active Cannabis",{"EARLY_PHASE1":2500,"PHASE1":2512,"PHASE2":2514,"PHASE3":2516,"PHASE4":2518,"NA":2520},{"trials":2501,"activeCount":140,"soonestReadout":2506},[2502],{"nctId":2503,"briefTitle":2504,"status":130,"phases":2505,"primaryCompletion":2506,"completion":2507,"start":2508,"enrollment":283,"conditions":2509,"interventions":2511},"NCT04982965","Brain Mechanisms Supporting Cannabis-induced Pain Relief",[88],"2027-01-15","2027-03-15","2021-05-07",[2510],"Pain, Acute",[2498],{"trials":2513,"activeCount":101},[],{"trials":2515,"activeCount":101},[],{"trials":2517,"activeCount":101},[],{"trials":2519,"activeCount":101},[],{"trials":2521,"activeCount":101},[],{"intervention":2523,"totalTrials":140,"cells":2524},"Inhaled treprostinil",{"EARLY_PHASE1":2525,"PHASE1":2536,"PHASE2":2538,"PHASE3":2540,"PHASE4":2542,"NA":2544},{"trials":2526,"activeCount":140,"soonestReadout":1356},[2527],{"nctId":2528,"briefTitle":2529,"status":338,"phases":2530,"primaryCompletion":1356,"completion":1356,"start":2531,"enrollment":2532,"conditions":2533,"interventions":2535},"NCT07116681","Effects of Inhaled Treprostinil on Exercise Performance in Exercise Induced Pulmonary Hypertension",[88],"2025-10-01",8,[2534],"Pulmonary Hypertension",[2523],{"trials":2537,"activeCount":101},[],{"trials":2539,"activeCount":101},[],{"trials":2541,"activeCount":101},[],{"trials":2543,"activeCount":101},[],{"trials":2545,"activeCount":101},[],{"intervention":2547,"totalTrials":140,"cells":2548},"10 mg Δ9-tetrahydrocannabinol",{"EARLY_PHASE1":2549,"PHASE1":2561,"PHASE2":2563,"PHASE3":2565,"PHASE4":2567,"NA":2569},{"trials":2550,"activeCount":140,"soonestReadout":2263},[2551],{"nctId":2552,"briefTitle":2553,"status":130,"phases":2554,"primaryCompletion":2263,"completion":2263,"start":2555,"enrollment":2556,"conditions":2557,"interventions":2559},"NCT04883255","Cannabis Use, Cognition, and the Endocannabinoid System in HIV",[88],"2023-05-03",138,[2558],"HIV-1-infection",[2547,2560],"600 mg cannabidiol",{"trials":2562,"activeCount":101},[],{"trials":2564,"activeCount":101},[],{"trials":2566,"activeCount":101},[],{"trials":2568,"activeCount":101},[],{"trials":2570,"activeCount":101},[],{"intervention":2560,"totalTrials":140,"cells":2572},{"EARLY_PHASE1":2573,"PHASE1":2579,"PHASE2":2581,"PHASE3":2583,"PHASE4":2585,"NA":2587},{"trials":2574,"activeCount":140,"soonestReadout":2263},[2575],{"nctId":2552,"briefTitle":2553,"status":130,"phases":2576,"primaryCompletion":2263,"completion":2263,"start":2555,"enrollment":2556,"conditions":2577,"interventions":2578},[88],[2558],[2547,2560],{"trials":2580,"activeCount":101},[],{"trials":2582,"activeCount":101},[],{"trials":2584,"activeCount":101},[],{"trials":2586,"activeCount":101},[],{"trials":2588,"activeCount":101},[],{"intervention":2590,"totalTrials":97,"cells":2591},"Xylocaine jelly 2%",{"EARLY_PHASE1":2592,"PHASE1":2594,"PHASE2":2596,"PHASE3":2598,"PHASE4":2600,"NA":2602},{"trials":2593,"activeCount":101},[],{"trials":2595,"activeCount":101},[],{"trials":2597,"activeCount":101},[],{"trials":2599,"activeCount":101},[],{"trials":2601,"activeCount":101},[],{"trials":2603,"activeCount":97,"soonestReadout":160},[2604,2613],{"nctId":2605,"briefTitle":2606,"status":338,"phases":2607,"primaryCompletion":160,"completion":2608,"start":385,"enrollment":2609,"conditions":2610,"interventions":2611},"NCT06974032","Empathy Through Pain Control: Lidocaine Gel vs. Placebo Prior to IUD Placement",[93],"2028-06-30",68,[32,2510,435],[2590,2612],"Surgilube",{"nctId":2614,"briefTitle":2615,"status":130,"phases":2616,"primaryCompletion":160,"completion":2608,"start":311,"enrollment":2617,"conditions":2618,"interventions":2619},"NCT06960317","Empathy Through Pain Control: Lidocaine Paracervical Block for IUD Placements",[93],204,[32,2510,435],[2620,2621,2590,2612],"Buffered Lidocaine","Unbuffered lidocaine",{"intervention":2612,"totalTrials":97,"cells":2623},{"EARLY_PHASE1":2624,"PHASE1":2626,"PHASE2":2628,"PHASE3":2630,"PHASE4":2632,"NA":2634},{"trials":2625,"activeCount":101},[],{"trials":2627,"activeCount":101},[],{"trials":2629,"activeCount":101},[],{"trials":2631,"activeCount":101},[],{"trials":2633,"activeCount":101},[],{"trials":2635,"activeCount":97,"soonestReadout":160},[2636,2640],{"nctId":2605,"briefTitle":2606,"status":338,"phases":2637,"primaryCompletion":160,"completion":2608,"start":385,"enrollment":2609,"conditions":2638,"interventions":2639},[93],[32,2510,435],[2590,2612],{"nctId":2614,"briefTitle":2615,"status":130,"phases":2641,"primaryCompletion":160,"completion":2608,"start":311,"enrollment":2617,"conditions":2642,"interventions":2643},[93],[32,2510,435],[2620,2621,2590,2612],{"intervention":2645,"totalTrials":97,"cells":2646},"Guselkumab",{"EARLY_PHASE1":2647,"PHASE1":2649,"PHASE2":2651,"PHASE3":2653,"PHASE4":2655,"NA":2657},{"trials":2648,"activeCount":101},[],{"trials":2650,"activeCount":101},[],{"trials":2652,"activeCount":101},[],{"trials":2654,"activeCount":101},[],{"trials":2656,"activeCount":101},[],{"trials":2658,"activeCount":97,"soonestReadout":2663},[2659,2667],{"nctId":2660,"briefTitle":2661,"status":130,"phases":2662,"primaryCompletion":2663,"completion":1788,"start":385,"enrollment":27,"conditions":2664,"interventions":2666},"NCT06586281","Elucidating Shared Mechanisms Contributing to NAFLD and PsA Disease Severity With Guselkumab Therapy",[93],"2026-09-01",[2665],"Psoriatic Arthritis",[2645],{"nctId":2668,"briefTitle":2669,"status":130,"phases":2670,"primaryCompletion":2671,"completion":1120,"start":2672,"enrollment":1038,"conditions":2673,"interventions":2677},"NCT02103361","Stelara and Tremfya Pregnancy Exposure Registry OTIS Autoimmune Diseases in Pregnancy Project",[],"2030-05","2013-11",[2674,2675,2665,2676],"Psoriasis","Pregnancy","Crohn Disease",[2678,2645],"Ustekinumab",{"intervention":2620,"totalTrials":97,"cells":2680},{"EARLY_PHASE1":2681,"PHASE1":2683,"PHASE2":2685,"PHASE3":2687,"PHASE4":2689,"NA":2691},{"trials":2682,"activeCount":101},[],{"trials":2684,"activeCount":101},[],{"trials":2686,"activeCount":101},[],{"trials":2688,"activeCount":101},[],{"trials":2690,"activeCount":101},[],{"trials":2692,"activeCount":97,"soonestReadout":160},[2693,2700],{"nctId":2694,"briefTitle":2695,"status":338,"phases":2696,"primaryCompletion":160,"completion":2608,"start":385,"enrollment":2609,"conditions":2697,"interventions":2698},"NCT06974019","Empathy Through Pain Control: Buffered Compared to Unbuffered 1% Lidocaine During IUD Placement",[93],[32,2510,435],[2620,2699],"Lidocaine 1% Injectable Solution",{"nctId":2614,"briefTitle":2615,"status":130,"phases":2701,"primaryCompletion":160,"completion":2608,"start":311,"enrollment":2617,"conditions":2702,"interventions":2703},[93],[32,2510,435],[2620,2621,2590,2612],{"intervention":2699,"totalTrials":97,"cells":2705},{"EARLY_PHASE1":2706,"PHASE1":2708,"PHASE2":2710,"PHASE3":2712,"PHASE4":2714,"NA":2730},{"trials":2707,"activeCount":101},[],{"trials":2709,"activeCount":101},[],{"trials":2711,"activeCount":101},[],{"trials":2713,"activeCount":101},[],{"trials":2715,"activeCount":101},[2716],{"nctId":2717,"briefTitle":2718,"status":113,"phases":2719,"primaryCompletion":2720,"completion":2720,"start":2721,"enrollment":2722,"conditions":2723,"interventions":2728},"NCT04254081","Addition of Buprenorphine to Paracervical Block for Pain Control During Osmotic Dilator Insertion",[92],"2021-05-04","2020-05-28",57,[2724,2725,2726,210,2727],"Procedural Pain","Buprenorphine","Adjuvants, Anesthesia","Analgesics",[2729,2699],"Buprenorphine 0.15 MG",{"trials":2731,"activeCount":140,"soonestReadout":160},[2732],{"nctId":2694,"briefTitle":2695,"status":338,"phases":2733,"primaryCompletion":160,"completion":2608,"start":385,"enrollment":2609,"conditions":2734,"interventions":2735},[93],[32,2510,435],[2620,2699],{"intervention":2737,"totalTrials":140,"cells":2738},"we will prepare 3cc of buffered lidocaine consisting of 2.7cc of 1% lidocaine and 0.3cc of 8.4% sodium bicarbonate",{"EARLY_PHASE1":2739,"PHASE1":2741,"PHASE2":2743,"PHASE3":2745,"PHASE4":2747,"NA":2749},{"trials":2740,"activeCount":101},[],{"trials":2742,"activeCount":101},[],{"trials":2744,"activeCount":101},[],{"trials":2746,"activeCount":101},[],{"trials":2748,"activeCount":101},[],{"trials":2750,"activeCount":140,"soonestReadout":2755},[2751],{"nctId":2752,"briefTitle":2753,"status":338,"phases":2754,"primaryCompletion":2755,"completion":1500,"start":2756,"enrollment":2609,"conditions":2757,"interventions":2758},"NCT07008222","Pain Related to Local Anesthetic Administration for Nexplanon Placement",[93],"2026-01","2025-06",[2753],[2737],{"intervention":51,"totalTrials":140,"cells":2760},{"EARLY_PHASE1":2761,"PHASE1":2763,"PHASE2":2765,"PHASE3":2767,"PHASE4":2769,"NA":2771},{"trials":2762,"activeCount":101},[],{"trials":2764,"activeCount":101},[],{"trials":2766,"activeCount":101},[],{"trials":2768,"activeCount":101},[],{"trials":2770,"activeCount":101},[],{"trials":2772,"activeCount":140,"soonestReadout":50},[2773],{"nctId":48,"briefTitle":49,"status":130,"phases":2774,"primaryCompletion":50,"completion":50,"start":2775,"enrollment":1764,"conditions":2776,"interventions":2778},[93],"2020-07-08",[2777],"Osteo Arthritis Knee",[51],{"intervention":2780,"totalTrials":140,"cells":2781},"recombinant FSH",{"EARLY_PHASE1":2782,"PHASE1":2784,"PHASE2":2786,"PHASE3":2788,"PHASE4":2790,"NA":2792},{"trials":2783,"activeCount":101},[],{"trials":2785,"activeCount":101},[],{"trials":2787,"activeCount":101},[],{"trials":2789,"activeCount":101},[],{"trials":2791,"activeCount":101},[],{"trials":2793,"activeCount":140,"soonestReadout":236},[2794],{"nctId":2795,"briefTitle":2796,"status":406,"phases":2797,"primaryCompletion":236,"completion":236,"start":2798,"enrollment":16,"conditions":2799,"interventions":2802},"NCT01421095","Ovarian Reserve Testing in Female Young Adult Cancer Survivors",[93],"2011-01-01",[2800,2801],"Cancer","Infertility",[2780],{"intervention":41,"totalTrials":140,"cells":2804},{"EARLY_PHASE1":2805,"PHASE1":2807,"PHASE2":2809,"PHASE3":2811,"PHASE4":2813,"NA":2815},{"trials":2806,"activeCount":101},[],{"trials":2808,"activeCount":101},[],{"trials":2810,"activeCount":101},[],{"trials":2812,"activeCount":101},[],{"trials":2814,"activeCount":101},[],{"trials":2816,"activeCount":140,"soonestReadout":40},[2817],{"nctId":38,"briefTitle":39,"status":406,"phases":2818,"primaryCompletion":40,"completion":2819,"start":2820,"enrollment":1587,"conditions":2821,"interventions":2824},[93],"2022-04","2018-11-08",[2822,2823],"Efficacy","Safety Issues",[41],{"intervention":2826,"totalTrials":140,"cells":2827},"COVID-19 Exposure",{"EARLY_PHASE1":2828,"PHASE1":2830,"PHASE2":2832,"PHASE3":2834,"PHASE4":2836,"NA":2838},{"trials":2829,"activeCount":101},[],{"trials":2831,"activeCount":101},[],{"trials":2833,"activeCount":101},[],{"trials":2835,"activeCount":101},[],{"trials":2837,"activeCount":101},[],{"trials":2839,"activeCount":140,"soonestReadout":2844},[2840],{"nctId":2841,"briefTitle":2842,"status":130,"phases":2843,"primaryCompletion":2844,"completion":2844,"start":2845,"enrollment":2846,"conditions":2847,"interventions":2853},"NCT05553743","Researchers At UC San Diego Are Learning About the Benefits of Human Milk and How It Influences Infant and Child Health",[],"2040-03","2014-03-27",5000,[2848,2849,2850,2851,2852],"Breastfeeding","COVID-19 Infection","COVID-19 Vaccine","Remdesivir","Antibiotics",[2826,2854],"Antibiotic",{"intervention":2854,"totalTrials":140,"cells":2856},{"EARLY_PHASE1":2857,"PHASE1":2859,"PHASE2":2861,"PHASE3":2863,"PHASE4":2865,"NA":2867},{"trials":2858,"activeCount":101},[],{"trials":2860,"activeCount":101},[],{"trials":2862,"activeCount":101},[],{"trials":2864,"activeCount":101},[],{"trials":2866,"activeCount":101},[],{"trials":2868,"activeCount":140,"soonestReadout":2844},[2869],{"nctId":2841,"briefTitle":2842,"status":130,"phases":2870,"primaryCompletion":2844,"completion":2844,"start":2845,"enrollment":2846,"conditions":2871,"interventions":2872},[],[2848,2849,2850,2851,2852],[2826,2854],{"intervention":2874,"totalTrials":140,"cells":2875},"Tralokinumab",{"EARLY_PHASE1":2876,"PHASE1":2878,"PHASE2":2880,"PHASE3":2882,"PHASE4":2884,"NA":2886},{"trials":2877,"activeCount":101},[],{"trials":2879,"activeCount":101},[],{"trials":2881,"activeCount":101},[],{"trials":2883,"activeCount":101},[],{"trials":2885,"activeCount":101},[],{"trials":2887,"activeCount":140,"soonestReadout":2892},[2888],{"nctId":2889,"briefTitle":2890,"status":130,"phases":2891,"primaryCompletion":2892,"completion":2893,"start":2894,"enrollment":2895,"conditions":2896,"interventions":2899},"NCT05938478","Monitoring Pregnancy and Infant Outcomes Following Tralokinumab Exposure During Pregnancy in the US and Canada - PROTECT",[],"2034-11-30","2035-09-30","2022-12-08",900,[2897,2898],"Atopic Dermatitis","Eczema",[2874],{"intervention":71,"totalTrials":140,"cells":2901},{"EARLY_PHASE1":2902,"PHASE1":2904,"PHASE2":2906,"PHASE3":2908,"PHASE4":2910,"NA":2912},{"trials":2903,"activeCount":101},[],{"trials":2905,"activeCount":101},[],{"trials":2907,"activeCount":101},[],{"trials":2909,"activeCount":101},[],{"trials":2911,"activeCount":101},[],{"trials":2913,"activeCount":140,"soonestReadout":70},[2914],{"nctId":68,"briefTitle":69,"status":406,"phases":2915,"primaryCompletion":70,"completion":2916,"start":2917,"enrollment":2918,"conditions":2919,"interventions":2920},[],"2025-07","2014-11",233,[2665,2674],[71],{"intervention":2621,"totalTrials":140,"cells":2922},{"EARLY_PHASE1":2923,"PHASE1":2925,"PHASE2":2927,"PHASE3":2929,"PHASE4":2931,"NA":2933},{"trials":2924,"activeCount":101},[],{"trials":2926,"activeCount":101},[],{"trials":2928,"activeCount":101},[],{"trials":2930,"activeCount":101},[],{"trials":2932,"activeCount":101},[],{"trials":2934,"activeCount":140,"soonestReadout":160},[2935],{"nctId":2614,"briefTitle":2615,"status":130,"phases":2936,"primaryCompletion":160,"completion":2608,"start":311,"enrollment":2617,"conditions":2937,"interventions":2938},[93],[32,2510,435],[2620,2621,2590,2612],{"intervention":2678,"totalTrials":140,"cells":2940},{"EARLY_PHASE1":2941,"PHASE1":2943,"PHASE2":2945,"PHASE3":2947,"PHASE4":2949,"NA":2951},{"trials":2942,"activeCount":101},[],{"trials":2944,"activeCount":101},[],{"trials":2946,"activeCount":101},[],{"trials":2948,"activeCount":101},[],{"trials":2950,"activeCount":101},[],{"trials":2952,"activeCount":140,"soonestReadout":2671},[2953],{"nctId":2668,"briefTitle":2669,"status":130,"phases":2954,"primaryCompletion":2671,"completion":1120,"start":2672,"enrollment":1038,"conditions":2955,"interventions":2956},[],[2674,2675,2665,2676],[2678,2645],{"intervention":2958,"totalTrials":1024,"cells":2959},"Nicotine Patches",{"EARLY_PHASE1":2960,"PHASE1":2962,"PHASE2":2964,"PHASE3":2966,"PHASE4":2997,"NA":3008},{"trials":2961,"activeCount":101},[],{"trials":2963,"activeCount":101},[],{"trials":2965,"activeCount":101},[],{"trials":2967,"activeCount":101},[2968,2979,2988],{"nctId":2969,"briefTitle":2970,"status":113,"phases":2971,"primaryCompletion":2972,"completion":2973,"start":2974,"enrollment":2975,"conditions":2976,"interventions":2978},"NCT01287377","Smoking Cessation With the Nicotine Patch: A Pilot Study of Patch Messaging",[91],"2011-05","2011-11","2010-11",243,[2977],"Smoking Cessation",[2958],{"nctId":2980,"briefTitle":2981,"status":113,"phases":2982,"primaryCompletion":2917,"completion":2917,"start":2983,"enrollment":2984,"conditions":2985,"interventions":2986},"NCT01736085","Providing Free Nicotine Patches to Quitline Smokers",[91],"2013-04",3706,[2977],[2987],"Nicotine patches",{"nctId":2989,"briefTitle":2990,"status":113,"phases":2991,"primaryCompletion":2992,"completion":2992,"start":2993,"enrollment":2994,"conditions":2995,"interventions":2996},"NCT01502306","A Randomized Trial of Medi-Cal Beneficiaries Calling the California Smokers' Helpline",[91],"2014-02","2012-06",3816,[2977],[2987],{"trials":2998,"activeCount":101},[2999],{"nctId":3000,"briefTitle":3001,"status":113,"phases":3002,"primaryCompletion":3003,"completion":3003,"start":3004,"enrollment":3005,"conditions":3006,"interventions":3007},"NCT01289275","Smoking Cessation in Hospitalized Smokers",[92],"2014-07","2011-08",1270,[2977],[2958],{"trials":3009,"activeCount":101},[],{"intervention":3011,"totalTrials":1024,"cells":3012},"Memantine",{"EARLY_PHASE1":3013,"PHASE1":3015,"PHASE2":3017,"PHASE3":3025,"PHASE4":3037,"NA":3060},{"trials":3014,"activeCount":101},[],{"trials":3016,"activeCount":101},[],{"trials":3018,"activeCount":101},[3019],{"nctId":3020,"briefTitle":3021,"status":113,"phases":3022,"primaryCompletion":116,"completion":116,"start":3003,"enrollment":608,"conditions":3023,"interventions":3024},"NCT01555697","Biomarker Strategies for Medication-Enhanced Cognitive Training in Schizophrenia",[89,90],[21],[3011],{"trials":3026,"activeCount":101},[3027],{"nctId":3028,"briefTitle":3029,"status":113,"phases":3030,"primaryCompletion":3031,"completion":3031,"start":3032,"enrollment":3033,"conditions":3034,"interventions":3036},"NCT04857983","Memantine Augmentation of Targeted Cognitive Training in Schizophrenia",[90,91],"2025-03-30","2021-07-06",62,[21,3035],"Schizoaffective Disorder",[3011],{"trials":3038,"activeCount":101},[3039,3049],{"nctId":3040,"briefTitle":3041,"status":113,"phases":3042,"primaryCompletion":3043,"completion":3043,"start":3044,"enrollment":1306,"conditions":3045,"interventions":3048},"NCT03860597","Memantine Effects on Sensorimotor Gating and Neurocognition in Schizophrenia",[92],"2021-03-31","2018-04-01",[21,3046,3035,3047],"Schizo Affective Disorder","Healthy",[3011,1295],{"nctId":3050,"briefTitle":3051,"status":113,"phases":3052,"primaryCompletion":3053,"completion":3054,"start":3055,"enrollment":3056,"conditions":3057,"interventions":3059},"NCT03703856","Biomarker Predictors of Memantine Sensitivity in Patients With Alzheimer's Disease",[92],"2025-01-08","2025-12-30","2019-01-31",53,[3058],"Alzheimer Disease",[3011],{"trials":3061,"activeCount":101},[],{"intervention":3063,"totalTrials":1149,"cells":3064},"Ezetimibe",{"EARLY_PHASE1":3065,"PHASE1":3067,"PHASE2":3069,"PHASE3":3081,"PHASE4":3095,"NA":3105},{"trials":3066,"activeCount":101},[],{"trials":3068,"activeCount":101},[],{"trials":3070,"activeCount":101},[3071],{"nctId":3072,"briefTitle":3073,"status":113,"phases":3074,"primaryCompletion":3075,"completion":3076,"start":3077,"enrollment":2117,"conditions":3078,"interventions":3080},"NCT01766713","Ezetimibe Versus Placebo in the Treatment of Non-alcoholic Steatohepatitis",[90],"2014-08","2014-09","2013-01",[3079],"Non Alcoholic Steatohepatitis",[3063],{"trials":3082,"activeCount":101},[3083],{"nctId":3084,"briefTitle":3085,"status":1066,"phases":3086,"primaryCompletion":3087,"completion":3088,"start":3089,"enrollment":97,"conditions":3090,"interventions":3093},"NCT00965055","Ezetimibe in Patients Hypo-responsive to Statins",[91],"2011-09","2012-09","2009-09",[3091,3092],"High Cholesterol","Coronary Artery Disease",[3063,3094],"Atorvastatin",{"trials":3096,"activeCount":101},[3097],{"nctId":3098,"briefTitle":3099,"status":113,"phases":3100,"primaryCompletion":3101,"completion":3101,"start":1058,"enrollment":1587,"conditions":3102,"interventions":3104},"NCT00376246","Effect of Ezetimibe on Flow-mediated Brachial Artery Reactivity in Healthy Subjects",[92],"2008-04",[3103],"Endothelial Dysfunction",[3063],{"trials":3106,"activeCount":101},[],{"intervention":1295,"totalTrials":1149,"cells":3108},{"EARLY_PHASE1":3109,"PHASE1":3115,"PHASE2":3117,"PHASE3":3132,"PHASE4":3134,"NA":3140},{"trials":3110,"activeCount":101},[3111],{"nctId":1286,"briefTitle":1287,"status":1066,"phases":3112,"primaryCompletion":1289,"completion":1289,"start":1290,"enrollment":30,"conditions":3113,"interventions":3114},[88],[1292],[1294,1281,1295],{"trials":3116,"activeCount":101},[],{"trials":3118,"activeCount":101},[3119],{"nctId":3120,"briefTitle":3121,"status":113,"phases":3122,"primaryCompletion":3123,"completion":3123,"start":3124,"enrollment":3125,"conditions":3126,"interventions":3129},"NCT02460692","Trial of Dronabinol and Vaporized Cannabis in Chronic Low Back Pain",[90],"2020-03-25","2016-12",131,[976,3127,3128],"Low Back Pain","Neuropathic Pain",[1295,3130,3131],"dronabinol","Vaporized Cannabis 3.7% THC\u002F5.6% CBD",{"trials":3133,"activeCount":101},[],{"trials":3135,"activeCount":101},[3136],{"nctId":3040,"briefTitle":3041,"status":113,"phases":3137,"primaryCompletion":3043,"completion":3043,"start":3044,"enrollment":1306,"conditions":3138,"interventions":3139},[92],[21,3046,3035,3047],[3011,1295],{"trials":3141,"activeCount":101},[],{"intervention":3143,"totalTrials":1149,"cells":3144},"Ranibizumab",{"EARLY_PHASE1":3145,"PHASE1":3147,"PHASE2":3159,"PHASE3":3161,"PHASE4":3171,"NA":3182},{"trials":3146,"activeCount":101},[],{"trials":3148,"activeCount":101},[3149],{"nctId":3150,"briefTitle":3151,"status":1160,"phases":3152,"primaryCompletion":3153,"completion":3153,"start":3154,"enrollment":101,"conditions":3155,"interventions":3158},"NCT01406639","Ranibizumab for the Management of Recurrent Nosebleeds in Patients With Hereditary Hemorrhagic Telangiectasia (HHT)",[89],"2012-05","2011-07",[3156,3157],"Hereditary Hemorrhagic Telangiectasia (HHT)","Nosebleeds",[3143],{"trials":3160,"activeCount":101},[],{"trials":3162,"activeCount":101},[3163],{"nctId":3164,"briefTitle":3165,"status":1066,"phases":3166,"primaryCompletion":117,"completion":117,"start":3154,"enrollment":27,"conditions":3167,"interventions":3169},"NCT01402544","Clinical Assessment Of Age-related Macular Degeneration Patients After Early Diagnosis and Treatment With Ranibizumab",[90,91],[3168],"Age-Related Macular Degeneration",[3170],"ranibizumab",{"trials":3172,"activeCount":101},[3173],{"nctId":3174,"briefTitle":3175,"status":113,"phases":3176,"primaryCompletion":3177,"completion":3077,"start":3178,"enrollment":3179,"conditions":3180,"interventions":3181},"NCT01464723","Study EvAluating Genotypes While Using Lucentis 2",[92],"2011-12","2008-05",66,[3168],[3143],{"trials":3183,"activeCount":101},[],{"intervention":3185,"totalTrials":97,"cells":3186},"Nebivolol",{"EARLY_PHASE1":3187,"PHASE1":3189,"PHASE2":3191,"PHASE3":3193,"PHASE4":3195,"NA":3215},{"trials":3188,"activeCount":101},[],{"trials":3190,"activeCount":101},[],{"trials":3192,"activeCount":101},[],{"trials":3194,"activeCount":101},[],{"trials":3196,"activeCount":101},[3197,3206],{"nctId":3198,"briefTitle":3199,"status":113,"phases":3200,"primaryCompletion":2993,"completion":3201,"start":3202,"enrollment":2117,"conditions":3203,"interventions":3205},"NCT01202175","Effects of the Beta-blocker Nebivolol (Bystolic) on Subjects With High Normal Blood Pressure and\u002For a Family History of Hypertension",[92],"2013-06","2010-07",[3204,344],"Pre-hypertension",[3185],{"nctId":3207,"briefTitle":3208,"status":113,"phases":3209,"primaryCompletion":3210,"completion":3210,"start":1133,"enrollment":3211,"conditions":3212,"interventions":3213},"NCT02710071","Treatment of OSA Associated Hypertension With Nebivolol or Hydrochlorothiazide",[92],"2016-04",41,[344],[3185,3214],"Hydrochlorothiazide",{"trials":3216,"activeCount":101},[],{"intervention":3218,"totalTrials":97,"cells":3219},"Paravertebral block",{"EARLY_PHASE1":3220,"PHASE1":3222,"PHASE2":3224,"PHASE3":3226,"PHASE4":3228,"NA":3251},{"trials":3221,"activeCount":101},[],{"trials":3223,"activeCount":101},[],{"trials":3225,"activeCount":101},[],{"trials":3227,"activeCount":101},[],{"trials":3229,"activeCount":101},[3230,3241],{"nctId":3231,"briefTitle":3232,"status":113,"phases":3233,"primaryCompletion":3234,"completion":3235,"start":3236,"enrollment":283,"conditions":3237,"interventions":3239},"NCT03860974","Serratus Plane Versus Paravertebral Nerve Blocks for Breast Surgery",[92],"2021-02-12","2021-02-13","2019-05-09",[3238],"Breast Surgery",[3240,3218],"Serratus Plane block",{"nctId":3242,"briefTitle":3243,"status":113,"phases":3244,"primaryCompletion":3245,"completion":3245,"start":3246,"enrollment":3247,"conditions":3248,"interventions":3249},"NCT04742309","Pectoralis Block vs Paravertebral Nerve Blocks for Breast Surgery",[92],"2023-08-31","2021-02-25",119,[3238],[3250,3218],"Pecs-2 block",{"trials":3252,"activeCount":101},[],{"intervention":3214,"totalTrials":97,"cells":3254},{"EARLY_PHASE1":3255,"PHASE1":3257,"PHASE2":3259,"PHASE3":3261,"PHASE4":3263,"NA":3278},{"trials":3256,"activeCount":101},[],{"trials":3258,"activeCount":101},[],{"trials":3260,"activeCount":101},[],{"trials":3262,"activeCount":101},[],{"trials":3264,"activeCount":101},[3265,3269],{"nctId":3207,"briefTitle":3208,"status":113,"phases":3266,"primaryCompletion":3210,"completion":3210,"start":1133,"enrollment":3211,"conditions":3267,"interventions":3268},[92],[344],[3185,3214],{"nctId":3270,"briefTitle":3271,"status":113,"phases":3272,"primaryCompletion":3273,"completion":3274,"start":1133,"enrollment":3211,"conditions":3275,"interventions":3276},"NCT02699125","Treatment of OSA Associated Hypertension With Alpha 2 Agonist or Diuretic",[92],"2016-06","2016-08",[18],[3277,3214],"Guanfacine",{"trials":3279,"activeCount":101},[],{"intervention":1106,"totalTrials":97,"cells":3281},{"EARLY_PHASE1":3282,"PHASE1":3284,"PHASE2":3286,"PHASE3":3292,"PHASE4":3294,"NA":3304},{"trials":3283,"activeCount":101},[],{"trials":3285,"activeCount":101},[],{"trials":3287,"activeCount":101},[3288],{"nctId":1085,"briefTitle":1086,"status":1066,"phases":3289,"primaryCompletion":1088,"completion":1088,"start":1089,"enrollment":1090,"conditions":3290,"interventions":3291},[90],[1092,1093],[1095,1096,1097,1098,1099,1100,1101,1102,1103,1104,1105,1076,1106],{"trials":3293,"activeCount":101},[],{"trials":3295,"activeCount":101},[3296],{"nctId":3297,"briefTitle":3298,"status":1160,"phases":3299,"primaryCompletion":3087,"completion":3087,"start":3300,"enrollment":101,"conditions":3301,"interventions":3303},"NCT00706173","Trial of Hydrocortisone for Post-Traumatic Stress Disorder (PTSD)",[92],"2009-08",[3302],"Post-traumatic Stress Disorder",[1106],{"trials":3305,"activeCount":101},[],{"intervention":924,"totalTrials":97,"cells":3307},{"EARLY_PHASE1":3308,"PHASE1":3310,"PHASE2":3312,"PHASE3":3318,"PHASE4":3320,"NA":3330},{"trials":3309,"activeCount":101},[],{"trials":3311,"activeCount":101},[],{"trials":3313,"activeCount":101},[3314],{"nctId":915,"briefTitle":916,"status":113,"phases":3315,"primaryCompletion":918,"completion":918,"start":919,"enrollment":27,"conditions":3316,"interventions":3317},[90],[921,18],[874,923,924],{"trials":3319,"activeCount":101},[],{"trials":3321,"activeCount":101},[3322],{"nctId":3323,"briefTitle":3324,"status":113,"phases":3325,"primaryCompletion":3326,"completion":3326,"start":3327,"enrollment":27,"conditions":3328,"interventions":3329},"NCT02714400","The Impact of Venlafaxine on Apnea Hypopnea Index in Obstructive Sleep Apnea",[92],"2016-07","2016-03",[18],[924],{"trials":3331,"activeCount":101},[],{"intervention":3333,"totalTrials":97,"cells":3334},"Bolus",{"EARLY_PHASE1":3335,"PHASE1":3337,"PHASE2":3339,"PHASE3":3341,"PHASE4":3343,"NA":3362},{"trials":3336,"activeCount":101},[],{"trials":3338,"activeCount":101},[],{"trials":3340,"activeCount":101},[],{"trials":3342,"activeCount":101},[],{"trials":3344,"activeCount":101},[3345,3354],{"nctId":3346,"briefTitle":3347,"status":113,"phases":3348,"primaryCompletion":3273,"completion":3273,"start":3349,"enrollment":22,"conditions":3350,"interventions":3352},"NCT02662023","Continuous TAP Blocks: Relative Effects of a Basal Infusion vs. Repeated Bolus Doses",[92],"2016-02",[3351],"Postoperative Pain",[3333,3353],"Basal",{"nctId":3355,"briefTitle":3356,"status":113,"phases":3357,"primaryCompletion":3358,"completion":3358,"start":3075,"enrollment":22,"conditions":3359,"interventions":3361},"NCT02219438","Continuous Adductor Canal Nerve Blocks: Relative Effects of a Basal Infusion v. Hourly Bolus Doses",[92],"2014-12",[3360],"Healthy Human Volunteers",[3333,3353],{"trials":3363,"activeCount":101},[],{"intervention":3353,"totalTrials":97,"cells":3365},{"EARLY_PHASE1":3366,"PHASE1":3368,"PHASE2":3370,"PHASE3":3372,"PHASE4":3374,"NA":3384},{"trials":3367,"activeCount":101},[],{"trials":3369,"activeCount":101},[],{"trials":3371,"activeCount":101},[],{"trials":3373,"activeCount":101},[],{"trials":3375,"activeCount":101},[3376,3380],{"nctId":3346,"briefTitle":3347,"status":113,"phases":3377,"primaryCompletion":3273,"completion":3273,"start":3349,"enrollment":22,"conditions":3378,"interventions":3379},[92],[3351],[3333,3353],{"nctId":3355,"briefTitle":3356,"status":113,"phases":3381,"primaryCompletion":3358,"completion":3358,"start":3075,"enrollment":22,"conditions":3382,"interventions":3383},[92],[3360],[3333,3353],{"trials":3385,"activeCount":101},[],{"intervention":3387,"totalTrials":140,"cells":3388},"Duloxetine",{"EARLY_PHASE1":3389,"PHASE1":3391,"PHASE2":3393,"PHASE3":3395,"PHASE4":3397,"NA":3406},{"trials":3390,"activeCount":101},[],{"trials":3392,"activeCount":101},[],{"trials":3394,"activeCount":101},[],{"trials":3396,"activeCount":101},[],{"trials":3398,"activeCount":101},[3399],{"nctId":3400,"briefTitle":3401,"status":1160,"phases":3402,"primaryCompletion":1133,"completion":1133,"start":2993,"enrollment":101,"conditions":3403,"interventions":3405},"NCT01619566","Cymbalta for Fibromyalgia Pain - Predictive Value of Small Fiber Changed",[92],[3404],"Fibromyalgia",[3387],{"trials":3407,"activeCount":101},[],{"intervention":3409,"totalTrials":140,"cells":3410},"Maraviroc",{"EARLY_PHASE1":3411,"PHASE1":3413,"PHASE2":3415,"PHASE3":3417,"PHASE4":3419,"NA":3431},{"trials":3412,"activeCount":101},[],{"trials":3414,"activeCount":101},[],{"trials":3416,"activeCount":101},[],{"trials":3418,"activeCount":101},[],{"trials":3420,"activeCount":101},[3421],{"nctId":3422,"briefTitle":3423,"status":113,"phases":3424,"primaryCompletion":3425,"completion":3426,"start":3427,"enrollment":1879,"conditions":3428,"interventions":3430},"NCT00925756","CCR5 Inhibitor Treatment Intensification on CD4+ T-cell Recovery",[92],"2012-05-02","2014-04-11","2008-10-20",[3429],"HIV Infections",[3409],{"trials":3432,"activeCount":101},[],{"intervention":3434,"totalTrials":140,"cells":3435},"Pregabalin 50mg",{"EARLY_PHASE1":3436,"PHASE1":3438,"PHASE2":3440,"PHASE3":3442,"PHASE4":3444,"NA":3454},{"trials":3437,"activeCount":101},[],{"trials":3439,"activeCount":101},[],{"trials":3441,"activeCount":101},[],{"trials":3443,"activeCount":101},[],{"trials":3445,"activeCount":101},[3446],{"nctId":3447,"briefTitle":3448,"status":113,"phases":3449,"primaryCompletion":1068,"completion":1068,"start":1111,"enrollment":3450,"conditions":3451,"interventions":3452},"NCT00706836","PharmacofMRI of Anxiolytic Medications (Pregabalin)",[92],16,[1950],[3434,3453],"Pregabalin 200 MG",{"trials":3455,"activeCount":101},[],{"intervention":3453,"totalTrials":140,"cells":3457},{"EARLY_PHASE1":3458,"PHASE1":3460,"PHASE2":3462,"PHASE3":3464,"PHASE4":3466,"NA":3472},{"trials":3459,"activeCount":101},[],{"trials":3461,"activeCount":101},[],{"trials":3463,"activeCount":101},[],{"trials":3465,"activeCount":101},[],{"trials":3467,"activeCount":101},[3468],{"nctId":3447,"briefTitle":3448,"status":113,"phases":3469,"primaryCompletion":1068,"completion":1068,"start":1111,"enrollment":3450,"conditions":3470,"interventions":3471},[92],[1950],[3434,3453],{"trials":3473,"activeCount":101},[],{"intervention":3475,"totalTrials":140,"cells":3476},"Febuxostat",{"EARLY_PHASE1":3477,"PHASE1":3479,"PHASE2":3481,"PHASE3":3483,"PHASE4":3485,"NA":3500},{"trials":3478,"activeCount":101},[],{"trials":3480,"activeCount":101},[],{"trials":3482,"activeCount":101},[],{"trials":3484,"activeCount":101},[],{"trials":3486,"activeCount":101},[3487],{"nctId":3488,"briefTitle":3489,"status":113,"phases":3490,"primaryCompletion":3491,"completion":3491,"start":3492,"enrollment":3493,"conditions":3494,"interventions":3499},"NCT01472692","Study of Febuxostat Effect on Blood Pressure in Patients With High Normal Blood Pressure",[92],"2014-03","2011-10",47,[3495,3496,3497,344,3498],"Prehypertension","Gout","Pulse Wave Velocity","24 Hour Blood Pressure",[3475],{"trials":3501,"activeCount":101},[],{"intervention":3503,"totalTrials":140,"cells":3504},"Depo Medroxyprogesterone acetate",{"EARLY_PHASE1":3505,"PHASE1":3507,"PHASE2":3509,"PHASE3":3511,"PHASE4":3513,"NA":3527},{"trials":3506,"activeCount":101},[],{"trials":3508,"activeCount":101},[],{"trials":3510,"activeCount":101},[],{"trials":3512,"activeCount":101},[],{"trials":3514,"activeCount":101},[3515],{"nctId":3516,"briefTitle":3517,"status":113,"phases":3518,"primaryCompletion":3519,"completion":3519,"start":3520,"enrollment":386,"conditions":3521,"interventions":3526},"NCT06816901","Measuring Lactation Initiation After Early Postpartum Injectable Progestin (DMPA) Use Among Women in Dhanusha District of Nepal: A Pilot Study",[92],"2025-07-31","2025-03-26",[3522,3523,3524,3525],"Postpartum Contraception","Depot Medroxyprogesterone Acetate","Lactation","DMPA",[3503],{"trials":3528,"activeCount":101},[],{"intervention":3530,"totalTrials":140,"cells":3531},"Intercostal nerve block ropivacaine with epinephrine",{"EARLY_PHASE1":3532,"PHASE1":3534,"PHASE2":3536,"PHASE3":3538,"PHASE4":3540,"NA":3552},{"trials":3533,"activeCount":101},[],{"trials":3535,"activeCount":101},[],{"trials":3537,"activeCount":101},[],{"trials":3539,"activeCount":101},[],{"trials":3541,"activeCount":101},[3542],{"nctId":3543,"briefTitle":3544,"status":113,"phases":3545,"primaryCompletion":3546,"completion":3547,"start":3548,"enrollment":27,"conditions":3549,"interventions":3551},"NCT04198662","Rib Fracture Analgesia Using Cryoanalgesia",[92],"2023-08-28","2024-08-27","2020-04-03",[3550],"Traumatic Rib Fracture(s)",[3530],{"trials":3553,"activeCount":101},[],{"intervention":3555,"totalTrials":140,"cells":3556},"0.1% and 0.4% perineural ropivicaine",{"EARLY_PHASE1":3557,"PHASE1":3559,"PHASE2":3561,"PHASE3":3563,"PHASE4":3565,"NA":3576},{"trials":3558,"activeCount":101},[],{"trials":3560,"activeCount":101},[],{"trials":3562,"activeCount":101},[],{"trials":3564,"activeCount":101},[],{"trials":3566,"activeCount":101},[3567],{"nctId":3568,"briefTitle":3569,"status":113,"phases":3570,"primaryCompletion":3571,"completion":3571,"start":3572,"enrollment":1123,"conditions":3573,"interventions":3575},"NCT00923598","Optimizing Local Anesthetic Concentration for Continuous Femoral Nerve Blocks",[92],"2011-04","2009-06",[137,3574],"Knee Pain",[3555],{"trials":3577,"activeCount":101},[],{"intervention":2729,"totalTrials":140,"cells":3579},{"EARLY_PHASE1":3580,"PHASE1":3582,"PHASE2":3584,"PHASE3":3586,"PHASE4":3588,"NA":3594},{"trials":3581,"activeCount":101},[],{"trials":3583,"activeCount":101},[],{"trials":3585,"activeCount":101},[],{"trials":3587,"activeCount":101},[],{"trials":3589,"activeCount":101},[3590],{"nctId":2717,"briefTitle":2718,"status":113,"phases":3591,"primaryCompletion":2720,"completion":2720,"start":2721,"enrollment":2722,"conditions":3592,"interventions":3593},[92],[2724,2725,2726,210,2727],[2729,2699],{"trials":3595,"activeCount":101},[],{"intervention":3597,"totalTrials":140,"cells":3598},"40 mg Pravastatin",{"EARLY_PHASE1":3599,"PHASE1":3601,"PHASE2":3603,"PHASE3":3605,"PHASE4":3607,"NA":3620},{"trials":3600,"activeCount":101},[],{"trials":3602,"activeCount":101},[],{"trials":3604,"activeCount":101},[],{"trials":3606,"activeCount":101},[],{"trials":3608,"activeCount":101},[3609],{"nctId":3610,"briefTitle":3611,"status":113,"phases":3612,"primaryCompletion":3613,"completion":3613,"start":3614,"enrollment":3615,"conditions":3616,"interventions":3618},"NCT00330980","Effects of Statin Medications on Mental Processes, Behavior, and Serotonin Levels",[92],"2004-03","2000-04",1000,[3617],"Dyslipidemias",[3597,3619],"20 mg Simvastatin",{"trials":3621,"activeCount":101},[],{"intervention":3619,"totalTrials":140,"cells":3623},{"EARLY_PHASE1":3624,"PHASE1":3626,"PHASE2":3628,"PHASE3":3630,"PHASE4":3632,"NA":3638},{"trials":3625,"activeCount":101},[],{"trials":3627,"activeCount":101},[],{"trials":3629,"activeCount":101},[],{"trials":3631,"activeCount":101},[],{"trials":3633,"activeCount":101},[3634],{"nctId":3610,"briefTitle":3611,"status":113,"phases":3635,"primaryCompletion":3613,"completion":3613,"start":3614,"enrollment":3615,"conditions":3636,"interventions":3637},[92],[3617],[3597,3619],{"trials":3639,"activeCount":101},[],{"intervention":3641,"totalTrials":140,"cells":3642},"Intravenous acetaminophen",{"EARLY_PHASE1":3643,"PHASE1":3645,"PHASE2":3647,"PHASE3":3649,"PHASE4":3651,"NA":3661},{"trials":3644,"activeCount":101},[],{"trials":3646,"activeCount":101},[],{"trials":3648,"activeCount":101},[],{"trials":3650,"activeCount":101},[],{"trials":3652,"activeCount":101},[3653],{"nctId":3654,"briefTitle":3655,"status":1160,"phases":3656,"enrollment":101,"conditions":3657,"interventions":3659},"NCT01231191","A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Relationship Between Intraoperative Intravenous Acetaminophen and Postoperative Opioid Avoidance for Ambulatory Surgical Procedures",[92],[3351,3658],"Intraoperative and Postoperative Opioid Requirements",[3641,3660],"Intravenous placebo",{"trials":3662,"activeCount":101},[],{"intervention":3660,"totalTrials":140,"cells":3664},{"EARLY_PHASE1":3665,"PHASE1":3667,"PHASE2":3669,"PHASE3":3671,"PHASE4":3673,"NA":3679},{"trials":3666,"activeCount":101},[],{"trials":3668,"activeCount":101},[],{"trials":3670,"activeCount":101},[],{"trials":3672,"activeCount":101},[],{"trials":3674,"activeCount":101},[3675],{"nctId":3654,"briefTitle":3655,"status":1160,"phases":3676,"enrollment":101,"conditions":3677,"interventions":3678},[92],[3351,3658],[3641,3660],{"trials":3680,"activeCount":101},[],{"intervention":3682,"totalTrials":140,"cells":3683},"Active bupivacaine 0.25% via an erector spinae plane perineural catheter",{"EARLY_PHASE1":3684,"PHASE1":3686,"PHASE2":3688,"PHASE3":3690,"PHASE4":3692,"NA":3704},{"trials":3685,"activeCount":101},[],{"trials":3687,"activeCount":101},[],{"trials":3689,"activeCount":101},[],{"trials":3691,"activeCount":101},[],{"trials":3693,"activeCount":101},[3694],{"nctId":3695,"briefTitle":3696,"status":113,"phases":3697,"primaryCompletion":3698,"completion":3699,"start":3700,"enrollment":2117,"conditions":3701,"interventions":3703},"NCT05121168","Continuous Erector Spinae Plane Blocks to Treat Pain Following Percutaneous Nephrolithotomy",[92],"2025-11-06","2025-11-08","2022-03-16",[240,3702],"Renal Stone",[3682],{"trials":3705,"activeCount":101},[],{"intervention":3707,"totalTrials":140,"cells":3708},"Doxycycline",{"EARLY_PHASE1":3709,"PHASE1":3711,"PHASE2":3713,"PHASE3":3715,"PHASE4":3717,"NA":3727},{"trials":3710,"activeCount":101},[],{"trials":3712,"activeCount":101},[],{"trials":3714,"activeCount":101},[],{"trials":3716,"activeCount":101},[],{"trials":3718,"activeCount":101},[3719],{"nctId":3720,"briefTitle":3721,"status":113,"phases":3722,"primaryCompletion":3723,"completion":3723,"start":3724,"enrollment":9,"conditions":3725,"interventions":3726},"NCT01375491","Examination of the Anti-inflammatory and Insulin Sensitizing Properties of Doxycycline in Humans",[92],"2011-06","2009-10",[964,15],[3707],{"trials":3728,"activeCount":101},[],{"intervention":123,"totalTrials":140,"cells":3730},{"EARLY_PHASE1":3731,"PHASE1":3733,"PHASE2":3735,"PHASE3":3737,"PHASE4":3739,"NA":3745},{"trials":3732,"activeCount":101},[],{"trials":3734,"activeCount":101},[],{"trials":3736,"activeCount":101},[],{"trials":3738,"activeCount":101},[],{"trials":3740,"activeCount":101},[3741],{"nctId":111,"briefTitle":112,"status":113,"phases":3742,"primaryCompletion":115,"completion":116,"start":117,"enrollment":118,"conditions":3743,"interventions":3744},[92],[120,121],[123,124,125,96,126],{"trials":3746,"activeCount":101},[],{"intervention":124,"totalTrials":140,"cells":3748},{"EARLY_PHASE1":3749,"PHASE1":3751,"PHASE2":3753,"PHASE3":3755,"PHASE4":3757,"NA":3763},{"trials":3750,"activeCount":101},[],{"trials":3752,"activeCount":101},[],{"trials":3754,"activeCount":101},[],{"trials":3756,"activeCount":101},[],{"trials":3758,"activeCount":101},[3759],{"nctId":111,"briefTitle":112,"status":113,"phases":3760,"primaryCompletion":115,"completion":116,"start":117,"enrollment":118,"conditions":3761,"interventions":3762},[92],[120,121],[123,124,125,96,126],{"trials":3764,"activeCount":101},[],{"intervention":125,"totalTrials":140,"cells":3766},{"EARLY_PHASE1":3767,"PHASE1":3769,"PHASE2":3771,"PHASE3":3773,"PHASE4":3775,"NA":3781},{"trials":3768,"activeCount":101},[],{"trials":3770,"activeCount":101},[],{"trials":3772,"activeCount":101},[],{"trials":3774,"activeCount":101},[],{"trials":3776,"activeCount":101},[3777],{"nctId":111,"briefTitle":112,"status":113,"phases":3778,"primaryCompletion":115,"completion":116,"start":117,"enrollment":118,"conditions":3779,"interventions":3780},[92],[120,121],[123,124,125,96,126],{"trials":3782,"activeCount":101},[],{"intervention":126,"totalTrials":140,"cells":3784},{"EARLY_PHASE1":3785,"PHASE1":3787,"PHASE2":3789,"PHASE3":3791,"PHASE4":3793,"NA":3799},{"trials":3786,"activeCount":101},[],{"trials":3788,"activeCount":101},[],{"trials":3790,"activeCount":101},[],{"trials":3792,"activeCount":101},[],{"trials":3794,"activeCount":101},[3795],{"nctId":111,"briefTitle":112,"status":113,"phases":3796,"primaryCompletion":115,"completion":116,"start":117,"enrollment":118,"conditions":3797,"interventions":3798},[92],[120,121],[123,124,125,96,126],{"trials":3800,"activeCount":101},[],{"intervention":3802,"totalTrials":140,"cells":3803},"zidovudine-lamivudine-nevirapine",{"EARLY_PHASE1":3804,"PHASE1":3806,"PHASE2":3808,"PHASE3":3810,"PHASE4":3812,"NA":3825},{"trials":3805,"activeCount":101},[],{"trials":3807,"activeCount":101},[],{"trials":3809,"activeCount":101},[],{"trials":3811,"activeCount":101},[],{"trials":3813,"activeCount":101},[3814],{"nctId":3815,"briefTitle":3816,"status":113,"phases":3817,"primaryCompletion":3003,"completion":3818,"start":3202,"enrollment":3819,"conditions":3820,"interventions":3823},"NCT01340950","Clinical Trial of Brain-Penetrating HIV Drugs to Prevent Cognitive Impairment in China",[92],"2015-07",250,[3429,3821,3822],"Central Nervous System Diseases","Dementia",[3802,3824],"tenofovir-lamivudine-efavirenz",{"trials":3826,"activeCount":101},[],{"intervention":3824,"totalTrials":140,"cells":3828},{"EARLY_PHASE1":3829,"PHASE1":3831,"PHASE2":3833,"PHASE3":3835,"PHASE4":3837,"NA":3843},{"trials":3830,"activeCount":101},[],{"trials":3832,"activeCount":101},[],{"trials":3834,"activeCount":101},[],{"trials":3836,"activeCount":101},[],{"trials":3838,"activeCount":101},[3839],{"nctId":3815,"briefTitle":3816,"status":113,"phases":3840,"primaryCompletion":3003,"completion":3818,"start":3202,"enrollment":3819,"conditions":3841,"interventions":3842},[92],[3429,3821,3822],[3802,3824],{"trials":3844,"activeCount":101},[],{"intervention":3846,"totalTrials":140,"cells":3847},"Mitomycin-C",{"EARLY_PHASE1":3848,"PHASE1":3850,"PHASE2":3852,"PHASE3":3854,"PHASE4":3856,"NA":3868},{"trials":3849,"activeCount":101},[],{"trials":3851,"activeCount":101},[],{"trials":3853,"activeCount":101},[],{"trials":3855,"activeCount":101},[],{"trials":3857,"activeCount":101},[3858],{"nctId":3859,"briefTitle":3860,"status":113,"phases":3861,"primaryCompletion":3862,"completion":3862,"start":3863,"enrollment":283,"conditions":3864,"interventions":3866},"NCT04352660","Subconjunctival Versus Direct Mitomycin C in Trabeculectomy",[92],"2019-04-14","2016-05-23",[3865],"Open Angle Glaucoma",[3846,3867],"Mitomycin-C sponge",{"trials":3869,"activeCount":101},[],{"intervention":3867,"totalTrials":140,"cells":3871},{"EARLY_PHASE1":3872,"PHASE1":3874,"PHASE2":3876,"PHASE3":3878,"PHASE4":3880,"NA":3886},{"trials":3873,"activeCount":101},[],{"trials":3875,"activeCount":101},[],{"trials":3877,"activeCount":101},[],{"trials":3879,"activeCount":101},[],{"trials":3881,"activeCount":101},[3882],{"nctId":3859,"briefTitle":3860,"status":113,"phases":3883,"primaryCompletion":3862,"completion":3862,"start":3863,"enrollment":283,"conditions":3884,"interventions":3885},[92],[3865],[3846,3867],{"trials":3887,"activeCount":101},[],{"intervention":3240,"totalTrials":140,"cells":3889},{"EARLY_PHASE1":3890,"PHASE1":3892,"PHASE2":3894,"PHASE3":3896,"PHASE4":3898,"NA":3904},{"trials":3891,"activeCount":101},[],{"trials":3893,"activeCount":101},[],{"trials":3895,"activeCount":101},[],{"trials":3897,"activeCount":101},[],{"trials":3899,"activeCount":101},[3900],{"nctId":3231,"briefTitle":3232,"status":113,"phases":3901,"primaryCompletion":3234,"completion":3235,"start":3236,"enrollment":283,"conditions":3902,"interventions":3903},[92],[3238],[3240,3218],{"trials":3905,"activeCount":101},[],{"intervention":3907,"totalTrials":140,"cells":3908},"Conjugated Estrogen Vaginal Cream",{"EARLY_PHASE1":3909,"PHASE1":3911,"PHASE2":3913,"PHASE3":3915,"PHASE4":3917,"NA":3930},{"trials":3910,"activeCount":101},[],{"trials":3912,"activeCount":101},[],{"trials":3914,"activeCount":101},[],{"trials":3916,"activeCount":101},[],{"trials":3918,"activeCount":101},[3919],{"nctId":3920,"briefTitle":3921,"status":113,"phases":3922,"primaryCompletion":3923,"completion":3923,"start":3924,"enrollment":3925,"conditions":3926,"interventions":3928},"NCT01958073","Vaginal Estrogen for the Prevention of Recurrent Urinary Tract Infection in Postmenopausal Women",[92],"2017-12","2013-10",35,[3927],"Recurrent Urinary Tract Infection",[3907,3929],"Estradiol Ring",{"trials":3931,"activeCount":101},[],{"intervention":3929,"totalTrials":140,"cells":3933},{"EARLY_PHASE1":3934,"PHASE1":3936,"PHASE2":3938,"PHASE3":3940,"PHASE4":3942,"NA":3948},{"trials":3935,"activeCount":101},[],{"trials":3937,"activeCount":101},[],{"trials":3939,"activeCount":101},[],{"trials":3941,"activeCount":101},[],{"trials":3943,"activeCount":101},[3944],{"nctId":3920,"briefTitle":3921,"status":113,"phases":3945,"primaryCompletion":3923,"completion":3923,"start":3924,"enrollment":3925,"conditions":3946,"interventions":3947},[92],[3927],[3907,3929],{"trials":3949,"activeCount":101},[],{"intervention":3951,"totalTrials":140,"cells":3952},"Alprazolam",{"EARLY_PHASE1":3953,"PHASE1":3955,"PHASE2":3957,"PHASE3":3959,"PHASE4":3961,"NA":3970},{"trials":3954,"activeCount":101},[],{"trials":3956,"activeCount":101},[],{"trials":3958,"activeCount":101},[],{"trials":3960,"activeCount":101},[],{"trials":3962,"activeCount":101},[3963],{"nctId":3964,"briefTitle":3965,"status":113,"phases":3966,"primaryCompletion":3089,"completion":3089,"start":3101,"enrollment":1879,"conditions":3967,"interventions":3969},"NCT00662259","Drug Treatment Validation of Functional Magnetic Resonance Imaging in Generalized Anxiety Disorder",[92],[3968],"Generalized Anxiety Disorder",[3951],{"trials":3971,"activeCount":101},[],{"intervention":3973,"totalTrials":140,"cells":3974},"Sugammadex",{"EARLY_PHASE1":3975,"PHASE1":3977,"PHASE2":3979,"PHASE3":3981,"PHASE4":3983,"NA":3995},{"trials":3976,"activeCount":101},[],{"trials":3978,"activeCount":101},[],{"trials":3980,"activeCount":101},[],{"trials":3982,"activeCount":101},[],{"trials":3984,"activeCount":101},[3985],{"nctId":3986,"briefTitle":3987,"status":113,"phases":3988,"primaryCompletion":3989,"completion":3990,"start":3991,"enrollment":974,"conditions":3992,"interventions":3993},"NCT04570150","Optimizing Post-operative Recovery in Bariatric Patients With Obstructive Sleep Apnea Undergoing Outpatient Surgery: A Comparison of Sugammadex and Neostigmine",[92],"2023-01-04","2024-01-04","2021-01-04",[434],[3973,3994],"Neostigmine",{"trials":3996,"activeCount":101},[],{"intervention":3994,"totalTrials":140,"cells":3998},{"EARLY_PHASE1":3999,"PHASE1":4001,"PHASE2":4003,"PHASE3":4005,"PHASE4":4007,"NA":4013},{"trials":4000,"activeCount":101},[],{"trials":4002,"activeCount":101},[],{"trials":4004,"activeCount":101},[],{"trials":4006,"activeCount":101},[],{"trials":4008,"activeCount":101},[4009],{"nctId":3986,"briefTitle":3987,"status":113,"phases":4010,"primaryCompletion":3989,"completion":3990,"start":3991,"enrollment":974,"conditions":4011,"interventions":4012},[92],[434],[3973,3994],{"trials":4014,"activeCount":101},[],{"intervention":4016,"totalTrials":140,"cells":4017},"Different formulations of once-daily lopinavir\u002Fritonavir",{"EARLY_PHASE1":4018,"PHASE1":4020,"PHASE2":4022,"PHASE3":4024,"PHASE4":4026,"NA":4039},{"trials":4019,"activeCount":101},[],{"trials":4021,"activeCount":101},[],{"trials":4023,"activeCount":101},[],{"trials":4025,"activeCount":101},[],{"trials":4027,"activeCount":101},[4028],{"nctId":4029,"briefTitle":4030,"status":113,"phases":4031,"primaryCompletion":4032,"completion":4033,"start":4034,"enrollment":4035,"conditions":4036,"interventions":4038},"NCT00281606","A Multicenter Study to Assess the Tolerability of Once Daily Lopinavir\u002FRitonavir (LPV\u002Fr) Liquid Versus Capsules",[92],"2007-10-16","2012-06-13","2006-02-14",65,[4037],"HIV Infection",[4016],{"trials":4040,"activeCount":101},[],{"intervention":4042,"totalTrials":140,"cells":4043},"Progestin Only Contraceptive Pills",{"EARLY_PHASE1":4044,"PHASE1":4046,"PHASE2":4048,"PHASE3":4050,"PHASE4":4052,"NA":4062},{"trials":4045,"activeCount":101},[],{"trials":4047,"activeCount":101},[],{"trials":4049,"activeCount":101},[],{"trials":4051,"activeCount":101},[],{"trials":4053,"activeCount":101},[4054],{"nctId":4055,"briefTitle":4056,"status":113,"phases":4057,"primaryCompletion":4058,"completion":4058,"start":4059,"enrollment":135,"conditions":4060,"interventions":4061},"NCT04965116","Progestin-Only Pill Use and Breastfeeding Study",[92],"2022-11-04","2021-10-25",[32,2848],[4042],{"trials":4063,"activeCount":101},[],{"intervention":4065,"totalTrials":140,"cells":4066},"Erector Spinae",{"EARLY_PHASE1":4067,"PHASE1":4069,"PHASE2":4071,"PHASE3":4073,"PHASE4":4075,"NA":4086},{"trials":4068,"activeCount":101},[],{"trials":4070,"activeCount":101},[],{"trials":4072,"activeCount":101},[],{"trials":4074,"activeCount":101},[],{"trials":4076,"activeCount":101},[4077],{"nctId":4078,"briefTitle":4079,"status":113,"phases":4080,"primaryCompletion":4081,"completion":4081,"start":4082,"enrollment":283,"conditions":4083,"interventions":4084},"NCT03549234","Erector Spinae Versus Paravertebral Nerve Blocks for Breast Surgery",[92],"2019-05-08","2018-07-12",[3238],[4065,4085],"Paravertebral",{"trials":4087,"activeCount":101},[],{"intervention":4085,"totalTrials":140,"cells":4089},{"EARLY_PHASE1":4090,"PHASE1":4092,"PHASE2":4094,"PHASE3":4096,"PHASE4":4098,"NA":4104},{"trials":4091,"activeCount":101},[],{"trials":4093,"activeCount":101},[],{"trials":4095,"activeCount":101},[],{"trials":4097,"activeCount":101},[],{"trials":4099,"activeCount":101},[4100],{"nctId":4078,"briefTitle":4079,"status":113,"phases":4101,"primaryCompletion":4081,"completion":4081,"start":4082,"enrollment":283,"conditions":4102,"interventions":4103},[92],[3238],[4065,4085],{"trials":4105,"activeCount":101},[],{"intervention":4107,"totalTrials":140,"cells":4108},"0.1% Ropivacaine",{"EARLY_PHASE1":4109,"PHASE1":4111,"PHASE2":4113,"PHASE3":4115,"PHASE4":4117,"NA":4128},{"trials":4110,"activeCount":101},[],{"trials":4112,"activeCount":101},[],{"trials":4114,"activeCount":101},[],{"trials":4116,"activeCount":101},[],{"trials":4118,"activeCount":101},[4119],{"nctId":4120,"briefTitle":4121,"status":113,"phases":4122,"primaryCompletion":3572,"completion":3572,"start":3178,"enrollment":2117,"conditions":4123,"interventions":4126},"NCT00912873","Optimizing Local Anesthetic Concentration for Continuous Lumbar Plexus Nerve Blocks",[92],[4124,4125],"Hip Arthroplasty","Hip Pain",[4107,4127],"0.4% Ropivacaine",{"trials":4129,"activeCount":101},[],{"intervention":4127,"totalTrials":140,"cells":4131},{"EARLY_PHASE1":4132,"PHASE1":4134,"PHASE2":4136,"PHASE3":4138,"PHASE4":4140,"NA":4146},{"trials":4133,"activeCount":101},[],{"trials":4135,"activeCount":101},[],{"trials":4137,"activeCount":101},[],{"trials":4139,"activeCount":101},[],{"trials":4141,"activeCount":101},[4142],{"nctId":4120,"briefTitle":4121,"status":113,"phases":4143,"primaryCompletion":3572,"completion":3572,"start":3178,"enrollment":2117,"conditions":4144,"interventions":4145},[92],[4124,4125],[4107,4127],{"trials":4147,"activeCount":101},[],{"intervention":4149,"totalTrials":140,"cells":4150},"Propranolol",{"EARLY_PHASE1":4151,"PHASE1":4153,"PHASE2":4155,"PHASE3":4157,"PHASE4":4159,"NA":4172},{"trials":4152,"activeCount":101},[],{"trials":4154,"activeCount":101},[],{"trials":4156,"activeCount":101},[],{"trials":4158,"activeCount":101},[],{"trials":4160,"activeCount":101},[4161],{"nctId":4162,"briefTitle":4163,"status":113,"phases":4164,"primaryCompletion":4165,"completion":4165,"start":4166,"enrollment":4167,"conditions":4168,"interventions":4171},"NCT02495883","Functional Imaging of Tremor Circuits and Mechanisms of Treatment Response",[92],"2017-04","2013-12",56,[4169,4170],"Essential Tremor","Tremor",[4149],{"trials":4173,"activeCount":101},[],{"intervention":4175,"totalTrials":140,"cells":4176},"Fluticasone 250 mg\u002Fsalmeterol 50 mg",{"EARLY_PHASE1":4177,"PHASE1":4179,"PHASE2":4181,"PHASE3":4183,"PHASE4":4185,"NA":4200},{"trials":4178,"activeCount":101},[],{"trials":4180,"activeCount":101},[],{"trials":4182,"activeCount":101},[],{"trials":4184,"activeCount":101},[],{"trials":4186,"activeCount":101},[4187],{"nctId":4188,"briefTitle":4189,"status":113,"phases":4190,"primaryCompletion":4191,"completion":4192,"start":4193,"enrollment":27,"conditions":4194,"interventions":4196},"NCT01696214","A Pilot Study to Determine the Feasibility and Utility of Implementing of the Full Scale TOM Trial",[92],"2015-05","2016-11","2012-10",[4195],"Asthma",[4175,4197,4198,4199],"Montelukast 10mg","Theophylline 400 mg","ipratropium",{"trials":4201,"activeCount":101},[],{"intervention":4197,"totalTrials":140,"cells":4203},{"EARLY_PHASE1":4204,"PHASE1":4206,"PHASE2":4208,"PHASE3":4210,"PHASE4":4212,"NA":4218},{"trials":4205,"activeCount":101},[],{"trials":4207,"activeCount":101},[],{"trials":4209,"activeCount":101},[],{"trials":4211,"activeCount":101},[],{"trials":4213,"activeCount":101},[4214],{"nctId":4188,"briefTitle":4189,"status":113,"phases":4215,"primaryCompletion":4191,"completion":4192,"start":4193,"enrollment":27,"conditions":4216,"interventions":4217},[92],[4195],[4175,4197,4198,4199],{"trials":4219,"activeCount":101},[],{"intervention":4198,"totalTrials":140,"cells":4221},{"EARLY_PHASE1":4222,"PHASE1":4224,"PHASE2":4226,"PHASE3":4228,"PHASE4":4230,"NA":4236},{"trials":4223,"activeCount":101},[],{"trials":4225,"activeCount":101},[],{"trials":4227,"activeCount":101},[],{"trials":4229,"activeCount":101},[],{"trials":4231,"activeCount":101},[4232],{"nctId":4188,"briefTitle":4189,"status":113,"phases":4233,"primaryCompletion":4191,"completion":4192,"start":4193,"enrollment":27,"conditions":4234,"interventions":4235},[92],[4195],[4175,4197,4198,4199],{"trials":4237,"activeCount":101},[],{"intervention":4199,"totalTrials":140,"cells":4239},{"EARLY_PHASE1":4240,"PHASE1":4242,"PHASE2":4244,"PHASE3":4246,"PHASE4":4248,"NA":4254},{"trials":4241,"activeCount":101},[],{"trials":4243,"activeCount":101},[],{"trials":4245,"activeCount":101},[],{"trials":4247,"activeCount":101},[],{"trials":4249,"activeCount":101},[4250],{"nctId":4188,"briefTitle":4189,"status":113,"phases":4251,"primaryCompletion":4191,"completion":4192,"start":4193,"enrollment":27,"conditions":4252,"interventions":4253},[92],[4195],[4175,4197,4198,4199],{"trials":4255,"activeCount":101},[],{"intervention":4257,"totalTrials":140,"cells":4258},"divalproex ER",{"EARLY_PHASE1":4259,"PHASE1":4261,"PHASE2":4263,"PHASE3":4265,"PHASE4":4267,"NA":4276},{"trials":4260,"activeCount":101},[],{"trials":4262,"activeCount":101},[],{"trials":4264,"activeCount":101},[],{"trials":4266,"activeCount":101},[],{"trials":4268,"activeCount":101},[4269],{"nctId":4270,"briefTitle":4271,"status":113,"phases":4272,"primaryCompletion":1068,"completion":1068,"start":1069,"enrollment":135,"conditions":4273,"interventions":4274},"NCT00397020","Naturalistic Study, Comparison of Divalproex Extended Release (ER) and Quetiapine for Adults With Acute Mania or Mixed Episodes",[92],[1292],[4257,4275],"quetiapine",{"trials":4277,"activeCount":101},[],{"intervention":4279,"totalTrials":140,"cells":4280},"Active bupivacaine 0.375% PENG block",{"EARLY_PHASE1":4281,"PHASE1":4283,"PHASE2":4285,"PHASE3":4287,"PHASE4":4289,"NA":4301},{"trials":4282,"activeCount":101},[],{"trials":4284,"activeCount":101},[],{"trials":4286,"activeCount":101},[],{"trials":4288,"activeCount":101},[],{"trials":4290,"activeCount":101},[4291],{"nctId":4292,"briefTitle":4293,"status":1160,"phases":4294,"primaryCompletion":1264,"completion":1264,"start":4295,"enrollment":101,"conditions":4296,"interventions":4300},"NCT05118620","Pericapsular Nerve Group Block (PENG) for Hip Surgery",[92],"2021-12-09",[4297,4298,4299],"Hip Arthropathy","Postoperative Pain, Acute","Pain, Postoperative",[4279],{"trials":4302,"activeCount":101},[],{"intervention":3277,"totalTrials":140,"cells":4304},{"EARLY_PHASE1":4305,"PHASE1":4307,"PHASE2":4309,"PHASE3":4311,"PHASE4":4313,"NA":4319},{"trials":4306,"activeCount":101},[],{"trials":4308,"activeCount":101},[],{"trials":4310,"activeCount":101},[],{"trials":4312,"activeCount":101},[],{"trials":4314,"activeCount":101},[4315],{"nctId":3270,"briefTitle":3271,"status":113,"phases":4316,"primaryCompletion":3273,"completion":3274,"start":1133,"enrollment":3211,"conditions":4317,"interventions":4318},[92],[18],[3277,3214],{"trials":4320,"activeCount":101},[],{"intervention":4322,"totalTrials":140,"cells":4323},"Bupivacaine 0.25%",{"EARLY_PHASE1":4324,"PHASE1":4326,"PHASE2":4328,"PHASE3":4330,"PHASE4":4332,"NA":4344},{"trials":4325,"activeCount":101},[],{"trials":4327,"activeCount":101},[],{"trials":4329,"activeCount":101},[],{"trials":4331,"activeCount":101},[],{"trials":4333,"activeCount":101},[4334],{"nctId":4335,"briefTitle":4336,"status":1160,"phases":4337,"primaryCompletion":4338,"completion":4338,"start":4339,"enrollment":101,"conditions":4340,"interventions":4342},"NCT05082155","Continuous Erector Spinae Plane Blocks to Treat Postoperative Pain After Open Gynecologic Procedures Via a Low Transverse (Pfannenstiel) Incision",[92],"2022-05-24","2022-01-01",[4341,4299,2510],"Surgical Incision",[4322,4343],"Normal Saline",{"trials":4345,"activeCount":101},[],{"intervention":4347,"totalTrials":140,"cells":4348},"Recombinant Follicle Stimulating Hormone",{"EARLY_PHASE1":4349,"PHASE1":4351,"PHASE2":4353,"PHASE3":4355,"PHASE4":4357,"NA":4370},{"trials":4350,"activeCount":101},[],{"trials":4352,"activeCount":101},[],{"trials":4354,"activeCount":101},[],{"trials":4356,"activeCount":101},[],{"trials":4358,"activeCount":101},[4359],{"nctId":4360,"briefTitle":4361,"status":113,"phases":4362,"primaryCompletion":4363,"completion":4363,"start":4364,"enrollment":1475,"conditions":4365,"interventions":4369},"NCT03252223","Ovarian Response to Recombinant Follicle Stimulating Hormone in Women With PCOS",[92],"2021-06-30","2017-10-02",[4366,3047,4367,4368],"Polycystic Ovary Syndrome","Anovulation","Hyperandrogenism",[4347],{"trials":4371,"activeCount":101},[],{"intervention":4373,"totalTrials":140,"cells":4374},"Gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid",{"EARLY_PHASE1":4375,"PHASE1":4377,"PHASE2":4379,"PHASE3":4381,"PHASE4":4383,"NA":4397},{"trials":4376,"activeCount":101},[],{"trials":4378,"activeCount":101},[],{"trials":4380,"activeCount":101},[],{"trials":4382,"activeCount":101},[],{"trials":4384,"activeCount":101},[4385],{"nctId":4386,"briefTitle":4387,"status":113,"phases":4388,"primaryCompletion":4389,"completion":4389,"start":4390,"enrollment":4391,"conditions":4392,"interventions":4396},"NCT04288323","Gadolinium Contrast-enhanced Abbreviated MRI (AMRI) vs. Standard Ultrasound for Hepatocellular Carcinoma (HCC) Surveillance in Patients With Cirrhosis",[92],"2025-12-16","2018-04-27",79,[4393,4394,4395],"Liver Cancer","Liver Cirrhoses","Liver Carcinoma",[4373],{"trials":4398,"activeCount":101},[],{"intervention":4400,"totalTrials":140,"cells":4401},"Ropivacaine 0.1%",{"EARLY_PHASE1":4402,"PHASE1":4404,"PHASE2":4406,"PHASE3":4408,"PHASE4":4410,"NA":4421},{"trials":4403,"activeCount":101},[],{"trials":4405,"activeCount":101},[],{"trials":4407,"activeCount":101},[],{"trials":4409,"activeCount":101},[],{"trials":4411,"activeCount":101},[4412],{"nctId":4413,"briefTitle":4414,"status":113,"phases":4415,"primaryCompletion":2672,"completion":2672,"start":4416,"enrollment":22,"conditions":4417,"interventions":4419},"NCT01898689","Optimizing Local Anesthetic Concentration for Continuous Popliteal-Sciatic Nerve Blocks",[92],"2013-07",[4418],"Relatively Healthy Volunteers",[4400,4420],"Ropivacaine 0.4%",{"trials":4422,"activeCount":101},[],{"intervention":4420,"totalTrials":140,"cells":4424},{"EARLY_PHASE1":4425,"PHASE1":4427,"PHASE2":4429,"PHASE3":4431,"PHASE4":4433,"NA":4439},{"trials":4426,"activeCount":101},[],{"trials":4428,"activeCount":101},[],{"trials":4430,"activeCount":101},[],{"trials":4432,"activeCount":101},[],{"trials":4434,"activeCount":101},[4435],{"nctId":4413,"briefTitle":4414,"status":113,"phases":4436,"primaryCompletion":2672,"completion":2672,"start":4416,"enrollment":22,"conditions":4437,"interventions":4438},[92],[4418],[4400,4420],{"trials":4440,"activeCount":101},[],{"intervention":4442,"totalTrials":140,"cells":4443},"0.25 mg alprazolam",{"EARLY_PHASE1":4444,"PHASE1":4446,"PHASE2":4448,"PHASE3":4450,"PHASE4":4452,"NA":4463},{"trials":4445,"activeCount":101},[],{"trials":4447,"activeCount":101},[],{"trials":4449,"activeCount":101},[],{"trials":4451,"activeCount":101},[],{"trials":4453,"activeCount":101},[4454],{"nctId":4455,"briefTitle":4456,"status":113,"phases":4457,"primaryCompletion":4458,"completion":4458,"start":4459,"enrollment":3450,"conditions":4460,"interventions":4461},"NCT00703885","PharmacofMRI (Functional Magnetic Resonance Imaging) of Anxiolytic Medications (Alprazolam)",[92],"2008-08","2008-01",[1950],[4442,4462],"1.0 mg alprazolam",{"trials":4464,"activeCount":101},[],{"intervention":4462,"totalTrials":140,"cells":4466},{"EARLY_PHASE1":4467,"PHASE1":4469,"PHASE2":4471,"PHASE3":4473,"PHASE4":4475,"NA":4481},{"trials":4468,"activeCount":101},[],{"trials":4470,"activeCount":101},[],{"trials":4472,"activeCount":101},[],{"trials":4474,"activeCount":101},[],{"trials":4476,"activeCount":101},[4477],{"nctId":4455,"briefTitle":4456,"status":113,"phases":4478,"primaryCompletion":4458,"completion":4458,"start":4459,"enrollment":3450,"conditions":4479,"interventions":4480},[92],[1950],[4442,4462],{"trials":4482,"activeCount":101},[],{"intervention":4484,"totalTrials":140,"cells":4485},"Perineural infusion [continuous peripheral nerve block(s)]",{"EARLY_PHASE1":4486,"PHASE1":4488,"PHASE2":4490,"PHASE3":4492,"PHASE4":4494,"NA":4507},{"trials":4487,"activeCount":101},[],{"trials":4489,"activeCount":101},[],{"trials":4491,"activeCount":101},[],{"trials":4493,"activeCount":101},[],{"trials":4495,"activeCount":101},[4496],{"nctId":4497,"briefTitle":4498,"status":113,"phases":4499,"primaryCompletion":4500,"completion":4501,"start":4502,"enrollment":4503,"conditions":4504,"interventions":4506},"NCT01824082","Treating Phantom Limb Pain Using Continuous Peripheral Nerve Blocks: A Department of Defense Funded Multicenter Study",[92],"2019-11","2020-10","2013-12-01",144,[4505],"Phantom Limb Pain",[4484],{"trials":4508,"activeCount":101},[],{"intervention":4510,"totalTrials":140,"cells":4511},"Active ropivacaine 0.3% erector spinae plane perineural administration",{"EARLY_PHASE1":4512,"PHASE1":4514,"PHASE2":4516,"PHASE3":4518,"PHASE4":4520,"NA":4532},{"trials":4513,"activeCount":101},[],{"trials":4515,"activeCount":101},[],{"trials":4517,"activeCount":101},[],{"trials":4519,"activeCount":101},[],{"trials":4521,"activeCount":101},[4522],{"nctId":4523,"briefTitle":4524,"status":1066,"phases":4525,"primaryCompletion":4526,"completion":1357,"start":4527,"enrollment":1024,"conditions":4528,"interventions":4531},"NCT04558281","Continuous Erector Spinae Plane Blocks for Rib Fractures",[92],"2022-03-26","2021-05-23",[4529,4530,434,435],"Rib Fractures","Trauma",[4510],{"trials":4533,"activeCount":101},[],{"intervention":4535,"totalTrials":140,"cells":4536},"Modafinil",{"EARLY_PHASE1":4537,"PHASE1":4539,"PHASE2":4541,"PHASE3":4543,"PHASE4":4545,"NA":4558},{"trials":4538,"activeCount":101},[],{"trials":4540,"activeCount":101},[],{"trials":4542,"activeCount":101},[],{"trials":4544,"activeCount":101},[],{"trials":4546,"activeCount":101},[4547],{"nctId":4548,"briefTitle":4549,"status":113,"phases":4550,"primaryCompletion":4551,"completion":4552,"start":4553,"enrollment":4554,"conditions":4555,"interventions":4557},"NCT03616717","Modafinil Effects on EEG Biomarkers of Reward and Motivation",[92],"2021-05-31","2021-09-30","2018-10-16",23,[4556],"Healthy Adults",[4535],{"trials":4559,"activeCount":101},[],{"intervention":4561,"totalTrials":140,"cells":4562},"ropivacaine 0.2%",{"EARLY_PHASE1":4563,"PHASE1":4565,"PHASE2":4567,"PHASE3":4569,"PHASE4":4571,"NA":4586},{"trials":4564,"activeCount":101},[],{"trials":4566,"activeCount":101},[],{"trials":4568,"activeCount":101},[],{"trials":4570,"activeCount":101},[],{"trials":4572,"activeCount":101},[4573],{"nctId":4574,"briefTitle":4575,"status":113,"phases":4576,"primaryCompletion":4577,"completion":4578,"start":4579,"enrollment":4580,"conditions":4581,"interventions":4585},"NCT02523235","Effects of Catheter Location on Postoperative Analgesia for Continuous Adductor Canal and Popliteal-Sciatic Nerve Blocks",[92],"2018-02","2018-03","2015-08",117,[4582,137,4583,4584],"Post-surgical Pain","Foot\u002FAnkle Surgery","Catheterization for Postop Analgesia",[4561],{"trials":4587,"activeCount":101},[],{"intervention":4589,"totalTrials":140,"cells":4590},"Intravitreal aflibercept",{"EARLY_PHASE1":4591,"PHASE1":4593,"PHASE2":4595,"PHASE3":4597,"PHASE4":4599,"NA":4611},{"trials":4592,"activeCount":101},[],{"trials":4594,"activeCount":101},[],{"trials":4596,"activeCount":101},[],{"trials":4598,"activeCount":101},[],{"trials":4600,"activeCount":101},[4601],{"nctId":4602,"briefTitle":4603,"status":113,"phases":4604,"primaryCompletion":4605,"completion":4605,"start":4606,"enrollment":2117,"conditions":4607,"interventions":4610},"NCT02689518","EAGLE: Evaluating Genotypes Using Intravitreal Aflibercept Injection",[92],"2019-11-12","2014-04",[4608,4609],"Macular Degeneration","Wet Macular Degeneration",[4589],{"trials":4612,"activeCount":101},[],{"intervention":4614,"totalTrials":140,"cells":4615},"Control: Femoral perineural local anesthetic",{"EARLY_PHASE1":4616,"PHASE1":4618,"PHASE2":4620,"PHASE3":4622,"PHASE4":4624,"NA":4635},{"trials":4617,"activeCount":101},[],{"trials":4619,"activeCount":101},[],{"trials":4621,"activeCount":101},[],{"trials":4623,"activeCount":101},[],{"trials":4625,"activeCount":101},[4626],{"nctId":4627,"briefTitle":4628,"status":113,"phases":4629,"primaryCompletion":3076,"completion":3076,"start":4630,"enrollment":608,"conditions":4631,"interventions":4633},"NCT01759277","Femoral Versus Adductor Canal Continuous Peripheral Nerve Blocks for Knee Arthroplasty",[92],"2012-12",[4632],"Postoperative Pain Following Knee Arthroplasty",[4614,4634],"Experimental: Adductor Canal perineural local anesthetic",{"trials":4636,"activeCount":101},[],{"intervention":4634,"totalTrials":140,"cells":4638},{"EARLY_PHASE1":4639,"PHASE1":4641,"PHASE2":4643,"PHASE3":4645,"PHASE4":4647,"NA":4653},{"trials":4640,"activeCount":101},[],{"trials":4642,"activeCount":101},[],{"trials":4644,"activeCount":101},[],{"trials":4646,"activeCount":101},[],{"trials":4648,"activeCount":101},[4649],{"nctId":4627,"briefTitle":4628,"status":113,"phases":4650,"primaryCompletion":3076,"completion":3076,"start":4630,"enrollment":608,"conditions":4651,"interventions":4652},[92],[4632],[4614,4634],{"trials":4654,"activeCount":101},[],{"intervention":4656,"totalTrials":140,"cells":4657},"[11C]raclopride",{"EARLY_PHASE1":4658,"PHASE1":4660,"PHASE2":4662,"PHASE3":4664,"PHASE4":4666,"NA":4678},{"trials":4659,"activeCount":101},[],{"trials":4661,"activeCount":101},[],{"trials":4663,"activeCount":101},[],{"trials":4665,"activeCount":101},[],{"trials":4667,"activeCount":101},[4668],{"nctId":4669,"briefTitle":4670,"status":113,"phases":4671,"primaryCompletion":4672,"completion":4672,"start":2972,"enrollment":1501,"conditions":4673,"interventions":4675},"NCT02020408","Monoamine Contributions to Neurocircuitry in Eating Disorders",[92],"2017-12-31",[4674],"Eating Disorder",[4656,4676,4677],"[11C]DASB","amphetamine",{"trials":4679,"activeCount":101},[],{"intervention":4676,"totalTrials":140,"cells":4681},{"EARLY_PHASE1":4682,"PHASE1":4684,"PHASE2":4686,"PHASE3":4688,"PHASE4":4690,"NA":4696},{"trials":4683,"activeCount":101},[],{"trials":4685,"activeCount":101},[],{"trials":4687,"activeCount":101},[],{"trials":4689,"activeCount":101},[],{"trials":4691,"activeCount":101},[4692],{"nctId":4669,"briefTitle":4670,"status":113,"phases":4693,"primaryCompletion":4672,"completion":4672,"start":2972,"enrollment":1501,"conditions":4694,"interventions":4695},[92],[4674],[4656,4676,4677],{"trials":4697,"activeCount":101},[],{"intervention":4677,"totalTrials":140,"cells":4699},{"EARLY_PHASE1":4700,"PHASE1":4702,"PHASE2":4704,"PHASE3":4706,"PHASE4":4708,"NA":4714},{"trials":4701,"activeCount":101},[],{"trials":4703,"activeCount":101},[],{"trials":4705,"activeCount":101},[],{"trials":4707,"activeCount":101},[],{"trials":4709,"activeCount":101},[4710],{"nctId":4669,"briefTitle":4670,"status":113,"phases":4711,"primaryCompletion":4672,"completion":4672,"start":2972,"enrollment":1501,"conditions":4712,"interventions":4713},[92],[4674],[4656,4676,4677],{"trials":4715,"activeCount":101},[],{"intervention":3250,"totalTrials":140,"cells":4717},{"EARLY_PHASE1":4718,"PHASE1":4720,"PHASE2":4722,"PHASE3":4724,"PHASE4":4726,"NA":4732},{"trials":4719,"activeCount":101},[],{"trials":4721,"activeCount":101},[],{"trials":4723,"activeCount":101},[],{"trials":4725,"activeCount":101},[],{"trials":4727,"activeCount":101},[4728],{"nctId":3242,"briefTitle":3243,"status":113,"phases":4729,"primaryCompletion":3245,"completion":3245,"start":3246,"enrollment":3247,"conditions":4730,"interventions":4731},[92],[3238],[3250,3218],{"trials":4733,"activeCount":101},[],{"intervention":4735,"totalTrials":140,"cells":4736},"Testosterone Cypionate 50 MG\u002FML Injectable Solution",{"EARLY_PHASE1":4737,"PHASE1":4739,"PHASE2":4741,"PHASE3":4743,"PHASE4":4745,"NA":4755},{"trials":4738,"activeCount":101},[],{"trials":4740,"activeCount":101},[],{"trials":4742,"activeCount":101},[],{"trials":4744,"activeCount":101},[],{"trials":4746,"activeCount":101},[4747],{"nctId":4748,"briefTitle":4749,"status":1066,"phases":4750,"primaryCompletion":4751,"completion":4752,"start":4751,"enrollment":97,"conditions":4753,"interventions":4754},"NCT06450405","Androgen Effects on the Reproductive Neuroendocrine Axis",[92],"2025-02-26","2025-03-03",[610,611],[4735],{"trials":4756,"activeCount":101},[],{"intervention":4758,"totalTrials":140,"cells":4759},"Testosterone Cyp 200Mg\u002FMl Inj",{"EARLY_PHASE1":4760,"PHASE1":4762,"PHASE2":4764,"PHASE3":4766,"PHASE4":4768,"NA":4779},{"trials":4761,"activeCount":101},[],{"trials":4763,"activeCount":101},[],{"trials":4765,"activeCount":101},[],{"trials":4767,"activeCount":101},[],{"trials":4769,"activeCount":101},[4770],{"nctId":4771,"briefTitle":4772,"status":1160,"phases":4773,"primaryCompletion":2608,"completion":133,"start":4774,"enrollment":101,"conditions":4775,"interventions":4777},"NCT04321551","Hormone Secretion in Transgender Males",[92],"2023-07-01",[4776,3047],"Transgender",[4758,4778],"Letrozole",{"trials":4780,"activeCount":101},[],{"intervention":4782,"totalTrials":140,"cells":4783},"Iohexol",{"EARLY_PHASE1":4784,"PHASE1":4786,"PHASE2":4788,"PHASE3":4790,"PHASE4":4792,"NA":4804},{"trials":4785,"activeCount":101},[],{"trials":4787,"activeCount":101},[],{"trials":4789,"activeCount":101},[],{"trials":4791,"activeCount":101},[],{"trials":4793,"activeCount":101},[4794],{"nctId":4795,"briefTitle":4796,"status":113,"phases":4797,"primaryCompletion":4798,"completion":4798,"start":4799,"enrollment":1306,"conditions":4800,"interventions":4803},"NCT04742816","Renal Effects of Hormones\u002FBiomarkers in Transgender PrEP Recipients",[92],"2021-12-31","2020-09-17",[4776,4801,4802],"Renal Function","Hormone Replacement Therapy",[4782],{"trials":4805,"activeCount":101},[],{"intervention":4807,"totalTrials":140,"cells":4808},"Donepezil",{"EARLY_PHASE1":4809,"PHASE1":4811,"PHASE2":4813,"PHASE3":4815,"PHASE4":4817,"NA":4826},{"trials":4810,"activeCount":101},[],{"trials":4812,"activeCount":101},[],{"trials":4814,"activeCount":101},[],{"trials":4816,"activeCount":101},[],{"trials":4818,"activeCount":101},[4819],{"nctId":4820,"briefTitle":4821,"status":113,"phases":4822,"primaryCompletion":4191,"completion":4191,"start":3076,"enrollment":4823,"conditions":4824,"interventions":4825},"NCT02264353","The Impact of Arousal Threshold in Obstructive Sleep Apnea",[92],44,[18],[4807],{"trials":4827,"activeCount":101},[],{"intervention":4829,"totalTrials":140,"cells":4830},"Milnacipram",{"EARLY_PHASE1":4831,"PHASE1":4833,"PHASE2":4835,"PHASE3":4837,"PHASE4":4839,"NA":4848},{"trials":4832,"activeCount":101},[],{"trials":4834,"activeCount":101},[],{"trials":4836,"activeCount":101},[],{"trials":4838,"activeCount":101},[],{"trials":4840,"activeCount":101},[4841],{"nctId":4842,"briefTitle":4843,"status":113,"phases":4844,"primaryCompletion":1133,"completion":1133,"start":4845,"enrollment":2532,"conditions":4846,"interventions":4847},"NCT01288807","Effect of Milnacipran on Pain in Fibromyalgia",[92],"2011-02",[3404],[4829],{"trials":4849,"activeCount":101},[],{"intervention":4851,"totalTrials":140,"cells":4852},"ropivacaine 0.25% with epinephrine and 6mg dexamethasone",{"EARLY_PHASE1":4853,"PHASE1":4855,"PHASE2":4857,"PHASE3":4859,"PHASE4":4861,"NA":4875},{"trials":4854,"activeCount":101},[],{"trials":4856,"activeCount":101},[],{"trials":4858,"activeCount":101},[],{"trials":4860,"activeCount":101},[],{"trials":4862,"activeCount":101},[4863],{"nctId":4864,"briefTitle":4865,"status":1066,"phases":4866,"primaryCompletion":4867,"completion":4867,"start":4868,"enrollment":4869,"conditions":4870,"interventions":4873},"NCT04917055","iPACK Block With Dexamethasone For Total Knee Replacement",[92],"2022-06-07","2021-06-07",14,[4871,433,435,4872],"Knee Osteoarthritis","Regional Anesthesia",[4851,4874],"Saline",{"trials":4876,"activeCount":101},[],{"intervention":4878,"totalTrials":140,"cells":4879},"Varenicline",{"EARLY_PHASE1":4880,"PHASE1":4882,"PHASE2":4884,"PHASE3":4886,"PHASE4":4888,"NA":4899},{"trials":4881,"activeCount":101},[],{"trials":4883,"activeCount":101},[],{"trials":4885,"activeCount":101},[],{"trials":4887,"activeCount":101},[],{"trials":4889,"activeCount":101},[4890],{"nctId":4891,"briefTitle":4892,"status":113,"phases":4893,"primaryCompletion":4894,"completion":4894,"start":4895,"enrollment":9,"conditions":4896,"interventions":4898},"NCT04011280","Novel Pharmacotherapy Approaches in Smokers With Serious Mental Illness",[92],"2022-03-04","2019-08-12",[1292,21,3035,4897],"Nicotine Dependence",[4878],{"trials":4900,"activeCount":101},[],{"intervention":4902,"totalTrials":140,"cells":4903},"Vitamin D Supplement",{"EARLY_PHASE1":4904,"PHASE1":4906,"PHASE2":4908,"PHASE3":4910,"PHASE4":4912,"NA":4924},{"trials":4905,"activeCount":101},[],{"trials":4907,"activeCount":101},[],{"trials":4909,"activeCount":101},[],{"trials":4911,"activeCount":101},[],{"trials":4913,"activeCount":101},[4914],{"nctId":4915,"briefTitle":4916,"status":113,"phases":4917,"primaryCompletion":4918,"completion":4919,"start":4920,"enrollment":1123,"conditions":4921,"interventions":4923},"NCT02367599","Effect of Vitamin D Supplementation on Bone Turnover Markers During PrEP in MSM",[92],"2018-06-13","2018-07-11","2014-12-15",[4922],"Patient Adherence",[4902],{"trials":4925,"activeCount":101},[],{"intervention":4927,"totalTrials":140,"cells":4928},"0.01% bimatoprost",{"EARLY_PHASE1":4929,"PHASE1":4931,"PHASE2":4933,"PHASE3":4935,"PHASE4":4937,"NA":4949},{"trials":4930,"activeCount":101},[],{"trials":4932,"activeCount":101},[],{"trials":4934,"activeCount":101},[],{"trials":4936,"activeCount":101},[],{"trials":4938,"activeCount":101},[4939],{"nctId":4940,"briefTitle":4941,"status":113,"phases":4942,"primaryCompletion":4193,"completion":4193,"start":4943,"enrollment":3450,"conditions":4944,"interventions":4948},"NCT01271686","24-hour IOP-lowering Effect of 0.01% Bimatoprost",[92],"2011-01",[4945,4946,4947],"Intraocular Pressure","Glaucoma","Ocular Hypertension",[4927],{"trials":4950,"activeCount":101},[],{"intervention":4952,"totalTrials":1024,"cells":4953},"Infliximab",{"EARLY_PHASE1":4954,"PHASE1":4956,"PHASE2":4968,"PHASE3":4970,"PHASE4":5004,"NA":5006},{"trials":4955,"activeCount":101},[],{"trials":4957,"activeCount":101},[4958],{"nctId":4959,"briefTitle":4960,"status":113,"phases":4961,"primaryCompletion":4962,"completion":4962,"start":4963,"enrollment":22,"conditions":4964,"interventions":4966},"NCT00271570","Infliximab (Remicade) for Patients With Acute Kawasaki Disease",[89],"2006-10","2004-04",[4965],"Kawasaki Disease",[4952,4967],"Intravenous immunoglobulin",{"trials":4969,"activeCount":101},[],{"trials":4971,"activeCount":101},[4972,4985,4996],{"nctId":4973,"briefTitle":4974,"status":113,"phases":4975,"primaryCompletion":4976,"completion":4977,"start":4978,"enrollment":4979,"conditions":4980,"interventions":4982},"NCT04898231","MIS-C Comparative Effectiveness Study",[90,91],"2023-12-22","2024-04-25","2020-12-22",73,[4981],"Multisystem Inflammatory Syndrome-Children",[4952,4983,4984],"Anakinra","Methylprednisolone",{"nctId":4986,"briefTitle":4987,"status":113,"phases":4988,"primaryCompletion":4989,"completion":4990,"start":4991,"enrollment":1630,"conditions":4992,"interventions":4994},"NCT03065244","KIDCARE (Kawasaki Disease Comparative Effectiveness Trial)",[91],"2020-08-31","2020-11-02","2017-02-17",[4993],"Mucocutaneous Lymph Node Syndrome",[4995,4952],"IVIG",{"nctId":4997,"briefTitle":4998,"status":113,"phases":4999,"primaryCompletion":4193,"completion":4193,"start":5000,"enrollment":5001,"conditions":5002,"interventions":5003},"NCT00760435","Infliximab Plus Intravenous Immunoglobulin for the Primary Treatment of Kawasaki Disease",[91],"2009-03",196,[4965],[4952],{"trials":5005,"activeCount":101},[],{"trials":5007,"activeCount":101},[],{"intervention":3094,"totalTrials":97,"cells":5009},{"EARLY_PHASE1":5010,"PHASE1":5012,"PHASE2":5014,"PHASE3":5025,"PHASE4":5031,"NA":5033},{"trials":5011,"activeCount":101},[],{"trials":5013,"activeCount":101},[],{"trials":5015,"activeCount":101},[5016],{"nctId":5017,"briefTitle":5018,"status":113,"phases":5019,"primaryCompletion":5020,"completion":5021,"start":5022,"enrollment":16,"conditions":5023,"interventions":5024},"NCT01431105","Pharmacokinetics (PK)\u002FSafety Study of Atorvastatin in Children With Kawasaki Disease and Coronary Artery Abnormalities",[89,90],"2018-01","2018-07","2012-07",[4965],[3094],{"trials":5026,"activeCount":101},[5027],{"nctId":3084,"briefTitle":3085,"status":1066,"phases":5028,"primaryCompletion":3087,"completion":3088,"start":3089,"enrollment":97,"conditions":5029,"interventions":5030},[91],[3091,3092],[3063,3094],{"trials":5032,"activeCount":101},[],{"trials":5034,"activeCount":101},[],{"intervention":4983,"totalTrials":97,"cells":5036},{"EARLY_PHASE1":5037,"PHASE1":5039,"PHASE2":5041,"PHASE3":5051,"PHASE4":5057,"NA":5059},{"trials":5038,"activeCount":101},[],{"trials":5040,"activeCount":101},[],{"trials":5042,"activeCount":101},[5043],{"nctId":5044,"briefTitle":5045,"status":113,"phases":5046,"primaryCompletion":5047,"completion":5048,"start":2917,"enrollment":1923,"conditions":5049,"interventions":5050},"NCT02179853","Anakinra in Infants and Children With Coronary Artery Abnormalities in Acute Kawasaki Disease",[89,90],"2022-10","2022-12",[4965],[4983],{"trials":5052,"activeCount":101},[5053],{"nctId":4973,"briefTitle":4974,"status":113,"phases":5054,"primaryCompletion":4976,"completion":4977,"start":4978,"enrollment":4979,"conditions":5055,"interventions":5056},[90,91],[4981],[4952,4983,4984],{"trials":5058,"activeCount":101},[],{"trials":5060,"activeCount":101},[],{"intervention":5062,"totalTrials":97,"cells":5063},"Cisplatin",{"EARLY_PHASE1":5064,"PHASE1":5066,"PHASE2":5077,"PHASE3":5079,"PHASE4":5091,"NA":5093},{"trials":5065,"activeCount":101},[],{"trials":5067,"activeCount":101},[5068],{"nctId":5069,"briefTitle":5070,"status":113,"phases":5071,"primaryCompletion":5072,"completion":1037,"start":1135,"enrollment":3925,"conditions":5073,"interventions":5075},"NCT01554410","Intensity Modulated Radiation Therapy With Cisplatin and Gemcitabine to Treat Locally Advanced Cervical Carcinoma",[89],"2019-07-16",[5074],"Cervical Carcinoma",[5062,5076],"Gemcitabine",{"trials":5078,"activeCount":101},[],{"trials":5080,"activeCount":101},[5081],{"nctId":5082,"briefTitle":5083,"status":113,"phases":5084,"primaryCompletion":5085,"completion":4339,"start":5086,"enrollment":5087,"conditions":5088,"interventions":5090},"NCT01554397","Study With Intensity Modulated Radiation Therapy With Cisplatin to Treat Stage I-IVA Cervical Cancer",[90,91],"2021-06-01","2011-10-13",101,[5089],"Cervical Cancer",[5062],{"trials":5092,"activeCount":101},[],{"trials":5094,"activeCount":101},[],{"intervention":5096,"totalTrials":140,"cells":5097},"Antibiotic administration",{"EARLY_PHASE1":5098,"PHASE1":5100,"PHASE2":5102,"PHASE3":5104,"PHASE4":5115,"NA":5117},{"trials":5099,"activeCount":101},[],{"trials":5101,"activeCount":101},[],{"trials":5103,"activeCount":101},[],{"trials":5105,"activeCount":101},[5106],{"nctId":5107,"briefTitle":5108,"status":113,"phases":5109,"primaryCompletion":5110,"completion":5110,"start":5111,"enrollment":901,"conditions":5112,"interventions":5114},"NCT05169255","Impact of Prolonged Antibiotic Therapy on Commensal Microbial Community Gene Expression.",[91],"2016-04-22","2012-12-07",[5113],"Microbial Colonization",[5096],{"trials":5116,"activeCount":101},[],{"trials":5118,"activeCount":101},[],{"intervention":5120,"totalTrials":140,"cells":5121},"40cc buffered 0.5% lidocaine with 2 units of vasopressin paracervical block",{"EARLY_PHASE1":5122,"PHASE1":5124,"PHASE2":5126,"PHASE3":5128,"PHASE4":5146,"NA":5148},{"trials":5123,"activeCount":101},[],{"trials":5125,"activeCount":101},[],{"trials":5127,"activeCount":101},[],{"trials":5129,"activeCount":101},[5130],{"nctId":5131,"briefTitle":5132,"status":113,"phases":5133,"primaryCompletion":5134,"completion":5135,"start":5136,"enrollment":5137,"conditions":5138,"interventions":5144},"NCT03636451","Effect of Paracervical Block Volume on Pain Control for Dilation and Curettage.o",[91],"2020-12-14","2022-09-27","2018-10-29",114,[5139,5140,5141,5142,5143],"Abortion, Spontaneous","Abortion in First Trimester","Pain Uterus","Abortion Early","Abortion, Missed",[5120,5145],"20cc 1% lidocaine with 2 units of vasopressin paracervical block",{"trials":5147,"activeCount":101},[],{"trials":5149,"activeCount":101},[],{"intervention":5145,"totalTrials":140,"cells":5151},{"EARLY_PHASE1":5152,"PHASE1":5154,"PHASE2":5156,"PHASE3":5158,"PHASE4":5164,"NA":5166},{"trials":5153,"activeCount":101},[],{"trials":5155,"activeCount":101},[],{"trials":5157,"activeCount":101},[],{"trials":5159,"activeCount":101},[5160],{"nctId":5131,"briefTitle":5132,"status":113,"phases":5161,"primaryCompletion":5134,"completion":5135,"start":5136,"enrollment":5137,"conditions":5162,"interventions":5163},[91],[5139,5140,5141,5142,5143],[5120,5145],{"trials":5165,"activeCount":101},[],{"trials":5167,"activeCount":101},[],{"intervention":5169,"totalTrials":140,"cells":5170},"Group1: IV t-PA and normothermia",{"EARLY_PHASE1":5171,"PHASE1":5173,"PHASE2":5175,"PHASE3":5177,"PHASE4":5187,"NA":5189},{"trials":5172,"activeCount":101},[],{"trials":5174,"activeCount":101},[],{"trials":5176,"activeCount":101},[],{"trials":5178,"activeCount":101},[5179],{"nctId":5180,"briefTitle":5181,"status":1066,"phases":5182,"primaryCompletion":1133,"completion":4191,"start":5183,"enrollment":163,"conditions":5184,"interventions":5186},"NCT01123161","The Intravascular Cooling in the Treatment of Stroke 2\u002F3 Trial",[90,91],"2010-06",[5185],"Stroke, Acute",[5169],{"trials":5188,"activeCount":101},[],{"trials":5190,"activeCount":101},[],{"intervention":4984,"totalTrials":140,"cells":5192},{"EARLY_PHASE1":5193,"PHASE1":5195,"PHASE2":5197,"PHASE3":5199,"PHASE4":5205,"NA":5207},{"trials":5194,"activeCount":101},[],{"trials":5196,"activeCount":101},[],{"trials":5198,"activeCount":101},[],{"trials":5200,"activeCount":101},[5201],{"nctId":4973,"briefTitle":4974,"status":113,"phases":5202,"primaryCompletion":4976,"completion":4977,"start":4978,"enrollment":4979,"conditions":5203,"interventions":5204},[90,91],[4981],[4952,4983,4984],{"trials":5206,"activeCount":101},[],{"trials":5208,"activeCount":101},[],{"intervention":5210,"totalTrials":140,"cells":5211},"atomoxetine",{"EARLY_PHASE1":5212,"PHASE1":5214,"PHASE2":5216,"PHASE3":5218,"PHASE4":5230,"NA":5232},{"trials":5213,"activeCount":101},[],{"trials":5215,"activeCount":101},[],{"trials":5217,"activeCount":101},[],{"trials":5219,"activeCount":101},[5220],{"nctId":5221,"briefTitle":5222,"status":113,"phases":5223,"primaryCompletion":5224,"completion":5224,"start":5225,"enrollment":5226,"conditions":5227,"interventions":5229},"NCT00260533","Efficacy and Tolerability of Atomoxetine (Strattera) in Adult Patients With Generalized Social Anxiety Disorder",[90,91],"2008-07","2005-11",27,[5228],"Generalized Social Phobia",[5210],{"trials":5231,"activeCount":101},[],{"trials":5233,"activeCount":101},[],{"intervention":4995,"totalTrials":140,"cells":5235},{"EARLY_PHASE1":5236,"PHASE1":5238,"PHASE2":5240,"PHASE3":5242,"PHASE4":5248,"NA":5250},{"trials":5237,"activeCount":101},[],{"trials":5239,"activeCount":101},[],{"trials":5241,"activeCount":101},[],{"trials":5243,"activeCount":101},[5244],{"nctId":4986,"briefTitle":4987,"status":113,"phases":5245,"primaryCompletion":4989,"completion":4990,"start":4991,"enrollment":1630,"conditions":5246,"interventions":5247},[91],[4993],[4995,4952],{"trials":5249,"activeCount":101},[],{"trials":5251,"activeCount":101},[],{"intervention":5253,"totalTrials":140,"cells":5254},"NAC\u002FTigecycline\u002FHeparin combination lock solution",{"EARLY_PHASE1":5255,"PHASE1":5257,"PHASE2":5259,"PHASE3":5261,"PHASE4":5274,"NA":5276},{"trials":5256,"activeCount":101},[],{"trials":5258,"activeCount":101},[],{"trials":5260,"activeCount":101},[],{"trials":5262,"activeCount":101},[5263],{"nctId":5264,"briefTitle":5265,"status":1066,"phases":5266,"primaryCompletion":5267,"completion":5267,"start":5268,"enrollment":5269,"conditions":5270,"interventions":5272},"NCT01483872","Use of a Novel Catheter Lock Solution For Treatment of Hemodialysis Catheter Infections",[91],"2013-09","2012-03",9,[5271],"Infection; Dialysis Catheter",[5253,5273],"Standard anticoagulant",{"trials":5275,"activeCount":101},[],{"trials":5277,"activeCount":101},[],{"intervention":5273,"totalTrials":140,"cells":5279},{"EARLY_PHASE1":5280,"PHASE1":5282,"PHASE2":5284,"PHASE3":5286,"PHASE4":5292,"NA":5294},{"trials":5281,"activeCount":101},[],{"trials":5283,"activeCount":101},[],{"trials":5285,"activeCount":101},[],{"trials":5287,"activeCount":101},[5288],{"nctId":5264,"briefTitle":5265,"status":1066,"phases":5289,"primaryCompletion":5267,"completion":5267,"start":5268,"enrollment":5269,"conditions":5290,"interventions":5291},[91],[5271],[5253,5273],{"trials":5293,"activeCount":101},[],{"trials":5295,"activeCount":101},[],{"intervention":5297,"totalTrials":140,"cells":5298},"Vaginal Misoprostol",{"EARLY_PHASE1":5299,"PHASE1":5301,"PHASE2":5303,"PHASE3":5305,"PHASE4":5316,"NA":5318},{"trials":5300,"activeCount":101},[],{"trials":5302,"activeCount":101},[],{"trials":5304,"activeCount":101},[],{"trials":5306,"activeCount":101},[5307],{"nctId":5308,"briefTitle":5309,"status":113,"phases":5310,"primaryCompletion":5311,"completion":3273,"start":3075,"enrollment":1024,"conditions":5312,"interventions":5314},"NCT02141555","Comparing Buccal and Vaginal Misoprostol in Management of Early Pregnancy Loss",[90,91],"2015-04",[5313],"Spontaneous Abortion in First Trimester",[5297,5315],"Buccal Misoprostol",{"trials":5317,"activeCount":101},[],{"trials":5319,"activeCount":101},[],{"intervention":5315,"totalTrials":140,"cells":5321},{"EARLY_PHASE1":5322,"PHASE1":5324,"PHASE2":5326,"PHASE3":5328,"PHASE4":5334,"NA":5336},{"trials":5323,"activeCount":101},[],{"trials":5325,"activeCount":101},[],{"trials":5327,"activeCount":101},[],{"trials":5329,"activeCount":101},[5330],{"nctId":5308,"briefTitle":5309,"status":113,"phases":5331,"primaryCompletion":5311,"completion":3273,"start":3075,"enrollment":1024,"conditions":5332,"interventions":5333},[90,91],[5313],[5297,5315],{"trials":5335,"activeCount":101},[],{"trials":5337,"activeCount":101},[],{"intervention":5339,"totalTrials":140,"cells":5340},"Ivabradine",{"EARLY_PHASE1":5341,"PHASE1":5343,"PHASE2":5345,"PHASE3":5347,"PHASE4":5359,"NA":5361},{"trials":5342,"activeCount":101},[],{"trials":5344,"activeCount":101},[],{"trials":5346,"activeCount":101},[],{"trials":5348,"activeCount":101},[5349],{"nctId":5350,"briefTitle":5351,"status":113,"phases":5352,"primaryCompletion":5353,"completion":5353,"start":5354,"enrollment":5355,"conditions":5356,"interventions":5358},"NCT03182725","Effect of Ivabradine on Patients With Postural Orthostatic Tachycardia Syndrome",[91],"2020-05-08","2018-02-06",37,[5357],"Postural Orthostatic Tachycardia Syndrome",[5339],{"trials":5360,"activeCount":101},[],{"trials":5362,"activeCount":101},[],{"intervention":5364,"totalTrials":140,"cells":5365},"Gadopiclenol",{"EARLY_PHASE1":5366,"PHASE1":5368,"PHASE2":5370,"PHASE3":5372,"PHASE4":5384,"NA":5386},{"trials":5367,"activeCount":101},[],{"trials":5369,"activeCount":101},[],{"trials":5371,"activeCount":101},[],{"trials":5373,"activeCount":101},[5374],{"nctId":5375,"briefTitle":5376,"status":5377,"phases":5378,"primaryCompletion":2756,"completion":2756,"start":5379,"enrollment":312,"conditions":5380,"interventions":5382},"NCT06406517","Comparative Effectiveness of Gadopiclenol for Evaluation of Adult Congenital Heart Anatomy and Hemodynamics","UNKNOWN",[91],"2024-05",[5381],"Congenital Heart Disease",[5364,5383],"Gadobenate dimeglumine",{"trials":5385,"activeCount":101},[],{"trials":5387,"activeCount":101},[],{"intervention":5383,"totalTrials":140,"cells":5389},{"EARLY_PHASE1":5390,"PHASE1":5392,"PHASE2":5394,"PHASE3":5396,"PHASE4":5402,"NA":5404},{"trials":5391,"activeCount":101},[],{"trials":5393,"activeCount":101},[],{"trials":5395,"activeCount":101},[],{"trials":5397,"activeCount":101},[5398],{"nctId":5375,"briefTitle":5376,"status":5377,"phases":5399,"primaryCompletion":2756,"completion":2756,"start":5379,"enrollment":312,"conditions":5400,"interventions":5401},[91],[5381],[5364,5383],{"trials":5403,"activeCount":101},[],{"trials":5405,"activeCount":101},[],{"intervention":5407,"totalTrials":140,"cells":5408},"tigecycline, N-acetylcysteine, heparin combination",{"EARLY_PHASE1":5409,"PHASE1":5411,"PHASE2":5413,"PHASE3":5415,"PHASE4":5425,"NA":5427},{"trials":5410,"activeCount":101},[],{"trials":5412,"activeCount":101},[],{"trials":5414,"activeCount":101},[],{"trials":5416,"activeCount":101},[5417],{"nctId":5418,"briefTitle":5419,"status":1160,"phases":5420,"primaryCompletion":5421,"start":2672,"enrollment":101,"conditions":5422,"interventions":5424},"NCT02040818","Treatment of Hemodialysis Catheter-Related Bacteremia",[90,91],"2017-01",[5423],"Hemodialysis Catheter-related Bacteremia",[5407],{"trials":5426,"activeCount":101},[],{"trials":5428,"activeCount":101},[],{"intervention":5430,"totalTrials":140,"cells":5431},"FDA Approved Antiretroviral Therapy",{"EARLY_PHASE1":5432,"PHASE1":5434,"PHASE2":5436,"PHASE3":5438,"PHASE4":5449,"NA":5451},{"trials":5433,"activeCount":101},[],{"trials":5435,"activeCount":101},[],{"trials":5437,"activeCount":101},[],{"trials":5439,"activeCount":101},[5440],{"nctId":5441,"briefTitle":5442,"status":113,"phases":5443,"primaryCompletion":5444,"completion":2993,"start":5445,"enrollment":5446,"conditions":5447,"interventions":5448},"NCT00624195","Clinical Trial of CNS-targeted HAART (CIT2)",[90,91],"2012-02","2007-03",59,[3429],[5430],{"trials":5450,"activeCount":101},[],{"trials":5452,"activeCount":101},[],{"intervention":5454,"totalTrials":140,"cells":5455},"Nicotine Patch",{"EARLY_PHASE1":5456,"PHASE1":5458,"PHASE2":5460,"PHASE3":5462,"PHASE4":5473,"NA":5475},{"trials":5457,"activeCount":101},[],{"trials":5459,"activeCount":101},[],{"trials":5461,"activeCount":101},[],{"trials":5463,"activeCount":101},[5464],{"nctId":5465,"briefTitle":5466,"status":113,"phases":5467,"primaryCompletion":5468,"completion":3177,"start":5469,"enrollment":5470,"conditions":5471,"interventions":5472},"NCT00851357","Telephone Counseling and the Distribution of Nicotine Patches to Smokers",[91],"2010-10","2009-02",4200,[2977],[5454],{"trials":5474,"activeCount":101},[],{"trials":5476,"activeCount":101},[],{"intervention":5478,"totalTrials":140,"cells":5479},"Nitisinone",{"EARLY_PHASE1":5480,"PHASE1":5482,"PHASE2":5484,"PHASE3":5486,"PHASE4":5495,"NA":5497},{"trials":5481,"activeCount":101},[],{"trials":5483,"activeCount":101},[],{"trials":5485,"activeCount":101},[],{"trials":5487,"activeCount":101},[5488],{"nctId":5489,"briefTitle":5490,"status":113,"phases":5491,"primaryCompletion":3273,"completion":3326,"start":4943,"enrollment":2532,"conditions":5492,"interventions":5494},"NCT01390077","Nitisinone (NTBC) In Different Age Groups Of Patients With Alkaptonuria",[90,91],[5493],"Alkaptonuria",[5478],{"trials":5496,"activeCount":101},[],{"trials":5498,"activeCount":101},[],{"intervention":5500,"totalTrials":140,"cells":5501},"sapropterin",{"EARLY_PHASE1":5502,"PHASE1":5504,"PHASE2":5506,"PHASE3":5508,"PHASE4":5519,"NA":5521},{"trials":5503,"activeCount":101},[],{"trials":5505,"activeCount":101},[],{"trials":5507,"activeCount":101},[],{"trials":5509,"activeCount":101},[5510],{"nctId":5511,"briefTitle":5512,"status":1160,"phases":5513,"primaryCompletion":5514,"completion":5514,"start":5515,"enrollment":101,"conditions":5516,"interventions":5518},"NCT00935753","Trial of Kuvan in Lesch-Nyhan Disease",[90,91],"2010-02","2009-04",[5517],"Behavioral Manifestations of Lesch-Nyhan Disease",[5500],{"trials":5520,"activeCount":101},[],{"trials":5522,"activeCount":101},[],{"intervention":5524,"totalTrials":1149,"cells":5525},"Lenalidomide",{"EARLY_PHASE1":5526,"PHASE1":5528,"PHASE2":5542,"PHASE3":5560,"PHASE4":5562,"NA":5564},{"trials":5527,"activeCount":101},[],{"trials":5529,"activeCount":101},[5530],{"nctId":5531,"briefTitle":5532,"status":113,"phases":5533,"primaryCompletion":5534,"completion":5534,"start":5535,"enrollment":1024,"conditions":5536,"interventions":5538},"NCT03113695","Obinutuzumab, High Dose Methylprednisolone (HDMP), and Lenalidomide for the Treatment of Patients With Richter's Syndrome",[89],"2022-05-02","2017-12-20",[5537,1138],"Richter's Syndrome",[5539,5540,5541],"Obinutuzumab","lenalidomide","HDMP",{"trials":5543,"activeCount":101},[5544,5553],{"nctId":5545,"briefTitle":5546,"status":1160,"phases":5547,"primaryCompletion":5548,"completion":5549,"start":115,"enrollment":101,"conditions":5550,"interventions":5552},"NCT02371577","Evaluation of the Immune Restoration Potential Of Lenalidomide",[90],"2018-12","2020-12",[5551],"Chronic Lymphocytic Leukemia (CLL)",[5524],{"nctId":5554,"briefTitle":5555,"status":1160,"phases":5556,"primaryCompletion":5557,"completion":5048,"start":4577,"enrollment":101,"conditions":5558,"interventions":5559},"NCT02371590","Lenalidomide and Obinutuzumab for Previously Untreated CLL",[90],"2019-12",[1137],[5524,5539],{"trials":5561,"activeCount":101},[],{"trials":5563,"activeCount":101},[],{"trials":5565,"activeCount":101},[],{"intervention":976,"totalTrials":1149,"cells":5567},{"EARLY_PHASE1":5568,"PHASE1":5570,"PHASE2":5572,"PHASE3":5606,"PHASE4":5608,"NA":5610},{"trials":5569,"activeCount":101},[],{"trials":5571,"activeCount":101},[],{"trials":5573,"activeCount":101},[5574,5584,5594],{"nctId":5575,"briefTitle":5576,"status":113,"phases":5577,"primaryCompletion":5578,"completion":5578,"start":5579,"enrollment":5580,"conditions":5581,"interventions":5583},"NCT02849587","The Impact and Detection of Driving Impairments Associated With Acute Cannabis Smoking",[89,90],"2019-06-17","2017-02-24",199,[5582],"Cannabis Intoxication",[976],{"nctId":5585,"briefTitle":5586,"status":113,"phases":5587,"primaryCompletion":5588,"completion":5588,"start":5589,"enrollment":1175,"conditions":5590,"interventions":5593},"NCT03099005","Effect of Cannabis and Endocannabinoids on HIV Neuropathic Pain",[90],"2022-12-31","2018-07-01",[976,5591,5592],"HIV Neuropathy","Pain Syndrome",[976],{"nctId":5595,"briefTitle":5596,"status":1160,"phases":5597,"primaryCompletion":5598,"completion":5598,"start":5599,"enrollment":101,"conditions":5600,"interventions":5604},"NCT05273658","Effects of Cannabis\u002FAlcohol on Driving Performance and Field Sobriety Tests",[89,90],"2023-06","2022-08",[5601,5602,5603,5582],"Driving Impaired","Alcohol Intoxication","Driving Under the Influence",[976,5605],"Alcohol",{"trials":5607,"activeCount":101},[],{"trials":5609,"activeCount":101},[],{"trials":5611,"activeCount":101},[],{"intervention":1099,"totalTrials":97,"cells":5613},{"EARLY_PHASE1":5614,"PHASE1":5616,"PHASE2":5618,"PHASE3":5633,"PHASE4":5635,"NA":5637},{"trials":5615,"activeCount":101},[],{"trials":5617,"activeCount":101},[],{"trials":5619,"activeCount":101},[5620,5629],{"nctId":5621,"briefTitle":5622,"status":1160,"phases":5623,"primaryCompletion":2992,"completion":3076,"start":5624,"enrollment":101,"conditions":5625,"interventions":5627},"NCT01157975","Study the Relationship Between Obesity and Hepatitis C Replication",[90],"2008-10",[5626],"Hepatitis C",[5628,1099],"Pioglitazone",{"nctId":1085,"briefTitle":1086,"status":1066,"phases":5630,"primaryCompletion":1088,"completion":1088,"start":1089,"enrollment":1090,"conditions":5631,"interventions":5632},[90],[1092,1093],[1095,1096,1097,1098,1099,1100,1101,1102,1103,1104,1105,1076,1106],{"trials":5634,"activeCount":101},[],{"trials":5636,"activeCount":101},[],{"trials":5638,"activeCount":101},[],{"intervention":5539,"totalTrials":97,"cells":5640},{"EARLY_PHASE1":5641,"PHASE1":5643,"PHASE2":5649,"PHASE3":5655,"PHASE4":5657,"NA":5659},{"trials":5642,"activeCount":101},[],{"trials":5644,"activeCount":101},[5645],{"nctId":5531,"briefTitle":5532,"status":113,"phases":5646,"primaryCompletion":5534,"completion":5534,"start":5535,"enrollment":1024,"conditions":5647,"interventions":5648},[89],[5537,1138],[5539,5540,5541],{"trials":5650,"activeCount":101},[5651],{"nctId":5554,"briefTitle":5555,"status":1160,"phases":5652,"primaryCompletion":5557,"completion":5048,"start":4577,"enrollment":101,"conditions":5653,"interventions":5654},[90],[1137],[5524,5539],{"trials":5656,"activeCount":101},[],{"trials":5658,"activeCount":101},[],{"trials":5660,"activeCount":101},[],{"intervention":5662,"totalTrials":97,"cells":5663},"Pembrolizumab",{"EARLY_PHASE1":5664,"PHASE1":5666,"PHASE2":5668,"PHASE3":5702,"PHASE4":5704,"NA":5706},{"trials":5665,"activeCount":101},[],{"trials":5667,"activeCount":101},[],{"trials":5669,"activeCount":101},[5670,5690],{"nctId":5671,"briefTitle":5672,"status":113,"phases":5673,"primaryCompletion":5674,"completion":5675,"start":5676,"enrollment":2312,"conditions":5677,"interventions":5688},"NCT03993353","Tadalafil and Pembrolizumab in Recurrent or Metastatic Head and Neck Cancer",[90],"2022-04-16","2024-01-09","2020-04-07",[1177,5678,5679,5680,5681,5682,2800,5683,5684,5685,5686,5687],"Head and Neck Squamous Cell Carcinoma","Head and Neck Carcinoma","Head and Neck Cancer Stage III","Head and Neck Cancer Stage IV","Head and Neck Cancer Metastatic","Cancer of Esophagus","Cancer, Metastatic","Cancer of Head and Neck","Cancer of Mouth","Cancer of Neck",[5662,5689],"Tadalafil",{"nctId":5691,"briefTitle":5692,"status":113,"phases":5693,"primaryCompletion":5694,"completion":5695,"start":5696,"enrollment":3450,"conditions":5697,"interventions":5699},"NCT03160079","Blinatumomab & Pembrolizumab for Adults With Relapsed\u002FRefractory B-cell ALL With High Marrow Lymphoblasts",[89,90],"2021-12-21","2023-06-23","2017-08-04",[5698],"B-Cell Acute Lymphoblastic Leukemia, Adult",[5700,5701],"blinatumomab","pembrolizumab",{"trials":5703,"activeCount":101},[],{"trials":5705,"activeCount":101},[],{"trials":5707,"activeCount":101},[],{"intervention":5709,"totalTrials":97,"cells":5710},"Psilocybin",{"EARLY_PHASE1":5711,"PHASE1":5713,"PHASE2":5723,"PHASE3":5734,"PHASE4":5736,"NA":5738},{"trials":5712,"activeCount":101},[],{"trials":5714,"activeCount":101},[5715],{"nctId":5716,"briefTitle":5717,"status":113,"phases":5718,"primaryCompletion":5719,"completion":5719,"start":5720,"enrollment":1764,"conditions":5721,"interventions":5722},"NCT05224336","Psilocybin-assisted Therapy for Phantom Limb Pain",[89],"2024-03-07","2022-10-03",[4505],[5709],{"trials":5724,"activeCount":101},[5725],{"nctId":5726,"briefTitle":5727,"status":113,"phases":5728,"primaryCompletion":5729,"completion":5730,"start":5731,"enrollment":3450,"conditions":5732,"interventions":5733},"NCT04661514","Evaluation of Psilocybin in Anorexia Nervosa: Safety and Efficacy",[90],"2022-03-10","2022-06-10","2021-05-01",[35],[5709],{"trials":5735,"activeCount":101},[],{"trials":5737,"activeCount":101},[],{"trials":5739,"activeCount":101},[],{"intervention":5741,"totalTrials":97,"cells":5742},"THC ~5%",{"EARLY_PHASE1":5743,"PHASE1":5745,"PHASE2":5747,"PHASE3":5773,"PHASE4":5775,"NA":5777},{"trials":5744,"activeCount":101},[],{"trials":5746,"activeCount":101},[],{"trials":5748,"activeCount":101},[5749,5762],{"nctId":5750,"briefTitle":5751,"status":113,"phases":5752,"primaryCompletion":5753,"completion":5753,"start":5754,"enrollment":5755,"conditions":5756,"interventions":5758},"NCT04360044","Efficacy of Inhaled Cannabis for Acute Migraine Treatment",[90],"2023-02-23","2020-11-20",92,[5757,976,951,981],"Migraine",[5741,5759,5760,5761],"CBD ~12%","THC ~5% and CBD ~12%","Sham Cannabis",{"nctId":5763,"briefTitle":5764,"status":5765,"phases":5766,"primaryCompletion":5767,"completion":5767,"start":5768,"enrollment":27,"conditions":5769,"interventions":5770},"NCT05427630","Dose-Ranging Trial of Inhaled Cannabis for Acute Migraine Treatment","SUSPENDED",[90],"2027-12-01","2023-02-15",[5757,976,951],[5771,5741,5772,5761],"THC ~2.5%","THC ~10%",{"trials":5774,"activeCount":101},[],{"trials":5776,"activeCount":101},[],{"trials":5778,"activeCount":101},[],{"intervention":5761,"totalTrials":97,"cells":5780},{"EARLY_PHASE1":5781,"PHASE1":5783,"PHASE2":5785,"PHASE3":5795,"PHASE4":5797,"NA":5799},{"trials":5782,"activeCount":101},[],{"trials":5784,"activeCount":101},[],{"trials":5786,"activeCount":101},[5787,5791],{"nctId":5750,"briefTitle":5751,"status":113,"phases":5788,"primaryCompletion":5753,"completion":5753,"start":5754,"enrollment":5755,"conditions":5789,"interventions":5790},[90],[5757,976,951,981],[5741,5759,5760,5761],{"nctId":5763,"briefTitle":5764,"status":5765,"phases":5792,"primaryCompletion":5767,"completion":5767,"start":5768,"enrollment":27,"conditions":5793,"interventions":5794},[90],[5757,976,951],[5771,5741,5772,5761],{"trials":5796,"activeCount":101},[],{"trials":5798,"activeCount":101},[],{"trials":5800,"activeCount":101},[],{"intervention":1294,"totalTrials":97,"cells":5802},{"EARLY_PHASE1":5803,"PHASE1":5809,"PHASE2":5811,"PHASE3":5817,"PHASE4":5819,"NA":5821},{"trials":5804,"activeCount":101},[5805],{"nctId":1286,"briefTitle":1287,"status":1066,"phases":5806,"primaryCompletion":1289,"completion":1289,"start":1290,"enrollment":30,"conditions":5807,"interventions":5808},[88],[1292],[1294,1281,1295],{"trials":5810,"activeCount":101},[],{"trials":5812,"activeCount":101},[5813],{"nctId":3120,"briefTitle":3121,"status":113,"phases":5814,"primaryCompletion":3123,"completion":3123,"start":3124,"enrollment":3125,"conditions":5815,"interventions":5816},[90],[976,3127,3128],[1295,3130,3131],{"trials":5818,"activeCount":101},[],{"trials":5820,"activeCount":101},[],{"trials":5822,"activeCount":101},[],{"intervention":5824,"totalTrials":140,"cells":5825},"Kaletra + Isentress",{"EARLY_PHASE1":5826,"PHASE1":5828,"PHASE2":5830,"PHASE3":5843,"PHASE4":5845,"NA":5847},{"trials":5827,"activeCount":101},[],{"trials":5829,"activeCount":101},[],{"trials":5831,"activeCount":101},[5832],{"nctId":5833,"briefTitle":5834,"status":113,"phases":5835,"primaryCompletion":5836,"completion":5837,"start":5838,"enrollment":5839,"conditions":5840,"interventions":5841},"NCT00752856","Raltegravir + Lopinavir\u002FRitonavir Versus Efavirenz + Tenofovir + Emtricitabine in Treatment Naive Patients",[90],"2011-05-05","2014-02-11","2008-08-26",51,[3429],[5824,5842],"Atripla",{"trials":5844,"activeCount":101},[],{"trials":5846,"activeCount":101},[],{"trials":5848,"activeCount":101},[],{"intervention":5842,"totalTrials":140,"cells":5850},{"EARLY_PHASE1":5851,"PHASE1":5853,"PHASE2":5855,"PHASE3":5861,"PHASE4":5863,"NA":5865},{"trials":5852,"activeCount":101},[],{"trials":5854,"activeCount":101},[],{"trials":5856,"activeCount":101},[5857],{"nctId":5833,"briefTitle":5834,"status":113,"phases":5858,"primaryCompletion":5836,"completion":5837,"start":5838,"enrollment":5839,"conditions":5859,"interventions":5860},[90],[3429],[5824,5842],{"trials":5862,"activeCount":101},[],{"trials":5864,"activeCount":101},[],{"trials":5866,"activeCount":101},[],{"intervention":5868,"totalTrials":140,"cells":5869},"Pitocin",{"EARLY_PHASE1":5870,"PHASE1":5872,"PHASE2":5874,"PHASE3":5884,"PHASE4":5886,"NA":5888},{"trials":5871,"activeCount":101},[],{"trials":5873,"activeCount":101},[],{"trials":5875,"activeCount":101},[5876],{"nctId":5877,"briefTitle":5878,"status":113,"phases":5879,"primaryCompletion":5880,"completion":5880,"start":5881,"enrollment":27,"conditions":5882,"interventions":5883},"NCT05326776","Peripheral Oxytocin and Touch",[90],"2023-08-03","2023-04-05",[4556],[5868],{"trials":5885,"activeCount":101},[],{"trials":5887,"activeCount":101},[],{"trials":5889,"activeCount":101},[],{"intervention":5628,"totalTrials":140,"cells":5891},{"EARLY_PHASE1":5892,"PHASE1":5894,"PHASE2":5896,"PHASE3":5902,"PHASE4":5904,"NA":5906},{"trials":5893,"activeCount":101},[],{"trials":5895,"activeCount":101},[],{"trials":5897,"activeCount":101},[5898],{"nctId":5621,"briefTitle":5622,"status":1160,"phases":5899,"primaryCompletion":2992,"completion":3076,"start":5624,"enrollment":101,"conditions":5900,"interventions":5901},[90],[5626],[5628,1099],{"trials":5903,"activeCount":101},[],{"trials":5905,"activeCount":101},[],{"trials":5907,"activeCount":101},[],{"intervention":1167,"totalTrials":140,"cells":5909},{"EARLY_PHASE1":5910,"PHASE1":5912,"PHASE2":5914,"PHASE3":5920,"PHASE4":5922,"NA":5924},{"trials":5911,"activeCount":101},[],{"trials":5913,"activeCount":101},[],{"trials":5915,"activeCount":101},[5916],{"nctId":1158,"briefTitle":1159,"status":1160,"phases":5917,"primaryCompletion":1162,"completion":908,"start":1163,"enrollment":101,"conditions":5918,"interventions":5919},[89,90],[1165],[1167,1148],{"trials":5921,"activeCount":101},[],{"trials":5923,"activeCount":101},[],{"trials":5925,"activeCount":101},[],{"intervention":1180,"totalTrials":140,"cells":5927},{"EARLY_PHASE1":5928,"PHASE1":5930,"PHASE2":5932,"PHASE3":5938,"PHASE4":5940,"NA":5942},{"trials":5929,"activeCount":101},[],{"trials":5931,"activeCount":101},[],{"trials":5933,"activeCount":101},[5934],{"nctId":1169,"briefTitle":1170,"status":1066,"phases":5935,"primaryCompletion":1172,"completion":1173,"start":1174,"enrollment":1175,"conditions":5936,"interventions":5937},[90],[1177,1178],[1180,1181,1148],{"trials":5939,"activeCount":101},[],{"trials":5941,"activeCount":101},[],{"trials":5943,"activeCount":101},[],{"intervention":1181,"totalTrials":140,"cells":5945},{"EARLY_PHASE1":5946,"PHASE1":5948,"PHASE2":5950,"PHASE3":5956,"PHASE4":5958,"NA":5960},{"trials":5947,"activeCount":101},[],{"trials":5949,"activeCount":101},[],{"trials":5951,"activeCount":101},[5952],{"nctId":1169,"briefTitle":1170,"status":1066,"phases":5953,"primaryCompletion":1172,"completion":1173,"start":1174,"enrollment":1175,"conditions":5954,"interventions":5955},[90],[1177,1178],[1180,1181,1148],{"trials":5957,"activeCount":101},[],{"trials":5959,"activeCount":101},[],{"trials":5961,"activeCount":101},[],{"intervention":5963,"totalTrials":140,"cells":5964},"Ramipril 2.5 MG Oral",{"EARLY_PHASE1":5965,"PHASE1":5967,"PHASE2":5969,"PHASE3":5980,"PHASE4":5982,"NA":5984},{"trials":5966,"activeCount":101},[],{"trials":5968,"activeCount":101},[],{"trials":5970,"activeCount":101},[5971],{"nctId":5972,"briefTitle":5973,"status":113,"phases":5974,"primaryCompletion":5975,"completion":5975,"start":5976,"enrollment":312,"conditions":5977,"interventions":5979},"NCT04366050","Ramipril for the Treatment of COVID-19",[90],"2021-05-12","2020-05-11",[5978],"COVID-19",[5963],{"trials":5981,"activeCount":101},[],{"trials":5983,"activeCount":101},[],{"trials":5985,"activeCount":101},[],{"intervention":5987,"totalTrials":140,"cells":5988},"Aramchol",{"EARLY_PHASE1":5989,"PHASE1":5991,"PHASE2":5993,"PHASE3":6003,"PHASE4":6005,"NA":6007},{"trials":5990,"activeCount":101},[],{"trials":5992,"activeCount":101},[],{"trials":5994,"activeCount":101},[5995],{"nctId":5996,"briefTitle":5997,"status":113,"phases":5998,"primaryCompletion":4577,"completion":4577,"start":5999,"enrollment":2117,"conditions":6000,"interventions":6002},"NCT02684591","Aramchol for HIV-associated Nonalcoholic Fatty Liver Disease and Lipodystrophy",[90],"2016-01",[6001,29],"Nonalcoholic Fatty Liver Disease",[5987],{"trials":6004,"activeCount":101},[],{"trials":6006,"activeCount":101},[],{"trials":6008,"activeCount":101},[],{"intervention":6010,"totalTrials":140,"cells":6011},"PEG-interferon alfa-2a",{"EARLY_PHASE1":6012,"PHASE1":6014,"PHASE2":6016,"PHASE3":6026,"PHASE4":6028,"NA":6030},{"trials":6013,"activeCount":101},[],{"trials":6015,"activeCount":101},[],{"trials":6017,"activeCount":101},[6018],{"nctId":6019,"briefTitle":6020,"status":5377,"phases":6021,"primaryCompletion":4459,"start":1058,"enrollment":3450,"conditions":6022,"interventions":6024},"NCT00423397","Gefitinib and PEG-Interferon Alfa-2a in Treating Patients With Unresectable or Metastatic Skin Cancer",[89,90],[6023],"Non-melanomatous Skin Cancer",[6010,6025],"gefitinib",{"trials":6027,"activeCount":101},[],{"trials":6029,"activeCount":101},[],{"trials":6031,"activeCount":101},[],{"intervention":6025,"totalTrials":140,"cells":6033},{"EARLY_PHASE1":6034,"PHASE1":6036,"PHASE2":6038,"PHASE3":6044,"PHASE4":6046,"NA":6048},{"trials":6035,"activeCount":101},[],{"trials":6037,"activeCount":101},[],{"trials":6039,"activeCount":101},[6040],{"nctId":6019,"briefTitle":6020,"status":5377,"phases":6041,"primaryCompletion":4459,"start":1058,"enrollment":3450,"conditions":6042,"interventions":6043},[89,90],[6023],[6010,6025],{"trials":6045,"activeCount":101},[],{"trials":6047,"activeCount":101},[],{"trials":6049,"activeCount":101},[],{"intervention":6051,"totalTrials":140,"cells":6052},"Cyclophosphamide 50 mg\u002Fkg IV Days 3 and 4 post transplant",{"EARLY_PHASE1":6053,"PHASE1":6055,"PHASE2":6057,"PHASE3":6069,"PHASE4":6071,"NA":6073},{"trials":6054,"activeCount":101},[],{"trials":6056,"activeCount":101},[],{"trials":6058,"activeCount":101},[6059],{"nctId":6060,"briefTitle":6061,"status":1066,"phases":6062,"primaryCompletion":6063,"completion":6064,"start":6065,"enrollment":1764,"conditions":6066,"interventions":6068},"NCT02623439","A Study of Haploidentical Bone Marrow Transplant for Patients With Hematologic Malignancies",[90],"2016-05-12","2023-01-01","2012-09-21",[6067],"Hematologic Malignancies",[6051],{"trials":6070,"activeCount":101},[],{"trials":6072,"activeCount":101},[],{"trials":6074,"activeCount":101},[],{"intervention":5689,"totalTrials":140,"cells":6076},{"EARLY_PHASE1":6077,"PHASE1":6079,"PHASE2":6081,"PHASE3":6087,"PHASE4":6089,"NA":6091},{"trials":6078,"activeCount":101},[],{"trials":6080,"activeCount":101},[],{"trials":6082,"activeCount":101},[6083],{"nctId":5671,"briefTitle":5672,"status":113,"phases":6084,"primaryCompletion":5674,"completion":5675,"start":5676,"enrollment":2312,"conditions":6085,"interventions":6086},[90],[1177,5678,5679,5680,5681,5682,2800,5683,5684,5685,5686,5687],[5662,5689],{"trials":6088,"activeCount":101},[],{"trials":6090,"activeCount":101},[],{"trials":6092,"activeCount":101},[],{"intervention":6094,"totalTrials":140,"cells":6095},"Colesevelam Hcl",{"EARLY_PHASE1":6096,"PHASE1":6098,"PHASE2":6100,"PHASE3":6109,"PHASE4":6111,"NA":6113},{"trials":6097,"activeCount":101},[],{"trials":6099,"activeCount":101},[],{"trials":6101,"activeCount":101},[6102],{"nctId":6103,"briefTitle":6104,"status":113,"phases":6105,"primaryCompletion":5444,"completion":5444,"start":5514,"enrollment":5446,"conditions":6106,"interventions":6108},"NCT01066364","Colesevelam Versus Placebo in the Treatment of Nonalcoholic Steatohepatitis",[90],[6107],"Nonalcoholic Steatohepatitis",[6094],{"trials":6110,"activeCount":101},[],{"trials":6112,"activeCount":101},[],{"trials":6114,"activeCount":101},[],{"intervention":5700,"totalTrials":140,"cells":6116},{"EARLY_PHASE1":6117,"PHASE1":6119,"PHASE2":6121,"PHASE3":6127,"PHASE4":6129,"NA":6131},{"trials":6118,"activeCount":101},[],{"trials":6120,"activeCount":101},[],{"trials":6122,"activeCount":101},[6123],{"nctId":5691,"briefTitle":5692,"status":113,"phases":6124,"primaryCompletion":5694,"completion":5695,"start":5696,"enrollment":3450,"conditions":6125,"interventions":6126},[89,90],[5698],[5700,5701],{"trials":6128,"activeCount":101},[],{"trials":6130,"activeCount":101},[],{"trials":6132,"activeCount":101},[],{"intervention":1258,"totalTrials":140,"cells":6134},{"EARLY_PHASE1":6135,"PHASE1":6137,"PHASE2":6139,"PHASE3":6145,"PHASE4":6147,"NA":6149},{"trials":6136,"activeCount":101},[],{"trials":6138,"activeCount":101},[],{"trials":6140,"activeCount":101},[6141],{"nctId":1250,"briefTitle":1251,"status":113,"phases":6142,"primaryCompletion":1253,"completion":1254,"start":1255,"enrollment":932,"conditions":6143,"interventions":6144},[89,90],[912],[1258,66],{"trials":6146,"activeCount":101},[],{"trials":6148,"activeCount":101},[],{"trials":6150,"activeCount":101},[],{"intervention":1095,"totalTrials":140,"cells":6152},{"EARLY_PHASE1":6153,"PHASE1":6155,"PHASE2":6157,"PHASE3":6163,"PHASE4":6165,"NA":6167},{"trials":6154,"activeCount":101},[],{"trials":6156,"activeCount":101},[],{"trials":6158,"activeCount":101},[6159],{"nctId":1085,"briefTitle":1086,"status":1066,"phases":6160,"primaryCompletion":1088,"completion":1088,"start":1089,"enrollment":1090,"conditions":6161,"interventions":6162},[90],[1092,1093],[1095,1096,1097,1098,1099,1100,1101,1102,1103,1104,1105,1076,1106],{"trials":6164,"activeCount":101},[],{"trials":6166,"activeCount":101},[],{"trials":6168,"activeCount":101},[],{"intervention":1096,"totalTrials":140,"cells":6170},{"EARLY_PHASE1":6171,"PHASE1":6173,"PHASE2":6175,"PHASE3":6181,"PHASE4":6183,"NA":6185},{"trials":6172,"activeCount":101},[],{"trials":6174,"activeCount":101},[],{"trials":6176,"activeCount":101},[6177],{"nctId":1085,"briefTitle":1086,"status":1066,"phases":6178,"primaryCompletion":1088,"completion":1088,"start":1089,"enrollment":1090,"conditions":6179,"interventions":6180},[90],[1092,1093],[1095,1096,1097,1098,1099,1100,1101,1102,1103,1104,1105,1076,1106],{"trials":6182,"activeCount":101},[],{"trials":6184,"activeCount":101},[],{"trials":6186,"activeCount":101},[],{"intervention":1097,"totalTrials":140,"cells":6188},{"EARLY_PHASE1":6189,"PHASE1":6191,"PHASE2":6193,"PHASE3":6199,"PHASE4":6201,"NA":6203},{"trials":6190,"activeCount":101},[],{"trials":6192,"activeCount":101},[],{"trials":6194,"activeCount":101},[6195],{"nctId":1085,"briefTitle":1086,"status":1066,"phases":6196,"primaryCompletion":1088,"completion":1088,"start":1089,"enrollment":1090,"conditions":6197,"interventions":6198},[90],[1092,1093],[1095,1096,1097,1098,1099,1100,1101,1102,1103,1104,1105,1076,1106],{"trials":6200,"activeCount":101},[],{"trials":6202,"activeCount":101},[],{"trials":6204,"activeCount":101},[],{"intervention":1098,"totalTrials":140,"cells":6206},{"EARLY_PHASE1":6207,"PHASE1":6209,"PHASE2":6211,"PHASE3":6217,"PHASE4":6219,"NA":6221},{"trials":6208,"activeCount":101},[],{"trials":6210,"activeCount":101},[],{"trials":6212,"activeCount":101},[6213],{"nctId":1085,"briefTitle":1086,"status":1066,"phases":6214,"primaryCompletion":1088,"completion":1088,"start":1089,"enrollment":1090,"conditions":6215,"interventions":6216},[90],[1092,1093],[1095,1096,1097,1098,1099,1100,1101,1102,1103,1104,1105,1076,1106],{"trials":6218,"activeCount":101},[],{"trials":6220,"activeCount":101},[],{"trials":6222,"activeCount":101},[],{"intervention":1100,"totalTrials":140,"cells":6224},{"EARLY_PHASE1":6225,"PHASE1":6227,"PHASE2":6229,"PHASE3":6235,"PHASE4":6237,"NA":6239},{"trials":6226,"activeCount":101},[],{"trials":6228,"activeCount":101},[],{"trials":6230,"activeCount":101},[6231],{"nctId":1085,"briefTitle":1086,"status":1066,"phases":6232,"primaryCompletion":1088,"completion":1088,"start":1089,"enrollment":1090,"conditions":6233,"interventions":6234},[90],[1092,1093],[1095,1096,1097,1098,1099,1100,1101,1102,1103,1104,1105,1076,1106],{"trials":6236,"activeCount":101},[],{"trials":6238,"activeCount":101},[],{"trials":6240,"activeCount":101},[],{"intervention":1101,"totalTrials":140,"cells":6242},{"EARLY_PHASE1":6243,"PHASE1":6245,"PHASE2":6247,"PHASE3":6253,"PHASE4":6255,"NA":6257},{"trials":6244,"activeCount":101},[],{"trials":6246,"activeCount":101},[],{"trials":6248,"activeCount":101},[6249],{"nctId":1085,"briefTitle":1086,"status":1066,"phases":6250,"primaryCompletion":1088,"completion":1088,"start":1089,"enrollment":1090,"conditions":6251,"interventions":6252},[90],[1092,1093],[1095,1096,1097,1098,1099,1100,1101,1102,1103,1104,1105,1076,1106],{"trials":6254,"activeCount":101},[],{"trials":6256,"activeCount":101},[],{"trials":6258,"activeCount":101},[],{"intervention":1102,"totalTrials":140,"cells":6260},{"EARLY_PHASE1":6261,"PHASE1":6263,"PHASE2":6265,"PHASE3":6271,"PHASE4":6273,"NA":6275},{"trials":6262,"activeCount":101},[],{"trials":6264,"activeCount":101},[],{"trials":6266,"activeCount":101},[6267],{"nctId":1085,"briefTitle":1086,"status":1066,"phases":6268,"primaryCompletion":1088,"completion":1088,"start":1089,"enrollment":1090,"conditions":6269,"interventions":6270},[90],[1092,1093],[1095,1096,1097,1098,1099,1100,1101,1102,1103,1104,1105,1076,1106],{"trials":6272,"activeCount":101},[],{"trials":6274,"activeCount":101},[],{"trials":6276,"activeCount":101},[],{"intervention":1103,"totalTrials":140,"cells":6278},{"EARLY_PHASE1":6279,"PHASE1":6281,"PHASE2":6283,"PHASE3":6289,"PHASE4":6291,"NA":6293},{"trials":6280,"activeCount":101},[],{"trials":6282,"activeCount":101},[],{"trials":6284,"activeCount":101},[6285],{"nctId":1085,"briefTitle":1086,"status":1066,"phases":6286,"primaryCompletion":1088,"completion":1088,"start":1089,"enrollment":1090,"conditions":6287,"interventions":6288},[90],[1092,1093],[1095,1096,1097,1098,1099,1100,1101,1102,1103,1104,1105,1076,1106],{"trials":6290,"activeCount":101},[],{"trials":6292,"activeCount":101},[],{"trials":6294,"activeCount":101},[],{"intervention":1104,"totalTrials":140,"cells":6296},{"EARLY_PHASE1":6297,"PHASE1":6299,"PHASE2":6301,"PHASE3":6307,"PHASE4":6309,"NA":6311},{"trials":6298,"activeCount":101},[],{"trials":6300,"activeCount":101},[],{"trials":6302,"activeCount":101},[6303],{"nctId":1085,"briefTitle":1086,"status":1066,"phases":6304,"primaryCompletion":1088,"completion":1088,"start":1089,"enrollment":1090,"conditions":6305,"interventions":6306},[90],[1092,1093],[1095,1096,1097,1098,1099,1100,1101,1102,1103,1104,1105,1076,1106],{"trials":6308,"activeCount":101},[],{"trials":6310,"activeCount":101},[],{"trials":6312,"activeCount":101},[],{"intervention":1105,"totalTrials":140,"cells":6314},{"EARLY_PHASE1":6315,"PHASE1":6317,"PHASE2":6319,"PHASE3":6325,"PHASE4":6327,"NA":6329},{"trials":6316,"activeCount":101},[],{"trials":6318,"activeCount":101},[],{"trials":6320,"activeCount":101},[6321],{"nctId":1085,"briefTitle":1086,"status":1066,"phases":6322,"primaryCompletion":1088,"completion":1088,"start":1089,"enrollment":1090,"conditions":6323,"interventions":6324},[90],[1092,1093],[1095,1096,1097,1098,1099,1100,1101,1102,1103,1104,1105,1076,1106],{"trials":6326,"activeCount":101},[],{"trials":6328,"activeCount":101},[],{"trials":6330,"activeCount":101},[],{"intervention":6332,"totalTrials":140,"cells":6333},"GA101",{"EARLY_PHASE1":6334,"PHASE1":6336,"PHASE2":6338,"PHASE3":6349,"PHASE4":6351,"NA":6353},{"trials":6335,"activeCount":101},[],{"trials":6337,"activeCount":101},[],{"trials":6339,"activeCount":101},[6340],{"nctId":6341,"briefTitle":6342,"status":113,"phases":6343,"primaryCompletion":6344,"completion":6344,"start":6345,"enrollment":1879,"conditions":6346,"interventions":6347},"NCT02315768","Ibrutinib in Combination With GA101 (Obinutuzumab) in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Patients.",[89,90],"2022-04-18","2015-08-26",[1137],[6332,6348],"Ibrutinib",{"trials":6350,"activeCount":101},[],{"trials":6352,"activeCount":101},[],{"trials":6354,"activeCount":101},[],{"intervention":6348,"totalTrials":140,"cells":6356},{"EARLY_PHASE1":6357,"PHASE1":6359,"PHASE2":6361,"PHASE3":6367,"PHASE4":6369,"NA":6371},{"trials":6358,"activeCount":101},[],{"trials":6360,"activeCount":101},[],{"trials":6362,"activeCount":101},[6363],{"nctId":6341,"briefTitle":6342,"status":113,"phases":6364,"primaryCompletion":6344,"completion":6344,"start":6345,"enrollment":1879,"conditions":6365,"interventions":6366},[89,90],[1137],[6332,6348],{"trials":6368,"activeCount":101},[],{"trials":6370,"activeCount":101},[],{"trials":6372,"activeCount":101},[],{"intervention":6374,"totalTrials":140,"cells":6375},"Dextroamphetamine",{"EARLY_PHASE1":6376,"PHASE1":6378,"PHASE2":6380,"PHASE3":6391,"PHASE4":6393,"NA":6395},{"trials":6377,"activeCount":101},[],{"trials":6379,"activeCount":101},[],{"trials":6381,"activeCount":101},[6382],{"nctId":6383,"briefTitle":6384,"status":113,"phases":6385,"primaryCompletion":6386,"completion":6386,"start":6387,"enrollment":6388,"conditions":6389,"interventions":6390},"NCT02634684","Pharmacologically-augmented Cognitive Therapies (PACTs) for Schizophrenia.",[90],"2020-08","2014-07-01",82,[21],[6374],{"trials":6392,"activeCount":101},[],{"trials":6394,"activeCount":101},[],{"trials":6396,"activeCount":101},[],{"intervention":6398,"totalTrials":140,"cells":6399},"Ivermectin",{"EARLY_PHASE1":6400,"PHASE1":6402,"PHASE2":6404,"PHASE3":6415,"PHASE4":6417,"NA":6419},{"trials":6401,"activeCount":101},[],{"trials":6403,"activeCount":101},[],{"trials":6405,"activeCount":101},[6406],{"nctId":6407,"briefTitle":6408,"status":113,"phases":6409,"primaryCompletion":6410,"completion":6411,"start":3326,"enrollment":910,"conditions":6412,"interventions":6414},"NCT02806414","Evaluation of the Inhibitory Effects of Topical Ivermectin on Markers of Rosacea Specific Inflammation.",[89,90],"2019-07","2021-05",[6413],"Rosacea",[6398],{"trials":6416,"activeCount":101},[],{"trials":6418,"activeCount":101},[],{"trials":6420,"activeCount":101},[],{"intervention":6422,"totalTrials":140,"cells":6423},"Pembrolizumab, Cetuximab",{"EARLY_PHASE1":6424,"PHASE1":6426,"PHASE2":6428,"PHASE3":6449,"PHASE4":6451,"NA":6453},{"trials":6425,"activeCount":101},[],{"trials":6427,"activeCount":101},[],{"trials":6429,"activeCount":101},[6430],{"nctId":6431,"briefTitle":6432,"status":113,"phases":6433,"primaryCompletion":6434,"completion":6435,"start":6436,"enrollment":6437,"conditions":6438,"interventions":6448},"NCT03082534","Pembrolizumab Combined With Cetuximab for Treatment of Recurrent\u002FMetastatic Head & Neck Squamous Cell Carcinoma",[90],"2025-07-21","2025-09-11","2017-03-28",78,[6439,6440,6441,1335,6442,6443,6444,6445,6446,6447,1177,5678],"HNSCC","Lip SCC","Oral Cavity Cancer","Larynx Cancer","Hypopharynx Cancer","Nasopharynx Cancer","Sinonasal Carcinoma","Cutaneous Squamous Cell Carcinoma","Head and Neck Neoplasms",[6422],{"trials":6450,"activeCount":101},[],{"trials":6452,"activeCount":101},[],{"trials":6454,"activeCount":101},[],{"intervention":6456,"totalTrials":140,"cells":6457},"Tenofovir",{"EARLY_PHASE1":6458,"PHASE1":6460,"PHASE2":6462,"PHASE3":6475,"PHASE4":6477,"NA":6479},{"trials":6459,"activeCount":101},[],{"trials":6461,"activeCount":101},[],{"trials":6463,"activeCount":101},[6464],{"nctId":6465,"briefTitle":6466,"status":113,"phases":6467,"primaryCompletion":6468,"completion":6469,"start":6470,"enrollment":6471,"conditions":6472,"interventions":6473},"NCT00214890","Viral Dynamics and Pharmacokinetics of Abacavir and Tenofovir",[90],"2008-06-26","2010-04-27","2004-12-07",21,[3429],[6456,6474],"Abacavir",{"trials":6476,"activeCount":101},[],{"trials":6478,"activeCount":101},[],{"trials":6480,"activeCount":101},[],{"intervention":6474,"totalTrials":140,"cells":6482},{"EARLY_PHASE1":6483,"PHASE1":6485,"PHASE2":6487,"PHASE3":6493,"PHASE4":6495,"NA":6497},{"trials":6484,"activeCount":101},[],{"trials":6486,"activeCount":101},[],{"trials":6488,"activeCount":101},[6489],{"nctId":6465,"briefTitle":6466,"status":113,"phases":6490,"primaryCompletion":6468,"completion":6469,"start":6470,"enrollment":6471,"conditions":6491,"interventions":6492},[90],[3429],[6456,6474],{"trials":6494,"activeCount":101},[],{"trials":6496,"activeCount":101},[],{"trials":6498,"activeCount":101},[],{"intervention":6500,"totalTrials":140,"cells":6501},"5-Azacitidine",{"EARLY_PHASE1":6502,"PHASE1":6504,"PHASE2":6506,"PHASE3":6518,"PHASE4":6520,"NA":6522},{"trials":6503,"activeCount":101},[],{"trials":6505,"activeCount":101},[],{"trials":6507,"activeCount":101},[6508],{"nctId":6509,"briefTitle":6510,"status":113,"phases":6511,"primaryCompletion":6512,"completion":6512,"start":6513,"enrollment":2117,"conditions":6514,"interventions":6516},"NCT00766116","Combination 5-azacitidine and Gemtuzumab Ozogamicin Therapy for Treatment of Relapsed Acute Myeloid Leukemia (AML)",[89,90],"2014-09-26","2005-07",[6515],"Acute Myeloid Leukemia",[6500,6517],"Gemtuzumab ozogamicin",{"trials":6519,"activeCount":101},[],{"trials":6521,"activeCount":101},[],{"trials":6523,"activeCount":101},[],{"intervention":6517,"totalTrials":140,"cells":6525},{"EARLY_PHASE1":6526,"PHASE1":6528,"PHASE2":6530,"PHASE3":6536,"PHASE4":6538,"NA":6540},{"trials":6527,"activeCount":101},[],{"trials":6529,"activeCount":101},[],{"trials":6531,"activeCount":101},[6532],{"nctId":6509,"briefTitle":6510,"status":113,"phases":6533,"primaryCompletion":6512,"completion":6512,"start":6513,"enrollment":2117,"conditions":6534,"interventions":6535},[89,90],[6515],[6500,6517],{"trials":6537,"activeCount":101},[],{"trials":6539,"activeCount":101},[],{"trials":6541,"activeCount":101},[],{"intervention":6543,"totalTrials":140,"cells":6544},"GA101\u002FHDMP",{"EARLY_PHASE1":6545,"PHASE1":6547,"PHASE2":6549,"PHASE3":6558,"PHASE4":6560,"NA":6562},{"trials":6546,"activeCount":101},[],{"trials":6548,"activeCount":101},[],{"trials":6550,"activeCount":101},[6551],{"nctId":6552,"briefTitle":6553,"status":5377,"phases":6554,"primaryCompletion":2033,"completion":6555,"start":3076,"enrollment":386,"conditions":6556,"interventions":6557},"NCT02229422","A Study of Obinutuzumab(GA101) in Combination With High-Dose Methylprednisolone(HDMP) in Chronic Lymphocytic Leukemia(CLL) Patients (GA101 & HDMP)",[89,90],"2025-12-25",[1138],[6543],{"trials":6559,"activeCount":101},[],{"trials":6561,"activeCount":101},[],{"trials":6563,"activeCount":101},[],{"intervention":6565,"totalTrials":140,"cells":6566},"glecaprevir\u002Fpibrentasvir",{"EARLY_PHASE1":6567,"PHASE1":6569,"PHASE2":6571,"PHASE3":6582,"PHASE4":6584,"NA":6586},{"trials":6568,"activeCount":101},[],{"trials":6570,"activeCount":101},[],{"trials":6572,"activeCount":101},[6573],{"nctId":6574,"briefTitle":6575,"status":113,"phases":6576,"primaryCompletion":6577,"completion":6577,"start":6578,"enrollment":932,"conditions":6579,"interventions":6581},"NCT04596475","Prevention of Transmission of Hepatitis C Virus (HCV) From HCV-Viremic Organ Donor",[89,90],"2022-04-21","2021-05-28",[5626,6580],"Hepatitis C Virus Infection, Response to Therapy of",[6565],{"trials":6583,"activeCount":101},[],{"trials":6585,"activeCount":101},[],{"trials":6587,"activeCount":101},[],{"intervention":6589,"totalTrials":140,"cells":6590},"Semaglutide",{"EARLY_PHASE1":6591,"PHASE1":6593,"PHASE2":6595,"PHASE3":6608,"PHASE4":6610,"NA":6612},{"trials":6592,"activeCount":101},[],{"trials":6594,"activeCount":101},[],{"trials":6596,"activeCount":101},[6597],{"nctId":6598,"briefTitle":6599,"status":5377,"phases":6600,"primaryCompletion":6601,"completion":2756,"start":6602,"enrollment":163,"conditions":6603,"interventions":6607},"NCT06005012","Semaglutide Treatment in the Real-world for Fibrosis Due to NAFLD in Obesity and T2DM",[90],"2025-03","2023-07-25",[6604,6605,6606],"Fibrosis, Liver","Type 2 Diabetes Mellitus in Obese","Non-Alcoholic Fatty Liver Disease",[6589],{"trials":6609,"activeCount":101},[],{"trials":6611,"activeCount":101},[],{"trials":6613,"activeCount":101},[],{"intervention":6615,"totalTrials":140,"cells":6616},"Epoetin Alfa and Iron",{"EARLY_PHASE1":6617,"PHASE1":6619,"PHASE2":6621,"PHASE3":6634,"PHASE4":6636,"NA":6638},{"trials":6618,"activeCount":101},[],{"trials":6620,"activeCount":101},[],{"trials":6622,"activeCount":101},[6623],{"nctId":6624,"briefTitle":6625,"status":1066,"phases":6626,"primaryCompletion":6627,"completion":6627,"start":4192,"enrollment":1024,"conditions":6628,"interventions":6632},"NCT02564796","Erythropoietin to Prevent Unnecessary Transfusions In Patients With Cyanotic CHD - A Prospective Control Trial",[90],"2020-06",[6629,6630,6631,5381],"Cyanotic Congenital Heart Disease","Anemia","Cyanosis",[6615,6633],"Iron",{"trials":6635,"activeCount":101},[],{"trials":6637,"activeCount":101},[],{"trials":6639,"activeCount":101},[],{"intervention":6633,"totalTrials":140,"cells":6641},{"EARLY_PHASE1":6642,"PHASE1":6644,"PHASE2":6646,"PHASE3":6652,"PHASE4":6654,"NA":6656},{"trials":6643,"activeCount":101},[],{"trials":6645,"activeCount":101},[],{"trials":6647,"activeCount":101},[6648],{"nctId":6624,"briefTitle":6625,"status":1066,"phases":6649,"primaryCompletion":6627,"completion":6627,"start":4192,"enrollment":1024,"conditions":6650,"interventions":6651},[90],[6629,6630,6631,5381],[6615,6633],{"trials":6653,"activeCount":101},[],{"trials":6655,"activeCount":101},[],{"trials":6657,"activeCount":101},[],{"intervention":6659,"totalTrials":140,"cells":6660},"CBD\u002FTHC",{"EARLY_PHASE1":6661,"PHASE1":6663,"PHASE2":6665,"PHASE3":6676,"PHASE4":6678,"NA":6680},{"trials":6662,"activeCount":101},[],{"trials":6664,"activeCount":101},[],{"trials":6666,"activeCount":101},[6667],{"nctId":6668,"briefTitle":6669,"status":113,"phases":6670,"primaryCompletion":6671,"completion":6672,"start":6673,"enrollment":2312,"conditions":6674,"interventions":6675},"NCT03805750","Trial of Cannabis for Essential Tremor",[89,90],"2020-09-01","2020-11-30","2019-01-22",[4169],[6659],{"trials":6677,"activeCount":101},[],{"trials":6679,"activeCount":101},[],{"trials":6681,"activeCount":101},[],{"intervention":6683,"totalTrials":140,"cells":6684},"Eszopiclone 2 mg",{"EARLY_PHASE1":6685,"PHASE1":6687,"PHASE2":6689,"PHASE3":6698,"PHASE4":6700,"NA":6702},{"trials":6686,"activeCount":101},[],{"trials":6688,"activeCount":101},[],{"trials":6690,"activeCount":101},[6691],{"nctId":6692,"briefTitle":6693,"status":113,"phases":6694,"primaryCompletion":6695,"completion":2531,"start":3245,"enrollment":1306,"conditions":6696,"interventions":6697},"NCT05951023","Endotype-Targeted Therapy to Rescue OSA Patients Struggling With CPAP Adherence (TOP-CPAP)",[90],"2025-07-23",[18],[6683],{"trials":6699,"activeCount":101},[],{"trials":6701,"activeCount":101},[],{"trials":6703,"activeCount":101},[],{"intervention":5605,"totalTrials":140,"cells":6705},{"EARLY_PHASE1":6706,"PHASE1":6708,"PHASE2":6710,"PHASE3":6716,"PHASE4":6718,"NA":6720},{"trials":6707,"activeCount":101},[],{"trials":6709,"activeCount":101},[],{"trials":6711,"activeCount":101},[6712],{"nctId":5595,"briefTitle":5596,"status":1160,"phases":6713,"primaryCompletion":5598,"completion":5598,"start":5599,"enrollment":101,"conditions":6714,"interventions":6715},[89,90],[5601,5602,5603,5582],[976,5605],{"trials":6717,"activeCount":101},[],{"trials":6719,"activeCount":101},[],{"trials":6721,"activeCount":101},[],{"intervention":6723,"totalTrials":140,"cells":6724},"Fludarabine",{"EARLY_PHASE1":6725,"PHASE1":6727,"PHASE2":6729,"PHASE3":6743,"PHASE4":6745,"NA":6747},{"trials":6726,"activeCount":101},[],{"trials":6728,"activeCount":101},[],{"trials":6730,"activeCount":101},[6731],{"nctId":6732,"briefTitle":6733,"status":1066,"phases":6734,"primaryCompletion":6735,"completion":6735,"start":6736,"enrollment":97,"conditions":6737,"interventions":6741},"NCT04425655","Fludarabine in Combination With Daunorubicin and Cytarabine Liposome in Newly-diagnosed Acute Myeloid Leukemia.",[90],"2022-07-01","2020-08-05",[6738,6739,6740],"Acute Myeloid Leukemia, Adult","AML","AML, Adult",[6723,6742],"Vyxeos",{"trials":6744,"activeCount":101},[],{"trials":6746,"activeCount":101},[],{"trials":6748,"activeCount":101},[],{"intervention":6742,"totalTrials":140,"cells":6750},{"EARLY_PHASE1":6751,"PHASE1":6753,"PHASE2":6755,"PHASE3":6761,"PHASE4":6763,"NA":6765},{"trials":6752,"activeCount":101},[],{"trials":6754,"activeCount":101},[],{"trials":6756,"activeCount":101},[6757],{"nctId":6732,"briefTitle":6733,"status":1066,"phases":6758,"primaryCompletion":6735,"completion":6735,"start":6736,"enrollment":97,"conditions":6759,"interventions":6760},[90],[6738,6739,6740],[6723,6742],{"trials":6762,"activeCount":101},[],{"trials":6764,"activeCount":101},[],{"trials":6766,"activeCount":101},[],{"intervention":6768,"totalTrials":140,"cells":6769},"Dasatinib and Rituximab",{"EARLY_PHASE1":6770,"PHASE1":6772,"PHASE2":6774,"PHASE3":6784,"PHASE4":6786,"NA":6788},{"trials":6771,"activeCount":101},[],{"trials":6773,"activeCount":101},[],{"trials":6775,"activeCount":101},[6776],{"nctId":6777,"briefTitle":6778,"status":1066,"phases":6779,"primaryCompletion":6780,"completion":6780,"start":6781,"enrollment":1149,"conditions":6782,"interventions":6783},"NCT00949988","A Study of Dasatinib and Rituximab for Relapsed\u002FRefractory Chronic Lymphocytic Leukemia",[89,90],"2012-04","2009-05",[1137],[6768],{"trials":6785,"activeCount":101},[],{"trials":6787,"activeCount":101},[],{"trials":6789,"activeCount":101},[],{"intervention":6791,"totalTrials":140,"cells":6792},"Suramin",{"EARLY_PHASE1":6793,"PHASE1":6795,"PHASE2":6797,"PHASE3":6806,"PHASE4":6808,"NA":6810},{"trials":6794,"activeCount":101},[],{"trials":6796,"activeCount":101},[],{"trials":6798,"activeCount":101},[6799],{"nctId":6800,"briefTitle":6801,"status":113,"phases":6802,"primaryCompletion":3327,"completion":3210,"start":4191,"enrollment":1764,"conditions":6803,"interventions":6805},"NCT02508259","University of California, San Diego (UCSD) Suramin Autism Treatment-1 (SAT1) Trial",[89,90],[6804],"Autism Spectrum Disorders",[6791,4874],{"trials":6807,"activeCount":101},[],{"trials":6809,"activeCount":101},[],{"trials":6811,"activeCount":101},[],{"intervention":6813,"totalTrials":140,"cells":6814},"anti-thymocyte globulin",{"EARLY_PHASE1":6815,"PHASE1":6817,"PHASE2":6819,"PHASE3":6836,"PHASE4":6838,"NA":6840},{"trials":6816,"activeCount":101},[],{"trials":6818,"activeCount":101},[],{"trials":6820,"activeCount":101},[6821],{"nctId":6822,"briefTitle":6823,"status":1066,"phases":6824,"primaryCompletion":6825,"completion":6825,"start":6826,"enrollment":1175,"conditions":6827,"interventions":6828},"NCT00074269","Allogeneic Stem Cell Transplant After ATG, High-Dose Melphalan, and Fludarabine for Patients With Breast Cancer",[90],"2008-03","2003-07",[26],[6813,6829,6830,6831,6832,6833,6834,6835],"filgrastim","graft-versus-tumor induction therapy","therapeutic allogeneic lymphocytes","cyclosporine","fludarabine phosphate","melphalan","methotrexate",{"trials":6837,"activeCount":101},[],{"trials":6839,"activeCount":101},[],{"trials":6841,"activeCount":101},[],{"intervention":6829,"totalTrials":140,"cells":6843},{"EARLY_PHASE1":6844,"PHASE1":6846,"PHASE2":6848,"PHASE3":6854,"PHASE4":6856,"NA":6858},{"trials":6845,"activeCount":101},[],{"trials":6847,"activeCount":101},[],{"trials":6849,"activeCount":101},[6850],{"nctId":6822,"briefTitle":6823,"status":1066,"phases":6851,"primaryCompletion":6825,"completion":6825,"start":6826,"enrollment":1175,"conditions":6852,"interventions":6853},[90],[26],[6813,6829,6830,6831,6832,6833,6834,6835],{"trials":6855,"activeCount":101},[],{"trials":6857,"activeCount":101},[],{"trials":6859,"activeCount":101},[],{"intervention":6830,"totalTrials":140,"cells":6861},{"EARLY_PHASE1":6862,"PHASE1":6864,"PHASE2":6866,"PHASE3":6872,"PHASE4":6874,"NA":6876},{"trials":6863,"activeCount":101},[],{"trials":6865,"activeCount":101},[],{"trials":6867,"activeCount":101},[6868],{"nctId":6822,"briefTitle":6823,"status":1066,"phases":6869,"primaryCompletion":6825,"completion":6825,"start":6826,"enrollment":1175,"conditions":6870,"interventions":6871},[90],[26],[6813,6829,6830,6831,6832,6833,6834,6835],{"trials":6873,"activeCount":101},[],{"trials":6875,"activeCount":101},[],{"trials":6877,"activeCount":101},[],{"intervention":6831,"totalTrials":140,"cells":6879},{"EARLY_PHASE1":6880,"PHASE1":6882,"PHASE2":6884,"PHASE3":6890,"PHASE4":6892,"NA":6894},{"trials":6881,"activeCount":101},[],{"trials":6883,"activeCount":101},[],{"trials":6885,"activeCount":101},[6886],{"nctId":6822,"briefTitle":6823,"status":1066,"phases":6887,"primaryCompletion":6825,"completion":6825,"start":6826,"enrollment":1175,"conditions":6888,"interventions":6889},[90],[26],[6813,6829,6830,6831,6832,6833,6834,6835],{"trials":6891,"activeCount":101},[],{"trials":6893,"activeCount":101},[],{"trials":6895,"activeCount":101},[],{"intervention":6832,"totalTrials":140,"cells":6897},{"EARLY_PHASE1":6898,"PHASE1":6900,"PHASE2":6902,"PHASE3":6908,"PHASE4":6910,"NA":6912},{"trials":6899,"activeCount":101},[],{"trials":6901,"activeCount":101},[],{"trials":6903,"activeCount":101},[6904],{"nctId":6822,"briefTitle":6823,"status":1066,"phases":6905,"primaryCompletion":6825,"completion":6825,"start":6826,"enrollment":1175,"conditions":6906,"interventions":6907},[90],[26],[6813,6829,6830,6831,6832,6833,6834,6835],{"trials":6909,"activeCount":101},[],{"trials":6911,"activeCount":101},[],{"trials":6913,"activeCount":101},[],{"intervention":6833,"totalTrials":140,"cells":6915},{"EARLY_PHASE1":6916,"PHASE1":6918,"PHASE2":6920,"PHASE3":6926,"PHASE4":6928,"NA":6930},{"trials":6917,"activeCount":101},[],{"trials":6919,"activeCount":101},[],{"trials":6921,"activeCount":101},[6922],{"nctId":6822,"briefTitle":6823,"status":1066,"phases":6923,"primaryCompletion":6825,"completion":6825,"start":6826,"enrollment":1175,"conditions":6924,"interventions":6925},[90],[26],[6813,6829,6830,6831,6832,6833,6834,6835],{"trials":6927,"activeCount":101},[],{"trials":6929,"activeCount":101},[],{"trials":6931,"activeCount":101},[],{"intervention":6834,"totalTrials":140,"cells":6933},{"EARLY_PHASE1":6934,"PHASE1":6936,"PHASE2":6938,"PHASE3":6944,"PHASE4":6946,"NA":6948},{"trials":6935,"activeCount":101},[],{"trials":6937,"activeCount":101},[],{"trials":6939,"activeCount":101},[6940],{"nctId":6822,"briefTitle":6823,"status":1066,"phases":6941,"primaryCompletion":6825,"completion":6825,"start":6826,"enrollment":1175,"conditions":6942,"interventions":6943},[90],[26],[6813,6829,6830,6831,6832,6833,6834,6835],{"trials":6945,"activeCount":101},[],{"trials":6947,"activeCount":101},[],{"trials":6949,"activeCount":101},[],{"intervention":6835,"totalTrials":140,"cells":6951},{"EARLY_PHASE1":6952,"PHASE1":6954,"PHASE2":6956,"PHASE3":6962,"PHASE4":6964,"NA":6966},{"trials":6953,"activeCount":101},[],{"trials":6955,"activeCount":101},[],{"trials":6957,"activeCount":101},[6958],{"nctId":6822,"briefTitle":6823,"status":1066,"phases":6959,"primaryCompletion":6825,"completion":6825,"start":6826,"enrollment":1175,"conditions":6960,"interventions":6961},[90],[26],[6813,6829,6830,6831,6832,6833,6834,6835],{"trials":6963,"activeCount":101},[],{"trials":6965,"activeCount":101},[],{"trials":6967,"activeCount":101},[],{"intervention":6969,"totalTrials":140,"cells":6970},"Tesamorelin",{"EARLY_PHASE1":6971,"PHASE1":6973,"PHASE2":6975,"PHASE3":6986,"PHASE4":6988,"NA":6990},{"trials":6972,"activeCount":101},[],{"trials":6974,"activeCount":101},[],{"trials":6976,"activeCount":101},[6977],{"nctId":6978,"briefTitle":6979,"status":113,"phases":6980,"primaryCompletion":6981,"completion":6981,"start":6982,"enrollment":4979,"conditions":6983,"interventions":6985},"NCT02572323","Phase II Trial of Tesamorelin for Cognition in Aging HIV-Infected Persons",[90],"2023-10-15","2017-02-15",[6984],"Mild Cognitive Impairment",[6969],{"trials":6987,"activeCount":101},[],{"trials":6989,"activeCount":101},[],{"trials":6991,"activeCount":101},[],{"intervention":6993,"totalTrials":140,"cells":6994},"oral sodium phenylbutyrate",{"EARLY_PHASE1":6995,"PHASE1":6997,"PHASE2":6999,"PHASE3":7014,"PHASE4":7016,"NA":7018},{"trials":6996,"activeCount":101},[],{"trials":6998,"activeCount":101},[],{"trials":7000,"activeCount":101},[7001],{"nctId":7002,"briefTitle":7003,"status":1160,"phases":7004,"primaryCompletion":4459,"completion":4459,"start":7005,"enrollment":101,"conditions":7006,"interventions":7010},"NCT00387530","Phenylbutyrate and Valganciclovir in Treating Patients With Relapsed or Refractory Epstein-Barr Virus-Positive Cancer",[90],"2006-05",[7007,1177,7008,7009],"Gastric Cancer","Lymphoma","Lymphoproliferative Disorder",[6993,7011,7012,7013],"valganciclovir","polymerase chain reaction","protein expression analysis",{"trials":7015,"activeCount":101},[],{"trials":7017,"activeCount":101},[],{"trials":7019,"activeCount":101},[],{"intervention":7011,"totalTrials":140,"cells":7021},{"EARLY_PHASE1":7022,"PHASE1":7024,"PHASE2":7026,"PHASE3":7032,"PHASE4":7034,"NA":7036},{"trials":7023,"activeCount":101},[],{"trials":7025,"activeCount":101},[],{"trials":7027,"activeCount":101},[7028],{"nctId":7002,"briefTitle":7003,"status":1160,"phases":7029,"primaryCompletion":4459,"completion":4459,"start":7005,"enrollment":101,"conditions":7030,"interventions":7031},[90],[7007,1177,7008,7009],[6993,7011,7012,7013],{"trials":7033,"activeCount":101},[],{"trials":7035,"activeCount":101},[],{"trials":7037,"activeCount":101},[],{"intervention":7012,"totalTrials":140,"cells":7039},{"EARLY_PHASE1":7040,"PHASE1":7042,"PHASE2":7044,"PHASE3":7050,"PHASE4":7052,"NA":7054},{"trials":7041,"activeCount":101},[],{"trials":7043,"activeCount":101},[],{"trials":7045,"activeCount":101},[7046],{"nctId":7002,"briefTitle":7003,"status":1160,"phases":7047,"primaryCompletion":4459,"completion":4459,"start":7005,"enrollment":101,"conditions":7048,"interventions":7049},[90],[7007,1177,7008,7009],[6993,7011,7012,7013],{"trials":7051,"activeCount":101},[],{"trials":7053,"activeCount":101},[],{"trials":7055,"activeCount":101},[],{"intervention":7013,"totalTrials":140,"cells":7057},{"EARLY_PHASE1":7058,"PHASE1":7060,"PHASE2":7062,"PHASE3":7068,"PHASE4":7070,"NA":7072},{"trials":7059,"activeCount":101},[],{"trials":7061,"activeCount":101},[],{"trials":7063,"activeCount":101},[7064],{"nctId":7002,"briefTitle":7003,"status":1160,"phases":7065,"primaryCompletion":4459,"completion":4459,"start":7005,"enrollment":101,"conditions":7066,"interventions":7067},[90],[7007,1177,7008,7009],[6993,7011,7012,7013],{"trials":7069,"activeCount":101},[],{"trials":7071,"activeCount":101},[],{"trials":7073,"activeCount":101},[],{"intervention":5759,"totalTrials":140,"cells":7075},{"EARLY_PHASE1":7076,"PHASE1":7078,"PHASE2":7080,"PHASE3":7086,"PHASE4":7088,"NA":7090},{"trials":7077,"activeCount":101},[],{"trials":7079,"activeCount":101},[],{"trials":7081,"activeCount":101},[7082],{"nctId":5750,"briefTitle":5751,"status":113,"phases":7083,"primaryCompletion":5753,"completion":5753,"start":5754,"enrollment":5755,"conditions":7084,"interventions":7085},[90],[5757,976,951,981],[5741,5759,5760,5761],{"trials":7087,"activeCount":101},[],{"trials":7089,"activeCount":101},[],{"trials":7091,"activeCount":101},[],{"intervention":5760,"totalTrials":140,"cells":7093},{"EARLY_PHASE1":7094,"PHASE1":7096,"PHASE2":7098,"PHASE3":7104,"PHASE4":7106,"NA":7108},{"trials":7095,"activeCount":101},[],{"trials":7097,"activeCount":101},[],{"trials":7099,"activeCount":101},[7100],{"nctId":5750,"briefTitle":5751,"status":113,"phases":7101,"primaryCompletion":5753,"completion":5753,"start":5754,"enrollment":5755,"conditions":7102,"interventions":7103},[90],[5757,976,951,981],[5741,5759,5760,5761],{"trials":7105,"activeCount":101},[],{"trials":7107,"activeCount":101},[],{"trials":7109,"activeCount":101},[],{"intervention":7111,"totalTrials":140,"cells":7112},"Fenretinide",{"EARLY_PHASE1":7113,"PHASE1":7115,"PHASE2":7117,"PHASE3":7129,"PHASE4":7131,"NA":7133},{"trials":7114,"activeCount":101},[],{"trials":7116,"activeCount":101},[],{"trials":7118,"activeCount":101},[7119],{"nctId":7120,"briefTitle":7121,"status":5765,"phases":7122,"primaryCompletion":7123,"completion":7124,"start":7125,"enrollment":6471,"conditions":7126,"interventions":7128},"NCT00546455","A Randomized, Double-blind Study of the Effects of Fenretinide Administered in Subjects With Obesity",[90],"2012-01","2099-01","2007-12",[15,7127],"Insulin Resistance",[7111],{"trials":7130,"activeCount":101},[],{"trials":7132,"activeCount":101},[],{"trials":7134,"activeCount":101},[],{"intervention":7136,"totalTrials":140,"cells":7137},"Sitagliptin",{"EARLY_PHASE1":7138,"PHASE1":7140,"PHASE2":7142,"PHASE3":7151,"PHASE4":7153,"NA":7155},{"trials":7139,"activeCount":101},[],{"trials":7141,"activeCount":101},[],{"trials":7143,"activeCount":101},[7144],{"nctId":7145,"briefTitle":7146,"status":113,"phases":7147,"primaryCompletion":5999,"completion":5999,"start":1089,"enrollment":2117,"conditions":7148,"interventions":7150},"NCT01963845","Sitagliptin Versus Placebo in the Treatment of Non-alcoholic Fatty Liver Disease",[90],[7149],"Non-alcoholic Fatty Liver Disease",[7136],{"trials":7152,"activeCount":101},[],{"trials":7154,"activeCount":101},[],{"trials":7156,"activeCount":101},[],{"intervention":7158,"totalTrials":140,"cells":7159},"Purysis CBD",{"EARLY_PHASE1":7160,"PHASE1":7162,"PHASE2":7164,"PHASE3":7174,"PHASE4":7176,"NA":7178},{"trials":7161,"activeCount":101},[],{"trials":7163,"activeCount":101},[],{"trials":7165,"activeCount":101},[7166],{"nctId":7167,"briefTitle":7168,"status":1066,"phases":7169,"primaryCompletion":7170,"completion":7170,"start":1289,"enrollment":1175,"conditions":7171,"interventions":7173},"NCT05832281","Role of CBD in Improving Alexithymia",[90],"2025-08-31",[7172,29],"Alexithymia",[7158],{"trials":7175,"activeCount":101},[],{"trials":7177,"activeCount":101},[],{"trials":7179,"activeCount":101},[],{"intervention":7181,"totalTrials":140,"cells":7182},"Moisturizer with each subject's own antimicrobial bacteria",{"EARLY_PHASE1":7183,"PHASE1":7185,"PHASE2":7187,"PHASE3":7196,"PHASE4":7198,"NA":7200},{"trials":7184,"activeCount":101},[],{"trials":7186,"activeCount":101},[],{"trials":7188,"activeCount":101},[7189],{"nctId":7190,"briefTitle":7191,"status":1160,"phases":7192,"primaryCompletion":7193,"completion":7193,"start":3818,"enrollment":101,"conditions":7194,"interventions":7195},"NCT02144142","Evaluation of the Kinetic Properties of an Autologous Microbiome Transplant in Adult Atopic Dermatitis Patients",[90],"2022-07",[2897,2898],[7181],{"trials":7197,"activeCount":101},[],{"trials":7199,"activeCount":101},[],{"trials":7201,"activeCount":101},[],{"intervention":7203,"totalTrials":140,"cells":7204},"Ixazomib",{"EARLY_PHASE1":7205,"PHASE1":7207,"PHASE2":7209,"PHASE3":7222,"PHASE4":7224,"NA":7226},{"trials":7206,"activeCount":101},[],{"trials":7208,"activeCount":101},[],{"trials":7210,"activeCount":101},[7211],{"nctId":7212,"briefTitle":7213,"status":1066,"phases":7214,"primaryCompletion":7215,"completion":7215,"start":1174,"enrollment":4554,"conditions":7216,"interventions":7218},"NCT03590652","Daratumumab, Ixazomib, Pomalidomide, and Dexamethasone as Salvage Therapy in Relapsed\u002FRefractory Multiple Myeloma",[90],"2025-07-02",[7217],"Relapsed\u002FRefractory Multiple Myeloma",[7203,7219,7220,7221],"Pomalidomide","Dexamethasone","Daratumumab-Hyaluronidase-Fihj@1,800 Mg-30,000 Unit\u002F15 mL@SUBCUT@VIAL",{"trials":7223,"activeCount":101},[],{"trials":7225,"activeCount":101},[],{"trials":7227,"activeCount":101},[],{"intervention":7219,"totalTrials":140,"cells":7229},{"EARLY_PHASE1":7230,"PHASE1":7232,"PHASE2":7234,"PHASE3":7240,"PHASE4":7242,"NA":7244},{"trials":7231,"activeCount":101},[],{"trials":7233,"activeCount":101},[],{"trials":7235,"activeCount":101},[7236],{"nctId":7212,"briefTitle":7213,"status":1066,"phases":7237,"primaryCompletion":7215,"completion":7215,"start":1174,"enrollment":4554,"conditions":7238,"interventions":7239},[90],[7217],[7203,7219,7220,7221],{"trials":7241,"activeCount":101},[],{"trials":7243,"activeCount":101},[],{"trials":7245,"activeCount":101},[],{"intervention":7221,"totalTrials":140,"cells":7247},{"EARLY_PHASE1":7248,"PHASE1":7250,"PHASE2":7252,"PHASE3":7258,"PHASE4":7260,"NA":7262},{"trials":7249,"activeCount":101},[],{"trials":7251,"activeCount":101},[],{"trials":7253,"activeCount":101},[7254],{"nctId":7212,"briefTitle":7213,"status":1066,"phases":7255,"primaryCompletion":7215,"completion":7215,"start":1174,"enrollment":4554,"conditions":7256,"interventions":7257},[90],[7217],[7203,7219,7220,7221],{"trials":7259,"activeCount":101},[],{"trials":7261,"activeCount":101},[],{"trials":7263,"activeCount":101},[],{"intervention":7265,"totalTrials":140,"cells":7266},"Alvimopan",{"EARLY_PHASE1":7267,"PHASE1":7269,"PHASE2":7271,"PHASE3":7283,"PHASE4":7285,"NA":7287},{"trials":7268,"activeCount":101},[],{"trials":7270,"activeCount":101},[],{"trials":7272,"activeCount":101},[7273],{"nctId":7274,"briefTitle":7275,"status":1066,"phases":7276,"primaryCompletion":7277,"completion":7277,"start":7278,"enrollment":7279,"conditions":7280,"interventions":7282},"NCT03352414","Phase 2 RCT of Alvimopan vs. Placebo After CRS\u002FHIPEC",[90],"2020-04-28","2018-03-08",84,[7281],"Ileus",[7265],{"trials":7284,"activeCount":101},[],{"trials":7286,"activeCount":101},[],{"trials":7288,"activeCount":101},[],{"intervention":7290,"totalTrials":140,"cells":7291},"Gabapentin",{"EARLY_PHASE1":7292,"PHASE1":7294,"PHASE2":7296,"PHASE3":7308,"PHASE4":7310,"NA":7312},{"trials":7293,"activeCount":101},[],{"trials":7295,"activeCount":101},[],{"trials":7297,"activeCount":101},[7298],{"nctId":7299,"briefTitle":7300,"status":113,"phases":7301,"primaryCompletion":7302,"completion":7302,"start":7303,"enrollment":5269,"conditions":7304,"interventions":7306},"NCT04429347","Gabapentin and Tizanidine for Insomnia in Chronic Pain",[90],"2024-12-01","2020-07-29",[7305,892],"Insomnia Due to Medical Condition",[7290,7307],"Tizanidine",{"trials":7309,"activeCount":101},[],{"trials":7311,"activeCount":101},[],{"trials":7313,"activeCount":101},[],{"intervention":7307,"totalTrials":140,"cells":7315},{"EARLY_PHASE1":7316,"PHASE1":7318,"PHASE2":7320,"PHASE3":7326,"PHASE4":7328,"NA":7330},{"trials":7317,"activeCount":101},[],{"trials":7319,"activeCount":101},[],{"trials":7321,"activeCount":101},[7322],{"nctId":7299,"briefTitle":7300,"status":113,"phases":7323,"primaryCompletion":7302,"completion":7302,"start":7303,"enrollment":5269,"conditions":7324,"interventions":7325},[90],[7305,892],[7290,7307],{"trials":7327,"activeCount":101},[],{"trials":7329,"activeCount":101},[],{"trials":7331,"activeCount":101},[],{"intervention":7333,"totalTrials":140,"cells":7334},"d-amphetamine",{"EARLY_PHASE1":7335,"PHASE1":7337,"PHASE2":7339,"PHASE3":7349,"PHASE4":7351,"NA":7353},{"trials":7336,"activeCount":101},[],{"trials":7338,"activeCount":101},[],{"trials":7340,"activeCount":101},[7341],{"nctId":7342,"briefTitle":7343,"status":113,"phases":7344,"primaryCompletion":7345,"completion":7345,"start":7346,"enrollment":2609,"conditions":7347,"interventions":7348},"NCT04414930","Pharmacologic Augmentation of Targeted Cognitive Training in Schizophrenia",[90],"2024-12-30","2020-11-09",[21,3035],[7333],{"trials":7350,"activeCount":101},[],{"trials":7352,"activeCount":101},[],{"trials":7354,"activeCount":101},[],{"intervention":7356,"totalTrials":140,"cells":7357},"Cromolyn Sodium",{"EARLY_PHASE1":7358,"PHASE1":7360,"PHASE2":7362,"PHASE3":7372,"PHASE4":7374,"NA":7376},{"trials":7359,"activeCount":101},[],{"trials":7361,"activeCount":101},[],{"trials":7363,"activeCount":101},[7364],{"nctId":7365,"briefTitle":7366,"status":113,"phases":7367,"primaryCompletion":2992,"completion":4606,"start":7368,"enrollment":1764,"conditions":7369,"interventions":7371},"NCT01933464","An Analysis of the Effect of Topical Cromolyn Sodium on Rosacea-associated Erythema",[89,90],"2013-08",[7370],"Papulopustular Rosacea",[7356,4343],{"trials":7373,"activeCount":101},[],{"trials":7375,"activeCount":101},[],{"trials":7377,"activeCount":101},[],{"intervention":1140,"totalTrials":140,"cells":7379},{"EARLY_PHASE1":7380,"PHASE1":7382,"PHASE2":7384,"PHASE3":7390,"PHASE4":7392,"NA":7394},{"trials":7381,"activeCount":101},[],{"trials":7383,"activeCount":101},[],{"trials":7385,"activeCount":101},[7386],{"nctId":1130,"briefTitle":1131,"status":113,"phases":7387,"primaryCompletion":1133,"completion":1134,"start":1135,"enrollment":135,"conditions":7388,"interventions":7389},[90],[1137,1138],[1140,1076],{"trials":7391,"activeCount":101},[],{"trials":7393,"activeCount":101},[],{"trials":7395,"activeCount":101},[],{"intervention":7397,"totalTrials":140,"cells":7398},"sodium dichloroacetate",{"EARLY_PHASE1":7399,"PHASE1":7401,"PHASE2":7403,"PHASE3":7415,"PHASE4":7417,"NA":7419},{"trials":7400,"activeCount":101},[],{"trials":7402,"activeCount":101},[],{"trials":7404,"activeCount":101},[7405],{"nctId":7406,"briefTitle":7407,"status":113,"phases":7408,"completion":7409,"start":7410,"enrollment":7411,"conditions":7412,"interventions":7414},"NCT00004493","Phase II Pilot Randomized Study of Sodium Dichloroacetate in Patients With Congenital Lactic Acidemia",[90],"2003-09","1998-09",75,[7413],"Lactic Acidosis",[7397],{"trials":7416,"activeCount":101},[],{"trials":7418,"activeCount":101},[],{"trials":7420,"activeCount":101},[],{"intervention":7422,"totalTrials":140,"cells":7423},"Alemtuzumab",{"EARLY_PHASE1":7424,"PHASE1":7426,"PHASE2":7428,"PHASE3":7438,"PHASE4":7440,"NA":7442},{"trials":7425,"activeCount":101},[],{"trials":7427,"activeCount":101},[],{"trials":7429,"activeCount":101},[7430],{"nctId":7431,"briefTitle":7432,"status":1066,"phases":7433,"primaryCompletion":3087,"completion":3087,"start":3089,"enrollment":875,"conditions":7434,"interventions":7436},"NCT00983528","Alemtuzumab and Clofarabine for Relapsed or Refractory Acute Lymphoblastic Leukemia",[89,90],[7435],"Acute Lymphoblastic Leukemia",[7422,7437],"Clofarabine",{"trials":7439,"activeCount":101},[],{"trials":7441,"activeCount":101},[],{"trials":7443,"activeCount":101},[],{"intervention":7437,"totalTrials":140,"cells":7445},{"EARLY_PHASE1":7446,"PHASE1":7448,"PHASE2":7450,"PHASE3":7456,"PHASE4":7458,"NA":7460},{"trials":7447,"activeCount":101},[],{"trials":7449,"activeCount":101},[],{"trials":7451,"activeCount":101},[7452],{"nctId":7431,"briefTitle":7432,"status":1066,"phases":7453,"primaryCompletion":3087,"completion":3087,"start":3089,"enrollment":875,"conditions":7454,"interventions":7455},[89,90],[7435],[7422,7437],{"trials":7457,"activeCount":101},[],{"trials":7459,"activeCount":101},[],{"trials":7461,"activeCount":101},[],{"intervention":7463,"totalTrials":140,"cells":7464},"Checkpoint blockade immunotherapy",{"EARLY_PHASE1":7465,"PHASE1":7467,"PHASE2":7469,"PHASE3":7481,"PHASE4":7483,"NA":7485},{"trials":7466,"activeCount":101},[],{"trials":7468,"activeCount":101},[],{"trials":7470,"activeCount":101},[7471],{"nctId":7472,"briefTitle":7473,"status":113,"phases":7474,"primaryCompletion":7475,"completion":7476,"start":7477,"enrollment":7478,"conditions":7479,"interventions":7480},"NCT02843165","Checkpoint Blockade Immunotherapy Combined With Stereotactic Body Radiation in Advanced Metastatic Disease",[90],"2021-08-16","2024-08-15","2016-09-02",106,[1407],[7463],{"trials":7482,"activeCount":101},[],{"trials":7484,"activeCount":101},[],{"trials":7486,"activeCount":101},[],{"intervention":7488,"totalTrials":140,"cells":7489},"CTNS-RD-04 or CTNS-RD-04-LB",{"EARLY_PHASE1":7490,"PHASE1":7492,"PHASE2":7494,"PHASE3":7506,"PHASE4":7508,"NA":7510},{"trials":7491,"activeCount":101},[],{"trials":7493,"activeCount":101},[],{"trials":7495,"activeCount":101},[7496],{"nctId":7497,"briefTitle":7498,"status":113,"phases":7499,"primaryCompletion":7500,"completion":7500,"start":7501,"enrollment":875,"conditions":7502,"interventions":7505},"NCT03897361","Stem Cell Gene Therapy for Cystinosis",[89,90],"2024-09-18","2019-07-08",[7503,7504],"Lysosomal Storage Diseases","Cystinosis",[7488],{"trials":7507,"activeCount":101},[],{"trials":7509,"activeCount":101},[],{"trials":7511,"activeCount":101},[],{"intervention":7513,"totalTrials":140,"cells":7514},"Bevacizumab",{"EARLY_PHASE1":7515,"PHASE1":7517,"PHASE2":7519,"PHASE3":7527,"PHASE4":7529,"NA":7531},{"trials":7516,"activeCount":101},[],{"trials":7518,"activeCount":101},[],{"trials":7520,"activeCount":101},[7521],{"nctId":7522,"briefTitle":7523,"status":113,"phases":7524,"primaryCompletion":1089,"completion":1089,"start":3572,"enrollment":27,"conditions":7525,"interventions":7526},"NCT01397695","Topical Bevacizumab for the Management of Recurrent Epistaxis in Patients With Hereditary Hemorrhagic Telangiectasia (HHT)",[90],[3156],[7513],{"trials":7528,"activeCount":101},[],{"trials":7530,"activeCount":101},[],{"trials":7532,"activeCount":101},[],{"intervention":7534,"totalTrials":140,"cells":7535},"Hypertonic Saline",{"EARLY_PHASE1":7536,"PHASE1":7538,"PHASE2":7540,"PHASE3":7550,"PHASE4":7552,"NA":7554},{"trials":7537,"activeCount":101},[],{"trials":7539,"activeCount":101},[],{"trials":7541,"activeCount":101},[7542],{"nctId":7543,"briefTitle":7544,"status":113,"phases":7545,"primaryCompletion":6780,"completion":6780,"start":7546,"enrollment":4823,"conditions":7547,"interventions":7549},"NCT01612494","Hypertonic Saline as Therapy for Pediatric Concussion",[89,90],"2010-03",[7548],"Pain",[7534],{"trials":7551,"activeCount":101},[],{"trials":7553,"activeCount":101},[],{"trials":7555,"activeCount":101},[],{"intervention":3131,"totalTrials":140,"cells":7557},{"EARLY_PHASE1":7558,"PHASE1":7560,"PHASE2":7562,"PHASE3":7568,"PHASE4":7570,"NA":7572},{"trials":7559,"activeCount":101},[],{"trials":7561,"activeCount":101},[],{"trials":7563,"activeCount":101},[7564],{"nctId":3120,"briefTitle":3121,"status":113,"phases":7565,"primaryCompletion":3123,"completion":3123,"start":3124,"enrollment":3125,"conditions":7566,"interventions":7567},[90],[976,3127,3128],[1295,3130,3131],{"trials":7569,"activeCount":101},[],{"trials":7571,"activeCount":101},[],{"trials":7573,"activeCount":101},[],{"intervention":7575,"totalTrials":140,"cells":7576},"Submucosal Bevacizumab",{"EARLY_PHASE1":7577,"PHASE1":7579,"PHASE2":7581,"PHASE3":7591,"PHASE4":7593,"NA":7595},{"trials":7578,"activeCount":101},[],{"trials":7580,"activeCount":101},[],{"trials":7582,"activeCount":101},[7583],{"nctId":7584,"briefTitle":7585,"status":113,"phases":7586,"primaryCompletion":7587,"completion":7587,"start":7588,"enrollment":1764,"conditions":7589,"interventions":7590},"NCT01402531","Submucosal Bevacizumab for the Management of Recurrent Epistaxis in Patients With Hereditary Hemorrhagic Telangiectasia (HHT)",[90],"2013-07-27","2010-07-22",[3156],[7575],{"trials":7592,"activeCount":101},[],{"trials":7594,"activeCount":101},[],{"trials":7596,"activeCount":101},[],{"intervention":5771,"totalTrials":140,"cells":7598},{"EARLY_PHASE1":7599,"PHASE1":7601,"PHASE2":7603,"PHASE3":7609,"PHASE4":7611,"NA":7613},{"trials":7600,"activeCount":101},[],{"trials":7602,"activeCount":101},[],{"trials":7604,"activeCount":101},[7605],{"nctId":5763,"briefTitle":5764,"status":5765,"phases":7606,"primaryCompletion":5767,"completion":5767,"start":5768,"enrollment":27,"conditions":7607,"interventions":7608},[90],[5757,976,951],[5771,5741,5772,5761],{"trials":7610,"activeCount":101},[],{"trials":7612,"activeCount":101},[],{"trials":7614,"activeCount":101},[],{"intervention":5772,"totalTrials":140,"cells":7616},{"EARLY_PHASE1":7617,"PHASE1":7619,"PHASE2":7621,"PHASE3":7627,"PHASE4":7629,"NA":7631},{"trials":7618,"activeCount":101},[],{"trials":7620,"activeCount":101},[],{"trials":7622,"activeCount":101},[7623],{"nctId":5763,"briefTitle":5764,"status":5765,"phases":7624,"primaryCompletion":5767,"completion":5767,"start":5768,"enrollment":27,"conditions":7625,"interventions":7626},[90],[5757,976,951],[5771,5741,5772,5761],{"trials":7628,"activeCount":101},[],{"trials":7630,"activeCount":101},[],{"trials":7632,"activeCount":101},[],{"intervention":7634,"totalTrials":140,"cells":7635},"Risperidone",{"EARLY_PHASE1":7636,"PHASE1":7638,"PHASE2":7651,"PHASE3":7653,"PHASE4":7655,"NA":7657},{"trials":7637,"activeCount":101},[],{"trials":7639,"activeCount":101},[7640],{"nctId":7641,"briefTitle":7642,"status":113,"phases":7643,"primaryCompletion":7644,"completion":7644,"start":7645,"enrollment":3819,"conditions":7646,"interventions":7648},"NCT00255879","Movement Disorders Caused by Antipsychotic Drugs in Older Patients",[89],"2004-08","1999-01",[7647],"Dyskinesia, Drug-Induced",[7649,7634,7650],"Quetiapine","Olanzapine",{"trials":7652,"activeCount":101},[],{"trials":7654,"activeCount":101},[],{"trials":7656,"activeCount":101},[],{"trials":7658,"activeCount":101},[],{"intervention":7650,"totalTrials":140,"cells":7660},{"EARLY_PHASE1":7661,"PHASE1":7663,"PHASE2":7669,"PHASE3":7671,"PHASE4":7673,"NA":7675},{"trials":7662,"activeCount":101},[],{"trials":7664,"activeCount":101},[7665],{"nctId":7641,"briefTitle":7642,"status":113,"phases":7666,"primaryCompletion":7644,"completion":7644,"start":7645,"enrollment":3819,"conditions":7667,"interventions":7668},[89],[7647],[7649,7634,7650],{"trials":7670,"activeCount":101},[],{"trials":7672,"activeCount":101},[],{"trials":7674,"activeCount":101},[],{"trials":7676,"activeCount":101},[],{"intervention":7678,"totalTrials":140,"cells":7679},"Intranodal injection of Ad-ISF35",{"EARLY_PHASE1":7680,"PHASE1":7682,"PHASE2":7692,"PHASE3":7694,"PHASE4":7696,"NA":7698},{"trials":7681,"activeCount":101},[],{"trials":7683,"activeCount":101},[7684],{"nctId":7685,"briefTitle":7686,"status":113,"phases":7687,"primaryCompletion":3724,"completion":3724,"start":7688,"enrollment":3450,"conditions":7689,"interventions":7691},"NCT00850057","Pharmacodynamic (PD) Study of Intranodal Adenovirus-CD154 (Ad-ISF35) in Patients With Chronic Lymphocytic Leukemia\u002FSmall Lymphocytic Lymphoma (CLL\u002FSLL)",[89],"2006-02",[1137,7690],"Small Lymphocytic Lymphoma",[7678],{"trials":7693,"activeCount":101},[],{"trials":7695,"activeCount":101},[],{"trials":7697,"activeCount":101},[],{"trials":7699,"activeCount":101},[],{"intervention":7701,"totalTrials":140,"cells":7702},"CRS-HIPEC + LSTA1",{"EARLY_PHASE1":7703,"PHASE1":7705,"PHASE2":7719,"PHASE3":7721,"PHASE4":7723,"NA":7725},{"trials":7704,"activeCount":101},[],{"trials":7706,"activeCount":101},[7707],{"nctId":7708,"briefTitle":7709,"status":1160,"phases":7710,"primaryCompletion":7711,"completion":7711,"start":7712,"enrollment":101,"conditions":7713,"interventions":7718},"NCT06216561","Intraperitoneal LSTA1 in CRS-HIPEC",[89],"2024-06-24","2023-11-30",[7714,7715,7716,7717],"Colorectal Cancer","Ovarian Carcinoma","Appendix Cancer","Peritoneal Metastases",[7701],{"trials":7720,"activeCount":101},[],{"trials":7722,"activeCount":101},[],{"trials":7724,"activeCount":101},[],{"trials":7726,"activeCount":101},[],{"intervention":7728,"totalTrials":140,"cells":7729},"Dapagliflozin 5mg",{"EARLY_PHASE1":7730,"PHASE1":7732,"PHASE2":7742,"PHASE3":7744,"PHASE4":7746,"NA":7748},{"trials":7731,"activeCount":101},[],{"trials":7733,"activeCount":101},[7734],{"nctId":7735,"briefTitle":7736,"status":113,"phases":7737,"primaryCompletion":4363,"completion":40,"start":7738,"enrollment":1923,"conditions":7739,"interventions":7741},"NCT03704818","Dapagliflozin Effects on Hypoglycemia",[89],"2018-10-08",[7740],"Type1 Diabetes Mellitus",[7728],{"trials":7743,"activeCount":101},[],{"trials":7745,"activeCount":101},[],{"trials":7747,"activeCount":101},[],{"trials":7749,"activeCount":101},[],{"intervention":7751,"totalTrials":140,"cells":7752},"Autologous Microbial Transplant",{"EARLY_PHASE1":7753,"PHASE1":7755,"PHASE2":7766,"PHASE3":7768,"PHASE4":7770,"NA":7772},{"trials":7754,"activeCount":101},[],{"trials":7756,"activeCount":101},[7757],{"nctId":7758,"briefTitle":7759,"status":113,"phases":7760,"primaryCompletion":3923,"completion":7761,"start":3210,"enrollment":7762,"conditions":7763,"interventions":7765},"NCT03158012","Evaluation of the Efficacy of an Autologous Microbiome Transplant in Adult Atopic Dermatitis Patients",[89],"2018-08",15,[7764],"Atopic Dermatitis Eczema",[7751],{"trials":7767,"activeCount":101},[],{"trials":7769,"activeCount":101},[],{"trials":7771,"activeCount":101},[],{"trials":7773,"activeCount":101},[],{"intervention":5541,"totalTrials":140,"cells":7775},{"EARLY_PHASE1":7776,"PHASE1":7778,"PHASE2":7784,"PHASE3":7786,"PHASE4":7788,"NA":7790},{"trials":7777,"activeCount":101},[],{"trials":7779,"activeCount":101},[7780],{"nctId":5531,"briefTitle":5532,"status":113,"phases":7781,"primaryCompletion":5534,"completion":5534,"start":5535,"enrollment":1024,"conditions":7782,"interventions":7783},[89],[5537,1138],[5539,5540,5541],{"trials":7785,"activeCount":101},[],{"trials":7787,"activeCount":101},[],{"trials":7789,"activeCount":101},[],{"trials":7791,"activeCount":101},[],{"intervention":7793,"totalTrials":140,"cells":7794},"aspirin",{"EARLY_PHASE1":7795,"PHASE1":7797,"PHASE2":7808,"PHASE3":7810,"PHASE4":7812,"NA":7814},{"trials":7796,"activeCount":101},[],{"trials":7798,"activeCount":101},[7799],{"nctId":7800,"briefTitle":7801,"status":1160,"phases":7802,"completion":5445,"start":7803,"enrollment":101,"conditions":7804,"interventions":7806},"NCT00265408","Pilot Study of Aspirin Versus Warfarin for Cervicocephalic Arterial Dissection",[89],"2005-12",[7805],"Ischemic Stroke",[7793,7807],"warfarin",{"trials":7809,"activeCount":101},[],{"trials":7811,"activeCount":101},[],{"trials":7813,"activeCount":101},[],{"trials":7815,"activeCount":101},[],{"intervention":7807,"totalTrials":140,"cells":7817},{"EARLY_PHASE1":7818,"PHASE1":7820,"PHASE2":7826,"PHASE3":7828,"PHASE4":7830,"NA":7832},{"trials":7819,"activeCount":101},[],{"trials":7821,"activeCount":101},[7822],{"nctId":7800,"briefTitle":7801,"status":1160,"phases":7823,"completion":5445,"start":7803,"enrollment":101,"conditions":7824,"interventions":7825},[89],[7805],[7793,7807],{"trials":7827,"activeCount":101},[],{"trials":7829,"activeCount":101},[],{"trials":7831,"activeCount":101},[],{"trials":7833,"activeCount":101},[],{"intervention":7835,"totalTrials":140,"cells":7836},"Lymphoseek plus Vital Blue Dye",{"EARLY_PHASE1":7837,"PHASE1":7839,"PHASE2":7850,"PHASE3":7852,"PHASE4":7854,"NA":7856},{"trials":7838,"activeCount":101},[],{"trials":7840,"activeCount":101},[7841],{"nctId":7842,"briefTitle":7843,"status":1066,"phases":7844,"primaryCompletion":7845,"completion":7845,"start":7846,"enrollment":97,"conditions":7847,"interventions":7849},"NCT02589366","Lymphoseek as Lymphoid Tissue Targeting Agent in Patients With Cancer of the Endometrium",[89],"2018-04","2015-11",[7848],"Endometrial Cancer",[7835],{"trials":7851,"activeCount":101},[],{"trials":7853,"activeCount":101},[],{"trials":7855,"activeCount":101},[],{"trials":7857,"activeCount":101},[],{"intervention":7859,"totalTrials":140,"cells":7860},"recombinant interferon alfa-2b",{"EARLY_PHASE1":7861,"PHASE1":7863,"PHASE2":7874,"PHASE3":7876,"PHASE4":7878,"NA":7880},{"trials":7862,"activeCount":101},[],{"trials":7864,"activeCount":101},[7865],{"nctId":7866,"briefTitle":7867,"status":113,"phases":7868,"primaryCompletion":7869,"completion":7869,"start":7688,"enrollment":932,"conditions":7870,"interventions":7872},"NCT00398450","Azacitidine and Interferon Alfa in Treating Patients With Metastatic Melanoma",[89],"2010-04",[7871],"Melanoma (Skin)",[7859,7873],"azacitidine",{"trials":7875,"activeCount":101},[],{"trials":7877,"activeCount":101},[],{"trials":7879,"activeCount":101},[],{"trials":7881,"activeCount":101},[],{"intervention":7873,"totalTrials":140,"cells":7883},{"EARLY_PHASE1":7884,"PHASE1":7886,"PHASE2":7892,"PHASE3":7894,"PHASE4":7896,"NA":7898},{"trials":7885,"activeCount":101},[],{"trials":7887,"activeCount":101},[7888],{"nctId":7866,"briefTitle":7867,"status":113,"phases":7889,"primaryCompletion":7869,"completion":7869,"start":7688,"enrollment":932,"conditions":7890,"interventions":7891},[89],[7871],[7859,7873],{"trials":7893,"activeCount":101},[],{"trials":7895,"activeCount":101},[],{"trials":7897,"activeCount":101},[],{"trials":7899,"activeCount":101},[],{"intervention":7901,"totalTrials":140,"cells":7902},"Lidoderm Patch",{"EARLY_PHASE1":7903,"PHASE1":7905,"PHASE2":7914,"PHASE3":7916,"PHASE4":7918,"NA":7920},{"trials":7904,"activeCount":101},[],{"trials":7906,"activeCount":101},[7907],{"nctId":7908,"briefTitle":7909,"status":113,"phases":7910,"completion":7688,"start":7803,"enrollment":932,"conditions":7911,"interventions":7913},"NCT00373893","Effects of Lidocaine Patch on Intradermal Capsaicin Induced Pain and Hyperalgesia",[89],[7548,7912],"Hyperalgesia",[7901],{"trials":7915,"activeCount":101},[],{"trials":7917,"activeCount":101},[],{"trials":7919,"activeCount":101},[],{"trials":7921,"activeCount":101},[],{"intervention":7923,"totalTrials":140,"cells":7924},"aspirin versus clopidogrel",{"EARLY_PHASE1":7925,"PHASE1":7927,"PHASE2":7940,"PHASE3":7942,"PHASE4":7944,"NA":7946},{"trials":7926,"activeCount":101},[],{"trials":7928,"activeCount":101},[7929],{"nctId":7930,"briefTitle":7931,"status":1160,"phases":7932,"completion":5445,"start":7933,"enrollment":101,"conditions":7934,"interventions":7939},"NCT00363753","Pilot Study of Continuing Aspirin Versus Switching to Clopidogrel After Stroke or Transient Ischemic Attack",[89],"2006-08",[7935,7936,7937,7938],"Transient Ischemic Attack","Stroke","Aspirin","Clopidogrel",[7923],{"trials":7941,"activeCount":101},[],{"trials":7943,"activeCount":101},[],{"trials":7945,"activeCount":101},[],{"trials":7947,"activeCount":101},[],{"intervention":7949,"totalTrials":140,"cells":7950},"Pre-Treatment with Dial liquid antibacterial soap",{"EARLY_PHASE1":7951,"PHASE1":7953,"PHASE2":7962,"PHASE3":7964,"PHASE4":7966,"NA":7968},{"trials":7952,"activeCount":101},[],{"trials":7954,"activeCount":101},[7955],{"nctId":7956,"briefTitle":7957,"status":1160,"phases":7958,"primaryCompletion":7959,"completion":5048,"start":3273,"enrollment":101,"conditions":7960,"interventions":7961},"NCT01960764","Examination of Whether Host Preconditioning Modifies Short-term Transplant Survival",[89],"2022-06",[2897,2898],[7949],{"trials":7963,"activeCount":101},[],{"trials":7965,"activeCount":101},[],{"trials":7967,"activeCount":101},[],{"trials":7969,"activeCount":101},[],{"intervention":7971,"totalTrials":140,"cells":7972},"catheter lock solution consisting of N-acetylcystein, tigecycline and heparin",{"EARLY_PHASE1":7973,"PHASE1":7975,"PHASE2":7985,"PHASE3":7987,"PHASE4":7989,"NA":7991},{"trials":7974,"activeCount":101},[],{"trials":7976,"activeCount":101},[7977],{"nctId":7978,"briefTitle":7979,"status":113,"phases":7980,"primaryCompletion":1068,"completion":1057,"start":4962,"enrollment":33,"conditions":7981,"interventions":7984},"NCT00614679","A Novel Catheter Lock Solution for Treatment of Tunneled Hemodialysis Catheter-Associated Bacteremia",[89],[7982,7983],"End-Stage Renal Disease","Hemodialysis Catheter-associated Infection",[7971],{"trials":7986,"activeCount":101},[],{"trials":7988,"activeCount":101},[],{"trials":7990,"activeCount":101},[],{"trials":7992,"activeCount":101},[],{"intervention":7994,"totalTrials":140,"cells":7995},"Cisplatin, Thiosulfate",{"EARLY_PHASE1":7996,"PHASE1":7998,"PHASE2":8010,"PHASE3":8012,"PHASE4":8014,"NA":8016},{"trials":7997,"activeCount":101},[],{"trials":7999,"activeCount":101},[8000],{"nctId":8001,"briefTitle":8002,"status":113,"phases":8003,"primaryCompletion":8004,"completion":8004,"start":8005,"enrollment":2532,"conditions":8006,"interventions":8009},"NCT01114958","Pilot Study of Intra-Arterial Cisplatin With IV Thiosulfate in Patients With Lung Cancer or Lung Metastases",[89],"2013-05-17","2009-09-03",[8007,8008],"Lung Neoplasms","Neoplasm Metastasis",[7994],{"trials":8011,"activeCount":101},[],{"trials":8013,"activeCount":101},[],{"trials":8015,"activeCount":101},[],{"trials":8017,"activeCount":101},[],{"intervention":8019,"totalTrials":140,"cells":8020},"Guselkumab 30mg",{"EARLY_PHASE1":8021,"PHASE1":8023,"PHASE2":8037,"PHASE3":8039,"PHASE4":8041,"NA":8043},{"trials":8022,"activeCount":101},[],{"trials":8024,"activeCount":101},[8025],{"nctId":8026,"briefTitle":8027,"status":113,"phases":8028,"primaryCompletion":8029,"completion":8029,"start":8030,"enrollment":8031,"conditions":8032,"interventions":8034},"NCT04736966","Guselkumab (Anti-IL 23 Monoclonal Antibody) for Alcohol Associated Liver Disease",[89],"2024-03-31","2021-03-03",13,[8033],"Alcoholic Liver Disease",[8019,8035,8036],"Guselkumab 70mg","Guselkumab 100mg",{"trials":8038,"activeCount":101},[],{"trials":8040,"activeCount":101},[],{"trials":8042,"activeCount":101},[],{"trials":8044,"activeCount":101},[],{"intervention":8035,"totalTrials":140,"cells":8046},{"EARLY_PHASE1":8047,"PHASE1":8049,"PHASE2":8055,"PHASE3":8057,"PHASE4":8059,"NA":8061},{"trials":8048,"activeCount":101},[],{"trials":8050,"activeCount":101},[8051],{"nctId":8026,"briefTitle":8027,"status":113,"phases":8052,"primaryCompletion":8029,"completion":8029,"start":8030,"enrollment":8031,"conditions":8053,"interventions":8054},[89],[8033],[8019,8035,8036],{"trials":8056,"activeCount":101},[],{"trials":8058,"activeCount":101},[],{"trials":8060,"activeCount":101},[],{"trials":8062,"activeCount":101},[],{"intervention":8036,"totalTrials":140,"cells":8064},{"EARLY_PHASE1":8065,"PHASE1":8067,"PHASE2":8073,"PHASE3":8075,"PHASE4":8077,"NA":8079},{"trials":8066,"activeCount":101},[],{"trials":8068,"activeCount":101},[8069],{"nctId":8026,"briefTitle":8027,"status":113,"phases":8070,"primaryCompletion":8029,"completion":8029,"start":8030,"enrollment":8031,"conditions":8071,"interventions":8072},[89],[8033],[8019,8035,8036],{"trials":8074,"activeCount":101},[],{"trials":8076,"activeCount":101},[],{"trials":8078,"activeCount":101},[],{"trials":8080,"activeCount":101},[],{"intervention":4967,"totalTrials":140,"cells":8082},{"EARLY_PHASE1":8083,"PHASE1":8085,"PHASE2":8091,"PHASE3":8093,"PHASE4":8095,"NA":8097},{"trials":8084,"activeCount":101},[],{"trials":8086,"activeCount":101},[8087],{"nctId":4959,"briefTitle":4960,"status":113,"phases":8088,"primaryCompletion":4962,"completion":4962,"start":4963,"enrollment":22,"conditions":8089,"interventions":8090},[89],[4965],[4952,4967],{"trials":8092,"activeCount":101},[],{"trials":8094,"activeCount":101},[],{"trials":8096,"activeCount":101},[],{"trials":8098,"activeCount":101},[],{"intervention":8100,"totalTrials":140,"cells":8101},"mQFPD",{"EARLY_PHASE1":8102,"PHASE1":8104,"PHASE2":8116,"PHASE3":8118,"PHASE4":8120,"NA":8122},{"trials":8103,"activeCount":101},[],{"trials":8105,"activeCount":101},[8106],{"nctId":8107,"briefTitle":8108,"status":113,"phases":8109,"primaryCompletion":918,"completion":8110,"start":8111,"enrollment":901,"conditions":8112,"interventions":8114},"NCT04939415","RCT of Modified Qing Fei Pai Du Tang (mQFPD) for COVID-19",[89],"2022-03-13","2021-07-01",[8113],"Covid19",[8100,8115],"organic brown rice",{"trials":8117,"activeCount":101},[],{"trials":8119,"activeCount":101},[],{"trials":8121,"activeCount":101},[],{"trials":8123,"activeCount":101},[],{"intervention":8115,"totalTrials":140,"cells":8125},{"EARLY_PHASE1":8126,"PHASE1":8128,"PHASE2":8134,"PHASE3":8136,"PHASE4":8138,"NA":8140},{"trials":8127,"activeCount":101},[],{"trials":8129,"activeCount":101},[8130],{"nctId":8107,"briefTitle":8108,"status":113,"phases":8131,"primaryCompletion":918,"completion":8110,"start":8111,"enrollment":901,"conditions":8132,"interventions":8133},[89],[8113],[8100,8115],{"trials":8135,"activeCount":101},[],{"trials":8137,"activeCount":101},[],{"trials":8139,"activeCount":101},[],{"trials":8141,"activeCount":101},[],{"intervention":8143,"totalTrials":140,"cells":8144},"Alteplase",{"EARLY_PHASE1":8145,"PHASE1":8147,"PHASE2":8155,"PHASE3":8157,"PHASE4":8159,"NA":8161},{"trials":8146,"activeCount":101},[],{"trials":8148,"activeCount":101},[8149],{"nctId":8150,"briefTitle":8151,"status":1160,"phases":8152,"primaryCompletion":5267,"start":3004,"enrollment":101,"conditions":8153,"interventions":8154},"NCT01150266","Study for the Use of Alteplase in Patients Who Awaken With Stroke",[89],[7805],[8143],{"trials":8156,"activeCount":101},[],{"trials":8158,"activeCount":101},[],{"trials":8160,"activeCount":101},[],{"trials":8162,"activeCount":101},[],{"intervention":8164,"totalTrials":140,"cells":8165},"SKY0402",{"EARLY_PHASE1":8166,"PHASE1":8168,"PHASE2":8177,"PHASE3":8179,"PHASE4":8181,"NA":8183},{"trials":8167,"activeCount":101},[],{"trials":8169,"activeCount":101},[8170],{"nctId":8171,"briefTitle":8172,"status":113,"phases":8173,"primaryCompletion":6780,"completion":6780,"start":5444,"enrollment":4869,"conditions":8174,"interventions":8176},"NCT01349140","EXPAREL Dose-Response for Single-Injection Femoral Nerve Blocks",[89],[8175],"Healthy Volunteers",[8164],{"trials":8178,"activeCount":101},[],{"trials":8180,"activeCount":101},[],{"trials":8182,"activeCount":101},[],{"trials":8184,"activeCount":101},[],{"intervention":8186,"totalTrials":140,"cells":8187},"Autologous Microbiome Transplant",{"EARLY_PHASE1":8188,"PHASE1":8190,"PHASE2":8198,"PHASE3":8200,"PHASE4":8202,"NA":8204},{"trials":8189,"activeCount":101},[],{"trials":8191,"activeCount":101},[8192],{"nctId":8193,"briefTitle":8194,"status":113,"phases":8195,"primaryCompletion":3273,"completion":3273,"start":1133,"enrollment":1175,"conditions":8196,"interventions":8197},"NCT01959113","Validation of the Short-term Antimicrobial Action of Transplanted Bacteria",[89],[2897],[8186],{"trials":8199,"activeCount":101},[],{"trials":8201,"activeCount":101},[],{"trials":8203,"activeCount":101},[],{"trials":8205,"activeCount":101},[],{"intervention":5076,"totalTrials":140,"cells":8207},{"EARLY_PHASE1":8208,"PHASE1":8210,"PHASE2":8216,"PHASE3":8218,"PHASE4":8220,"NA":8222},{"trials":8209,"activeCount":101},[],{"trials":8211,"activeCount":101},[8212],{"nctId":5069,"briefTitle":5070,"status":113,"phases":8213,"primaryCompletion":5072,"completion":1037,"start":1135,"enrollment":3925,"conditions":8214,"interventions":8215},[89],[5074],[5062,5076],{"trials":8217,"activeCount":101},[],{"trials":8219,"activeCount":101},[],{"trials":8221,"activeCount":101},[],{"trials":8223,"activeCount":101},[],{"intervention":8225,"totalTrials":140,"cells":8226},"tissue plasminogen activator",{"EARLY_PHASE1":8227,"PHASE1":8229,"PHASE2":8239,"PHASE3":8241,"PHASE4":8243,"NA":8245},{"trials":8228,"activeCount":101},[],{"trials":8230,"activeCount":101},[8231],{"nctId":8232,"briefTitle":8233,"status":113,"phases":8234,"primaryCompletion":5624,"completion":6781,"start":8235,"enrollment":8236,"conditions":8237,"interventions":8238},"NCT00283088","Intravenous Thrombolysis Plus Hypothermia for Acute Treatment of Ischemic Stroke",[89],"2003-10",130,[7936],[8225],{"trials":8240,"activeCount":101},[],{"trials":8242,"activeCount":101},[],{"trials":8244,"activeCount":101},[],{"trials":8246,"activeCount":101},[],{"intervention":8248,"totalTrials":140,"cells":8249},"Omega-3 Long Chain Fatty Acid",{"EARLY_PHASE1":8250,"PHASE1":8252,"PHASE2":8262,"PHASE3":8264,"PHASE4":8266,"NA":8268},{"trials":8251,"activeCount":101},[],{"trials":8253,"activeCount":101},[8254],{"nctId":8255,"briefTitle":8256,"status":113,"phases":8257,"primaryCompletion":3273,"completion":3273,"start":3004,"enrollment":8258,"conditions":8259,"interventions":8261},"NCT01429454","NAPLS Omega-3 Fatty Acid Versus Placebo Study",[89],127,[8260],"Psychosis",[8248],{"trials":8263,"activeCount":101},[],{"trials":8265,"activeCount":101},[],{"trials":8267,"activeCount":101},[],{"trials":8269,"activeCount":101},[],{"intervention":8271,"totalTrials":97,"cells":8272},"Naloxone",{"EARLY_PHASE1":8273,"PHASE1":8291,"PHASE2":8293,"PHASE3":8295,"PHASE4":8297,"NA":8299},{"trials":8274,"activeCount":101},[8275,8283],{"nctId":8276,"briefTitle":8277,"status":113,"phases":8278,"primaryCompletion":8279,"completion":8279,"start":8280,"enrollment":1501,"conditions":8281,"interventions":8282},"NCT04034004","Chronic Low Back Pain and Meditation",[88],"2022-12-22","2021-01-01",[7548],[8271],{"nctId":8284,"briefTitle":8285,"status":113,"phases":8286,"primaryCompletion":8287,"completion":8287,"start":8288,"enrollment":901,"conditions":8289,"interventions":8290},"NCT03419858","The Role of Opioidergic Systems in Breathing Based Analgesia",[88],"2017-06-27","2017-03-13",[7548],[8271],{"trials":8292,"activeCount":101},[],{"trials":8294,"activeCount":101},[],{"trials":8296,"activeCount":101},[],{"trials":8298,"activeCount":101},[],{"trials":8300,"activeCount":101},[],{"intervention":8302,"totalTrials":140,"cells":8303},"Trazodone",{"EARLY_PHASE1":8304,"PHASE1":8314,"PHASE2":8316,"PHASE3":8318,"PHASE4":8320,"NA":8322},{"trials":8305,"activeCount":101},[8306],{"nctId":8307,"briefTitle":8308,"status":1160,"phases":8309,"primaryCompletion":5048,"completion":5048,"start":8310,"enrollment":101,"conditions":8311,"interventions":8313},"NCT02699138","Obstructive Sleep Apnea and Arousal Threshold in Patients With Post-traumatic Stress Disorder",[88],"2021-10",[8312],"Sleep Apnea, Obstructive; Post-Traumatic Stress Disorders",[8302],{"trials":8315,"activeCount":101},[],{"trials":8317,"activeCount":101},[],{"trials":8319,"activeCount":101},[],{"trials":8321,"activeCount":101},[],{"trials":8323,"activeCount":101},[],{"intervention":8325,"totalTrials":140,"cells":8326},"Topical aminocaproic acid (ACA) mixed with Vanicream",{"EARLY_PHASE1":8327,"PHASE1":8336,"PHASE2":8338,"PHASE3":8340,"PHASE4":8342,"NA":8344},{"trials":8328,"activeCount":101},[8329],{"nctId":8330,"briefTitle":8331,"status":113,"phases":8332,"primaryCompletion":4630,"completion":4630,"start":3154,"enrollment":7762,"conditions":8333,"interventions":8334},"NCT01398280","Effects of Aminocaproic Acid (ACA) on Rosacea-specific Inflammation",[88],[6413],[8325,8335],"Vehicle cream",{"trials":8337,"activeCount":101},[],{"trials":8339,"activeCount":101},[],{"trials":8341,"activeCount":101},[],{"trials":8343,"activeCount":101},[],{"trials":8345,"activeCount":101},[],{"intervention":8335,"totalTrials":140,"cells":8347},{"EARLY_PHASE1":8348,"PHASE1":8354,"PHASE2":8356,"PHASE3":8358,"PHASE4":8360,"NA":8362},{"trials":8349,"activeCount":101},[8350],{"nctId":8330,"briefTitle":8331,"status":113,"phases":8351,"primaryCompletion":4630,"completion":4630,"start":3154,"enrollment":7762,"conditions":8352,"interventions":8353},[88],[6413],[8325,8335],{"trials":8355,"activeCount":101},[],{"trials":8357,"activeCount":101},[],{"trials":8359,"activeCount":101},[],{"trials":8361,"activeCount":101},[],{"trials":8363,"activeCount":101},[],{"intervention":8365,"totalTrials":140,"cells":8366},"Atorvastatin and anakinra",{"EARLY_PHASE1":8367,"PHASE1":8377,"PHASE2":8379,"PHASE3":8381,"PHASE4":8383,"NA":8385},{"trials":8368,"activeCount":101},[8369],{"nctId":8370,"briefTitle":8371,"status":113,"phases":8372,"primaryCompletion":8373,"completion":8373,"start":8374,"enrollment":1175,"conditions":8375,"interventions":8376},"NCT04747847","Pilot Study of Atorvastatin and Anakinra in Children With Coronary Artery Abnormalities Secondary to Kawasaki Disease",[88],"2022-08-17","2019-06-22",[4965],[8365],{"trials":8378,"activeCount":101},[],{"trials":8380,"activeCount":101},[],{"trials":8382,"activeCount":101},[],{"trials":8384,"activeCount":101},[],{"trials":8386,"activeCount":101},[],{"intervention":8388,"totalTrials":140,"cells":8389},"Hyperbaric Oxygen Therapy-",{"EARLY_PHASE1":8390,"PHASE1":8403,"PHASE2":8405,"PHASE3":8407,"PHASE4":8409,"NA":8411},{"trials":8391,"activeCount":101},[8392],{"nctId":8393,"briefTitle":8394,"status":1066,"phases":8395,"primaryCompletion":8396,"completion":8396,"start":8397,"enrollment":8398,"conditions":8399,"interventions":8402},"NCT03143920","Hyperbaric Oxygen Therapy for Inflammatory Conditions of the Urinary Bladder",[88],"2022-07-07","2017-11-01",11,[8400,8401,3927],"Chronic Interstitial Cystitis","Painful Bladder Syndrome",[8388],{"trials":8404,"activeCount":101},[],{"trials":8406,"activeCount":101},[],{"trials":8408,"activeCount":101},[],{"trials":8410,"activeCount":101},[],{"trials":8412,"activeCount":101},[],{"intervention":8414,"totalTrials":140,"cells":8415},"Deoxycholic Acid",{"EARLY_PHASE1":8416,"PHASE1":8427,"PHASE2":8429,"PHASE3":8431,"PHASE4":8433,"NA":8435},{"trials":8417,"activeCount":101},[8418],{"nctId":8419,"briefTitle":8420,"status":113,"phases":8421,"primaryCompletion":8422,"completion":8422,"start":8423,"enrollment":7762,"conditions":8424,"interventions":8426},"NCT04054011","Safety and Efficacy of Deoxycholic Acid Injection for Reduction of Upper Inner Thigh Fat",[88],"2020-05-19","2019-07-05",[8425],"Adiposity",[8414],{"trials":8428,"activeCount":101},[],{"trials":8430,"activeCount":101},[],{"trials":8432,"activeCount":101},[],{"trials":8434,"activeCount":101},[],{"trials":8436,"activeCount":101},[],{"intervention":8438,"totalTrials":140,"cells":8439},"Botulinum toxin type A",{"EARLY_PHASE1":8440,"PHASE1":8452,"PHASE2":8454,"PHASE3":8456,"PHASE4":8458,"NA":8460},{"trials":8441,"activeCount":101},[8442],{"nctId":8443,"briefTitle":8444,"status":113,"phases":8445,"primaryCompletion":8446,"completion":8446,"start":8447,"enrollment":1764,"conditions":8448,"interventions":8450},"NCT05330078","Examining the Therapeutic Potential of Botulinum Toxin Type A in the Treatment of Keloids",[88],"2023-05-31","2022-03-11",[8449],"Keloid",[8438,8451],"Vehicle",{"trials":8453,"activeCount":101},[],{"trials":8455,"activeCount":101},[],{"trials":8457,"activeCount":101},[],{"trials":8459,"activeCount":101},[],{"trials":8461,"activeCount":101},[],{"intervention":8451,"totalTrials":140,"cells":8463},{"EARLY_PHASE1":8464,"PHASE1":8470,"PHASE2":8472,"PHASE3":8474,"PHASE4":8476,"NA":8478},{"trials":8465,"activeCount":101},[8466],{"nctId":8443,"briefTitle":8444,"status":113,"phases":8467,"primaryCompletion":8446,"completion":8446,"start":8447,"enrollment":1764,"conditions":8468,"interventions":8469},[88],[8449],[8438,8451],{"trials":8471,"activeCount":101},[],{"trials":8473,"activeCount":101},[],{"trials":8475,"activeCount":101},[],{"trials":8477,"activeCount":101},[],{"trials":8479,"activeCount":101},[],{"intervention":8481,"totalTrials":140,"cells":8482},"amisulpride",{"EARLY_PHASE1":8483,"PHASE1":8495,"PHASE2":8497,"PHASE3":8499,"PHASE4":8501,"NA":8503},{"trials":8484,"activeCount":101},[8485],{"nctId":8486,"briefTitle":8487,"status":113,"phases":8488,"primaryCompletion":8489,"completion":8490,"start":8491,"enrollment":1090,"conditions":8492,"interventions":8493},"NCT04128683","Dopamine Receptor Contributions to Prediction Error and Reversal Learning in Anorexia Nervosa",[88],"2023-09-06","2025-01-01","2020-10-20",[35],[8481,8494],"bromocriptine",{"trials":8496,"activeCount":101},[],{"trials":8498,"activeCount":101},[],{"trials":8500,"activeCount":101},[],{"trials":8502,"activeCount":101},[],{"trials":8504,"activeCount":101},[],{"intervention":8494,"totalTrials":140,"cells":8506},{"EARLY_PHASE1":8507,"PHASE1":8513,"PHASE2":8515,"PHASE3":8517,"PHASE4":8519,"NA":8521},{"trials":8508,"activeCount":101},[8509],{"nctId":8486,"briefTitle":8487,"status":113,"phases":8510,"primaryCompletion":8489,"completion":8490,"start":8491,"enrollment":1090,"conditions":8511,"interventions":8512},[88],[35],[8481,8494],{"trials":8514,"activeCount":101},[],{"trials":8516,"activeCount":101},[],{"trials":8518,"activeCount":101},[],{"trials":8520,"activeCount":101},[],{"trials":8522,"activeCount":101},[],{"intervention":8524,"totalTrials":140,"cells":8525},"Anakinra 100Mg\u002F0.67Ml Inj Syringe",{"EARLY_PHASE1":8526,"PHASE1":8538,"PHASE2":8540,"PHASE3":8542,"PHASE4":8544,"NA":8546},{"trials":8527,"activeCount":101},[8528],{"nctId":8529,"briefTitle":8530,"status":5377,"phases":8531,"primaryCompletion":8532,"completion":8532,"start":8533,"enrollment":27,"conditions":8534,"interventions":8537},"NCT03991520","Pilot Study of the IL-1 Antagonist Anakinra for the Treatment of Endometriosis Related Symptoms",[88],"2022-01","2020-06-16",[8535,4983,8536],"Endometriosis","Markers of Inflammation",[8524],{"trials":8539,"activeCount":101},[],{"trials":8541,"activeCount":101},[],{"trials":8543,"activeCount":101},[],{"trials":8545,"activeCount":101},[],{"trials":8547,"activeCount":101},[],{"intervention":8549,"totalTrials":140,"cells":8550},"Mifepristone",{"EARLY_PHASE1":8551,"PHASE1":8563,"PHASE2":8565,"PHASE3":8567,"PHASE4":8569,"NA":8571},{"trials":8552,"activeCount":101},[8553],{"nctId":8554,"briefTitle":8555,"status":1066,"phases":8556,"primaryCompletion":8557,"completion":8558,"start":5183,"enrollment":1024,"conditions":8559,"interventions":8562},"NCT01138553","Preoperative Testing of the Anti-Progesterone Mifepristone in Early Stage Breast Cancer",[88],"2014-06","2015-10",[8560,8561],"Invasive Breast Cancer","Ductal Carcinoma in Situ",[8549],{"trials":8564,"activeCount":101},[],{"trials":8566,"activeCount":101},[],{"trials":8568,"activeCount":101},[],{"trials":8570,"activeCount":101},[],{"trials":8572,"activeCount":101},[],{"intervention":8574,"totalTrials":140,"cells":8575},"Methylphenidate",{"EARLY_PHASE1":8576,"PHASE1":8586,"PHASE2":8588,"PHASE3":8590,"PHASE4":8592,"NA":8594},{"trials":8577,"activeCount":101},[8578],{"nctId":8579,"briefTitle":8580,"status":113,"phases":8581,"primaryCompletion":8582,"completion":8582,"start":3491,"enrollment":22,"conditions":8583,"interventions":8585},"NCT02021214","Effects of Methylphenidate (Ritalin®) on the Neural Basis of Anxiety",[88],"2014-10",[8584],"PTSD",[8574],{"trials":8587,"activeCount":101},[],{"trials":8589,"activeCount":101},[],{"trials":8591,"activeCount":101},[],{"trials":8593,"activeCount":101},[],{"trials":8595,"activeCount":101},[],{"intervention":8597,"totalTrials":1024,"cells":8598},"normal saline",{"EARLY_PHASE1":8599,"PHASE1":8601,"PHASE2":8603,"PHASE3":8609,"PHASE4":8611,"NA":8617},{"trials":8600,"activeCount":101},[],{"trials":8602,"activeCount":101},[],{"trials":8604,"activeCount":101},[8605],{"nctId":7365,"briefTitle":7366,"status":113,"phases":8606,"primaryCompletion":2992,"completion":4606,"start":7368,"enrollment":1764,"conditions":8607,"interventions":8608},[89,90],[7370],[7356,4343],{"trials":8610,"activeCount":101},[],{"trials":8612,"activeCount":101},[8613],{"nctId":4335,"briefTitle":4336,"status":1160,"phases":8614,"primaryCompletion":4338,"completion":4338,"start":4339,"enrollment":101,"conditions":8615,"interventions":8616},[92],[4341,4299,2510],[4322,4343],{"trials":8618,"activeCount":101},[8619,8631],{"nctId":8620,"briefTitle":8621,"status":113,"phases":8622,"primaryCompletion":8623,"completion":8624,"start":5999,"enrollment":8625,"conditions":8626,"interventions":8628},"NCT02613052","Agitated Saline, Albumin, or Propofol-albumin Mixture for Enhanced Contrast in TEE Examinations",[93],"2017-06","2017-09",17,[8627],"Transesophageal Echocardiography Contrast Agents",[8597,8629,8630],"human albumin","human albumin and propofol",{"nctId":8632,"briefTitle":8633,"status":1066,"phases":8634,"primaryCompletion":8635,"completion":8635,"start":5624,"enrollment":97,"conditions":8636,"interventions":8640},"NCT00768248","Naval Medical Center San Diego (NMCSD) - Ambulatory Continuous Peripheral Nerve Blocks for Treatment of Post-Amputation Phantom Limb and Stump Pain",[93],"2010-01",[8637,8638,8639],"Amputation","Phantom Limb","Stump Pain",[8641,8597],"perineural ropivacaine",{"intervention":7220,"totalTrials":1024,"cells":8643},{"EARLY_PHASE1":8644,"PHASE1":8646,"PHASE2":8648,"PHASE3":8654,"PHASE4":8672,"NA":8674},{"trials":8645,"activeCount":101},[],{"trials":8647,"activeCount":101},[],{"trials":8649,"activeCount":101},[8650],{"nctId":7212,"briefTitle":7213,"status":1066,"phases":8651,"primaryCompletion":7215,"completion":7215,"start":1174,"enrollment":4554,"conditions":8652,"interventions":8653},[90],[7217],[7203,7219,7220,7221],{"trials":8655,"activeCount":101},[8656,8664],{"nctId":8657,"briefTitle":8658,"status":113,"phases":8659,"primaryCompletion":3003,"completion":3076,"start":3004,"enrollment":22,"conditions":8660,"interventions":8662},"NCT01154192","Theca Cell Function in Adolescents With Polycystic Ovary Syndrome (PCOS)",[91],[8661],"PCOS",[7220,8663],"recombinant human chorionic gonadotropin",{"nctId":8665,"briefTitle":8666,"status":113,"phases":8667,"primaryCompletion":3003,"completion":3003,"start":5514,"enrollment":2117,"conditions":8668,"interventions":8670},"NCT01062568","The Adrenal Contribution to Androgen Production in Girls During Puberty",[91],[8669],"Development",[8671,7220],"Adrenocorticotropin",{"trials":8673,"activeCount":101},[],{"trials":8675,"activeCount":101},[8676],{"nctId":8677,"briefTitle":8678,"status":113,"phases":8679,"primaryCompletion":5267,"completion":5267,"start":3089,"enrollment":3211,"conditions":8680,"interventions":8681},"NCT00989781","Mechanisms of Increased Androgen Production Among Women With Polycystic Ovary Syndrome",[93],[4366],[8663,8682,8671,7220,8683],"Recombinant human follicle stimulating hormone","Glucose",{"intervention":7649,"totalTrials":1149,"cells":8685},{"EARLY_PHASE1":8686,"PHASE1":8688,"PHASE2":8694,"PHASE3":8696,"PHASE4":8698,"NA":8704},{"trials":8687,"activeCount":101},[],{"trials":8689,"activeCount":101},[8690],{"nctId":7641,"briefTitle":7642,"status":113,"phases":8691,"primaryCompletion":7644,"completion":7644,"start":7645,"enrollment":3819,"conditions":8692,"interventions":8693},[89],[7647],[7649,7634,7650],{"trials":8695,"activeCount":101},[],{"trials":8697,"activeCount":101},[],{"trials":8699,"activeCount":101},[8700],{"nctId":4270,"briefTitle":4271,"status":113,"phases":8701,"primaryCompletion":1068,"completion":1068,"start":1069,"enrollment":135,"conditions":8702,"interventions":8703},[92],[1292],[4257,4275],{"trials":8705,"activeCount":101},[8706],{"nctId":8707,"briefTitle":8708,"status":113,"phases":8709,"primaryCompletion":8710,"completion":8710,"start":8711,"enrollment":6471,"conditions":8712,"interventions":8713},"NCT00518973","Trial of Quetiapine in Anorexia Nervosa",[93],"2010-05","2006-07",[35],[7649],{"intervention":8663,"totalTrials":1149,"cells":8715},{"EARLY_PHASE1":8716,"PHASE1":8718,"PHASE2":8720,"PHASE3":8722,"PHASE4":8736,"NA":8738},{"trials":8717,"activeCount":101},[],{"trials":8719,"activeCount":101},[],{"trials":8721,"activeCount":101},[],{"trials":8723,"activeCount":101},[8724,8728],{"nctId":8657,"briefTitle":8658,"status":113,"phases":8725,"primaryCompletion":3003,"completion":3076,"start":3004,"enrollment":22,"conditions":8726,"interventions":8727},[91],[8661],[7220,8663],{"nctId":8729,"briefTitle":8730,"status":113,"phases":8731,"primaryCompletion":7869,"completion":8732,"start":8733,"enrollment":910,"conditions":8734,"interventions":8735},"NCT00747617","Theca Cell Function in Women With Polycystic Ovary Syndrome (PCOS)",[91],"2010-09","2007-09",[4366],[8663],{"trials":8737,"activeCount":101},[],{"trials":8739,"activeCount":101},[8740],{"nctId":8677,"briefTitle":8678,"status":113,"phases":8741,"primaryCompletion":5267,"completion":5267,"start":3089,"enrollment":3211,"conditions":8742,"interventions":8743},[93],[4366],[8663,8682,8671,7220,8683],{"intervention":4874,"totalTrials":1149,"cells":8745},{"EARLY_PHASE1":8746,"PHASE1":8748,"PHASE2":8750,"PHASE3":8756,"PHASE4":8758,"NA":8764},{"trials":8747,"activeCount":101},[],{"trials":8749,"activeCount":101},[],{"trials":8751,"activeCount":101},[8752],{"nctId":6800,"briefTitle":6801,"status":113,"phases":8753,"primaryCompletion":3327,"completion":3210,"start":4191,"enrollment":1764,"conditions":8754,"interventions":8755},[89,90],[6804],[6791,4874],{"trials":8757,"activeCount":101},[],{"trials":8759,"activeCount":101},[8760],{"nctId":4864,"briefTitle":4865,"status":1066,"phases":8761,"primaryCompletion":4867,"completion":4867,"start":4868,"enrollment":4869,"conditions":8762,"interventions":8763},[92],[4871,433,435,4872],[4851,4874],{"trials":8765,"activeCount":101},[8766],{"nctId":8767,"briefTitle":8768,"status":113,"phases":8769,"primaryCompletion":5224,"completion":8770,"start":3613,"enrollment":4391,"conditions":8771,"interventions":8773},"NCT00746889","Using Ultrasound to Predict Response to Intraarticular Corticosteroids in Knee Osteoarthritis",[93],"2008-09",[8772],"Osteoarthritis",[8774,8775],"triamcinolone acetonide","saline",{"intervention":8777,"totalTrials":97,"cells":8778},"Oxytocin",{"EARLY_PHASE1":8779,"PHASE1":8781,"PHASE2":8783,"PHASE3":8785,"PHASE4":8787,"NA":8789},{"trials":8780,"activeCount":101},[],{"trials":8782,"activeCount":101},[],{"trials":8784,"activeCount":101},[],{"trials":8786,"activeCount":101},[],{"trials":8788,"activeCount":101},[],{"trials":8790,"activeCount":101},[8791,8797],{"nctId":8792,"briefTitle":8793,"status":1066,"phases":8794,"primaryCompletion":5548,"completion":5548,"start":3723,"enrollment":1306,"conditions":8795,"interventions":8796},"NCT01621737","Antipsychotic Effects of Oxytocin",[93],[21],[8777,8777],{"nctId":8798,"briefTitle":8799,"status":1066,"phases":8800,"primaryCompletion":3571,"completion":3571,"start":5469,"enrollment":8625,"conditions":8801,"interventions":8802},"NCT00989937","Oxytocin Add-on Study for Stable Anxiety Patients",[93],[1950],[8777],{"intervention":4778,"totalTrials":97,"cells":8804},{"EARLY_PHASE1":8805,"PHASE1":8807,"PHASE2":8809,"PHASE3":8811,"PHASE4":8813,"NA":8819},{"trials":8806,"activeCount":101},[],{"trials":8808,"activeCount":101},[],{"trials":8810,"activeCount":101},[],{"trials":8812,"activeCount":101},[],{"trials":8814,"activeCount":101},[8815],{"nctId":4771,"briefTitle":4772,"status":1160,"phases":8816,"primaryCompletion":2608,"completion":133,"start":4774,"enrollment":101,"conditions":8817,"interventions":8818},[92],[4776,3047],[4758,4778],{"trials":8820,"activeCount":101},[8821],{"nctId":8822,"briefTitle":8823,"status":113,"phases":8824,"primaryCompletion":3077,"completion":3077,"start":8825,"enrollment":5269,"conditions":8826,"interventions":8827},"NCT02389088","Effect of Increased Circulating Androgens on Granulosa Cell Responses to FSH.",[93],"2006-04",[4366],[4778],{"intervention":8671,"totalTrials":97,"cells":8829},{"EARLY_PHASE1":8830,"PHASE1":8832,"PHASE2":8834,"PHASE3":8836,"PHASE4":8842,"NA":8844},{"trials":8831,"activeCount":101},[],{"trials":8833,"activeCount":101},[],{"trials":8835,"activeCount":101},[],{"trials":8837,"activeCount":101},[8838],{"nctId":8665,"briefTitle":8666,"status":113,"phases":8839,"primaryCompletion":3003,"completion":3003,"start":5514,"enrollment":2117,"conditions":8840,"interventions":8841},[91],[8669],[8671,7220],{"trials":8843,"activeCount":101},[],{"trials":8845,"activeCount":101},[8846],{"nctId":8677,"briefTitle":8678,"status":113,"phases":8847,"primaryCompletion":5267,"completion":5267,"start":3089,"enrollment":3211,"conditions":8848,"interventions":8849},[93],[4366],[8663,8682,8671,7220,8683],{"intervention":8851,"totalTrials":97,"cells":8852},"Ranolazine",{"EARLY_PHASE1":8853,"PHASE1":8855,"PHASE2":8857,"PHASE3":8859,"PHASE4":8861,"NA":8863},{"trials":8854,"activeCount":101},[],{"trials":8856,"activeCount":101},[],{"trials":8858,"activeCount":101},[],{"trials":8860,"activeCount":101},[],{"trials":8862,"activeCount":101},[],{"trials":8864,"activeCount":101},[8865,8872],{"nctId":8866,"briefTitle":8867,"status":113,"phases":8868,"primaryCompletion":3358,"completion":1133,"start":4845,"enrollment":1764,"conditions":8869,"interventions":8871},"NCT01505179","The Effects of Ranolazine on Exercise Capacity in Patients With Heart Failure With Preserved Ejection Fraction",[93],[8870],"Heart Failure With Preserved Ejection Fraction",[8851],{"nctId":8873,"briefTitle":8874,"status":1066,"phases":8875,"primaryCompletion":7546,"completion":7546,"start":7125,"enrollment":4869,"conditions":8876,"interventions":8880},"NCT00574756","Effect of Ranolazine on Echocardiographic Indices of Diastolic Dysfunction",[93],[8851,8877,8878,8879],"Diastolic Heart Failure","Tissue Doppler Ultrasound","Echocardiography",[8881],"ranolazine",{"intervention":8883,"totalTrials":97,"cells":8884},"Omegaven",{"EARLY_PHASE1":8885,"PHASE1":8887,"PHASE2":8889,"PHASE3":8898,"PHASE4":8900,"NA":8902},{"trials":8886,"activeCount":101},[],{"trials":8888,"activeCount":101},[],{"trials":8890,"activeCount":101},[8891],{"nctId":8892,"briefTitle":8893,"status":113,"phases":8894,"primaryCompletion":5557,"completion":5557,"start":3491,"enrollment":1123,"conditions":8895,"interventions":8897},"NCT02486042","Omega-3 Long Chain Polyunsaturated Fatty Acid (LCPUFA) Supplementation in Very Low Birth Weight Infants for The Prevention Retinopathy of Prematurity",[90],[8896],"Retinopathy of Prematurity",[8883],{"trials":8899,"activeCount":101},[],{"trials":8901,"activeCount":101},[],{"trials":8903,"activeCount":101},[8904],{"nctId":8905,"briefTitle":8906,"status":8907,"phases":8908,"conditions":8909,"interventions":8911},"NCT02148146","Use of Omega 3 Oil Emulsion for Parenteral Nutrition Associated Cholestasis","NO_LONGER_AVAILABLE",[],[8910],"Cholestasis",[8883],{"intervention":8913,"totalTrials":140,"cells":8914},"GLP-1",{"EARLY_PHASE1":8915,"PHASE1":8917,"PHASE2":8919,"PHASE3":8921,"PHASE4":8923,"NA":8925},{"trials":8916,"activeCount":101},[],{"trials":8918,"activeCount":101},[],{"trials":8920,"activeCount":101},[],{"trials":8922,"activeCount":101},[],{"trials":8924,"activeCount":101},[],{"trials":8926,"activeCount":101},[8927],{"nctId":8928,"briefTitle":8929,"status":113,"phases":8930,"primaryCompletion":8931,"completion":8931,"start":8932,"enrollment":974,"conditions":8933,"interventions":8934},"NCT07368855","GLP-1 Medicines and Mental Health Changes",[93],"2025-07-01","2024-05-01",[15,24,8913],[8913],{"intervention":8936,"totalTrials":140,"cells":8937},"systemic chemotherapy",{"EARLY_PHASE1":8938,"PHASE1":8940,"PHASE2":8942,"PHASE3":8944,"PHASE4":8946,"NA":8948},{"trials":8939,"activeCount":101},[],{"trials":8941,"activeCount":101},[],{"trials":8943,"activeCount":101},[],{"trials":8945,"activeCount":101},[],{"trials":8947,"activeCount":101},[],{"trials":8949,"activeCount":101},[8950],{"nctId":8951,"briefTitle":8952,"status":1066,"phases":8953,"primaryCompletion":8954,"completion":8955,"start":8956,"enrollment":97,"conditions":8957,"interventions":8958},"NCT02420509","Postoperative Chemotherapy in High-Grade Appendiceal Adenocarcinoma With Peritoneal Carcinomatosis",[],"2017-02-09","2019-04-02","2015-08-27",[2800],[8936],{"intervention":8960,"totalTrials":140,"cells":8961},"Mood stabilizer treatment",{"EARLY_PHASE1":8962,"PHASE1":8964,"PHASE2":8966,"PHASE3":8968,"PHASE4":8970,"NA":8972},{"trials":8963,"activeCount":101},[],{"trials":8965,"activeCount":101},[],{"trials":8967,"activeCount":101},[],{"trials":8969,"activeCount":101},[],{"trials":8971,"activeCount":101},[],{"trials":8973,"activeCount":101},[8974],{"nctId":8975,"briefTitle":8976,"status":113,"phases":8977,"primaryCompletion":3210,"completion":3210,"start":3571,"enrollment":8978,"conditions":8979,"interventions":8981},"NCT01272531","Pharmacogenomics of Mood Stabilizer Response in Bipolar Disorder (PGBD)",[],560,[8980],"Bipolar Affective Disorder",[8960],{"intervention":8983,"totalTrials":140,"cells":8984},"Metformin",{"EARLY_PHASE1":8985,"PHASE1":8987,"PHASE2":8989,"PHASE3":8991,"PHASE4":8993,"NA":8995},{"trials":8986,"activeCount":101},[],{"trials":8988,"activeCount":101},[],{"trials":8990,"activeCount":101},[],{"trials":8992,"activeCount":101},[],{"trials":8994,"activeCount":101},[],{"trials":8996,"activeCount":101},[8997],{"nctId":8998,"briefTitle":8999,"status":113,"phases":9000,"primaryCompletion":9001,"completion":3124,"start":3004,"enrollment":9002,"conditions":9003,"interventions":9005},"NCT01302379","Reach for Health Study: Obesity-related Mechanisms and Mortality in Breast Cancer Survivors",[93],"2015-12",333,[9004],"Breast Neoplasms",[8983],{"intervention":9007,"totalTrials":140,"cells":9008},"Stribild",{"EARLY_PHASE1":9009,"PHASE1":9011,"PHASE2":9013,"PHASE3":9015,"PHASE4":9017,"NA":9019},{"trials":9010,"activeCount":101},[],{"trials":9012,"activeCount":101},[],{"trials":9014,"activeCount":101},[],{"trials":9016,"activeCount":101},[],{"trials":9018,"activeCount":101},[],{"trials":9020,"activeCount":101},[9021],{"nctId":9022,"briefTitle":9023,"status":113,"phases":9024,"primaryCompletion":9025,"completion":9025,"start":5999,"enrollment":4869,"conditions":9026,"interventions":9027},"NCT02251236","Elvitegravir (EVG) Cerebrospinal Fluid (CSF) Pharmacokinetics in HIV-Infected Individuals",[93],"2017-01-18",[29],[9007,9028],"Genvoya",{"intervention":9028,"totalTrials":140,"cells":9030},{"EARLY_PHASE1":9031,"PHASE1":9033,"PHASE2":9035,"PHASE3":9037,"PHASE4":9039,"NA":9041},{"trials":9032,"activeCount":101},[],{"trials":9034,"activeCount":101},[],{"trials":9036,"activeCount":101},[],{"trials":9038,"activeCount":101},[],{"trials":9040,"activeCount":101},[],{"trials":9042,"activeCount":101},[9043],{"nctId":9022,"briefTitle":9023,"status":113,"phases":9044,"primaryCompletion":9025,"completion":9025,"start":5999,"enrollment":4869,"conditions":9045,"interventions":9046},[93],[29],[9007,9028],{"intervention":9048,"totalTrials":140,"cells":9049},"Preprocedural pain control",{"EARLY_PHASE1":9050,"PHASE1":9052,"PHASE2":9054,"PHASE3":9056,"PHASE4":9058,"NA":9060},{"trials":9051,"activeCount":101},[],{"trials":9053,"activeCount":101},[],{"trials":9055,"activeCount":101},[],{"trials":9057,"activeCount":101},[],{"trials":9059,"activeCount":101},[],{"trials":9061,"activeCount":101},[9062],{"nctId":9063,"briefTitle":9064,"status":1066,"phases":9065,"primaryCompletion":9066,"completion":9066,"start":9067,"enrollment":4869,"conditions":9068,"interventions":9070},"NCT02354092","Paracervical Block for Pain Control With Osmotic Dilator Placement",[93],"2015-08-25","2015-04-02",[9069,7548],"Abortion Late",[9048],{"intervention":9072,"totalTrials":140,"cells":9073},"Ciprofloxacin",{"EARLY_PHASE1":9074,"PHASE1":9076,"PHASE2":9078,"PHASE3":9080,"PHASE4":9082,"NA":9084},{"trials":9075,"activeCount":101},[],{"trials":9077,"activeCount":101},[],{"trials":9079,"activeCount":101},[],{"trials":9081,"activeCount":101},[],{"trials":9083,"activeCount":101},[],{"trials":9085,"activeCount":101},[9086],{"nctId":9087,"briefTitle":9088,"status":113,"phases":9089,"primaryCompletion":341,"completion":6601,"start":5999,"enrollment":608,"conditions":9090,"interventions":9093},"NCT02944825","Antibiotic Prophylaxis With Routine Ureteral Stent Removal",[93],[9091,9092],"Urolithiasis","UTI",[9072,9094,9095],"trimethoprim\u002Fsulfamethoxazole","No Intervention",{"intervention":9094,"totalTrials":140,"cells":9097},{"EARLY_PHASE1":9098,"PHASE1":9100,"PHASE2":9102,"PHASE3":9104,"PHASE4":9106,"NA":9108},{"trials":9099,"activeCount":101},[],{"trials":9101,"activeCount":101},[],{"trials":9103,"activeCount":101},[],{"trials":9105,"activeCount":101},[],{"trials":9107,"activeCount":101},[],{"trials":9109,"activeCount":101},[9110],{"nctId":9087,"briefTitle":9088,"status":113,"phases":9111,"primaryCompletion":341,"completion":6601,"start":5999,"enrollment":608,"conditions":9112,"interventions":9113},[93],[9091,9092],[9072,9094,9095],{"intervention":9095,"totalTrials":140,"cells":9115},{"EARLY_PHASE1":9116,"PHASE1":9118,"PHASE2":9120,"PHASE3":9122,"PHASE4":9124,"NA":9126},{"trials":9117,"activeCount":101},[],{"trials":9119,"activeCount":101},[],{"trials":9121,"activeCount":101},[],{"trials":9123,"activeCount":101},[],{"trials":9125,"activeCount":101},[],{"trials":9127,"activeCount":101},[9128],{"nctId":9087,"briefTitle":9088,"status":113,"phases":9129,"primaryCompletion":341,"completion":6601,"start":5999,"enrollment":608,"conditions":9130,"interventions":9131},[93],[9091,9092],[9072,9094,9095],{"intervention":9133,"totalTrials":140,"cells":9134},"Fluarix",{"EARLY_PHASE1":9135,"PHASE1":9137,"PHASE2":9139,"PHASE3":9141,"PHASE4":9143,"NA":9145},{"trials":9136,"activeCount":101},[],{"trials":9138,"activeCount":101},[],{"trials":9140,"activeCount":101},[],{"trials":9142,"activeCount":101},[],{"trials":9144,"activeCount":101},[],{"trials":9146,"activeCount":101},[9147],{"nctId":9148,"briefTitle":9149,"status":113,"phases":9150,"primaryCompletion":9151,"completion":8532,"start":3274,"enrollment":941,"conditions":9152,"interventions":9154},"NCT02707692","Perturbing of HIV Reservoir With Immune Stimulation",[93],"2020-04",[9153,29],"AIDS",[9133,9155],"Pneumovax",{"intervention":9155,"totalTrials":140,"cells":9157},{"EARLY_PHASE1":9158,"PHASE1":9160,"PHASE2":9162,"PHASE3":9164,"PHASE4":9166,"NA":9168},{"trials":9159,"activeCount":101},[],{"trials":9161,"activeCount":101},[],{"trials":9163,"activeCount":101},[],{"trials":9165,"activeCount":101},[],{"trials":9167,"activeCount":101},[],{"trials":9169,"activeCount":101},[9170],{"nctId":9148,"briefTitle":9149,"status":113,"phases":9171,"primaryCompletion":9151,"completion":8532,"start":3274,"enrollment":941,"conditions":9172,"interventions":9173},[93],[9153,29],[9133,9155],{"intervention":9175,"totalTrials":140,"cells":9176},"zolpidem",{"EARLY_PHASE1":9177,"PHASE1":9179,"PHASE2":9181,"PHASE3":9183,"PHASE4":9185,"NA":9187},{"trials":9178,"activeCount":101},[],{"trials":9180,"activeCount":101},[],{"trials":9182,"activeCount":101},[],{"trials":9184,"activeCount":101},[],{"trials":9186,"activeCount":101},[],{"trials":9188,"activeCount":101},[9189],{"nctId":9190,"briefTitle":9191,"status":113,"phases":9192,"primaryCompletion":9193,"completion":9193,"start":9194,"enrollment":135,"conditions":9195,"interventions":9196},"NCT00777829","Memory Consolidation in Pharmacologically Enhanced Naps",[93],"2011-06-01","2008-09-01",[1042],[9175],{"intervention":9198,"totalTrials":140,"cells":9199},"DACH polymer platinate AP5346",{"EARLY_PHASE1":9200,"PHASE1":9202,"PHASE2":9204,"PHASE3":9206,"PHASE4":9208,"NA":9210},{"trials":9201,"activeCount":101},[],{"trials":9203,"activeCount":101},[],{"trials":9205,"activeCount":101},[],{"trials":9207,"activeCount":101},[],{"trials":9209,"activeCount":101},[],{"trials":9211,"activeCount":101},[9212],{"nctId":9213,"briefTitle":9214,"status":5377,"phases":9215,"start":7005,"enrollment":932,"conditions":9216,"interventions":9217},"NCT00415298","AP5346 or Oxaliplatin in Treating Patients With Metastatic and\u002For Unresectable Recurrent Head and Neck Cancer",[93],[1177],[9198,9218,9219],"oxaliplatin","gene expression analysis",{"intervention":9218,"totalTrials":140,"cells":9221},{"EARLY_PHASE1":9222,"PHASE1":9224,"PHASE2":9226,"PHASE3":9228,"PHASE4":9230,"NA":9232},{"trials":9223,"activeCount":101},[],{"trials":9225,"activeCount":101},[],{"trials":9227,"activeCount":101},[],{"trials":9229,"activeCount":101},[],{"trials":9231,"activeCount":101},[],{"trials":9233,"activeCount":101},[9234],{"nctId":9213,"briefTitle":9214,"status":5377,"phases":9235,"start":7005,"enrollment":932,"conditions":9236,"interventions":9237},[93],[1177],[9198,9218,9219],{"intervention":9219,"totalTrials":140,"cells":9239},{"EARLY_PHASE1":9240,"PHASE1":9242,"PHASE2":9244,"PHASE3":9246,"PHASE4":9248,"NA":9250},{"trials":9241,"activeCount":101},[],{"trials":9243,"activeCount":101},[],{"trials":9245,"activeCount":101},[],{"trials":9247,"activeCount":101},[],{"trials":9249,"activeCount":101},[],{"trials":9251,"activeCount":101},[9252],{"nctId":9213,"briefTitle":9214,"status":5377,"phases":9253,"start":7005,"enrollment":932,"conditions":9254,"interventions":9255},[93],[1177],[9198,9218,9219],{"intervention":9257,"totalTrials":140,"cells":9258},"Zaleplon",{"EARLY_PHASE1":9259,"PHASE1":9261,"PHASE2":9263,"PHASE3":9265,"PHASE4":9267,"NA":9269},{"trials":9260,"activeCount":101},[],{"trials":9262,"activeCount":101},[],{"trials":9264,"activeCount":101},[],{"trials":9266,"activeCount":101},[],{"trials":9268,"activeCount":101},[],{"trials":9270,"activeCount":101},[9271],{"nctId":9272,"briefTitle":9273,"status":113,"phases":9274,"primaryCompletion":9275,"completion":9275,"start":9276,"enrollment":8398,"conditions":9277,"interventions":9278},"NCT03304652","Cerebral MRI During Sleep",[],"2018-10-31","2017-10-01",[1042],[9257],{"intervention":9280,"totalTrials":140,"cells":9281},"Pilocarpine",{"EARLY_PHASE1":9282,"PHASE1":9284,"PHASE2":9286,"PHASE3":9288,"PHASE4":9290,"NA":9292},{"trials":9283,"activeCount":101},[],{"trials":9285,"activeCount":101},[],{"trials":9287,"activeCount":101},[],{"trials":9289,"activeCount":101},[],{"trials":9291,"activeCount":101},[],{"trials":9293,"activeCount":101},[9294],{"nctId":9295,"briefTitle":9296,"status":1066,"phases":9297,"primaryCompletion":9298,"completion":9298,"start":9299,"enrollment":97,"conditions":9300,"interventions":9302},"NCT03460964","Measuring Sweat Glucose of Patients With Diabetes - The ENGAGE Study",[93],"2019-09-05","2018-05-01",[9301],"Diabetes Mellitus",[9280],{"intervention":9304,"totalTrials":140,"cells":9305},"Personalized Genomics",{"EARLY_PHASE1":9306,"PHASE1":9308,"PHASE2":9310,"PHASE3":9312,"PHASE4":9314,"NA":9316},{"trials":9307,"activeCount":101},[],{"trials":9309,"activeCount":101},[],{"trials":9311,"activeCount":101},[],{"trials":9313,"activeCount":101},[],{"trials":9315,"activeCount":101},[],{"trials":9317,"activeCount":101},[9318],{"nctId":9319,"briefTitle":9320,"status":113,"phases":9321,"primaryCompletion":4166,"completion":3491,"start":9322,"enrollment":5839,"conditions":9323,"interventions":9324},"NCT01859403","Nutrigenomics: Personalizing Weight Loss for Obese Veterans",[93],"2012-11",[15],[9304,9325],"Usual Care",{"intervention":9325,"totalTrials":140,"cells":9327},{"EARLY_PHASE1":9328,"PHASE1":9330,"PHASE2":9332,"PHASE3":9334,"PHASE4":9336,"NA":9338},{"trials":9329,"activeCount":101},[],{"trials":9331,"activeCount":101},[],{"trials":9333,"activeCount":101},[],{"trials":9335,"activeCount":101},[],{"trials":9337,"activeCount":101},[],{"trials":9339,"activeCount":101},[9340],{"nctId":9319,"briefTitle":9320,"status":113,"phases":9341,"primaryCompletion":4166,"completion":3491,"start":9322,"enrollment":5839,"conditions":9342,"interventions":9343},[93],[15],[9304,9325],{"intervention":9345,"totalTrials":140,"cells":9346},"Lexapro, an antidepressant medicine",{"EARLY_PHASE1":9347,"PHASE1":9349,"PHASE2":9351,"PHASE3":9353,"PHASE4":9355,"NA":9357},{"trials":9348,"activeCount":101},[],{"trials":9350,"activeCount":101},[],{"trials":9352,"activeCount":101},[],{"trials":9354,"activeCount":101},[],{"trials":9356,"activeCount":101},[],{"trials":9358,"activeCount":101},[9359],{"nctId":9360,"briefTitle":9361,"status":113,"phases":9362,"completion":9363,"start":8825,"enrollment":386,"conditions":9364,"interventions":9365},"NCT00416221","PACEPro - Mood Management Pilot",[93],"2007-01",[24],[9345],{"intervention":9367,"totalTrials":140,"cells":9368},"Whole Genome Sequencing",{"EARLY_PHASE1":9369,"PHASE1":9371,"PHASE2":9373,"PHASE3":9375,"PHASE4":9377,"NA":9379},{"trials":9370,"activeCount":101},[],{"trials":9372,"activeCount":101},[],{"trials":9374,"activeCount":101},[],{"trials":9376,"activeCount":101},[],{"trials":9378,"activeCount":101},[],{"trials":9380,"activeCount":101},[9381],{"nctId":9382,"briefTitle":9383,"status":1160,"phases":9384,"primaryCompletion":9385,"completion":9385,"start":8582,"enrollment":101,"conditions":9386,"interventions":9388},"NCT02255825","Development of an Optimal Approach to Return of Results for Next-generation Sequencing for Prenatal Diagnosis",[93],"2019-06-04",[9387],"Major Fetal Anomaly",[9367],{"intervention":8629,"totalTrials":140,"cells":9390},{"EARLY_PHASE1":9391,"PHASE1":9393,"PHASE2":9395,"PHASE3":9397,"PHASE4":9399,"NA":9401},{"trials":9392,"activeCount":101},[],{"trials":9394,"activeCount":101},[],{"trials":9396,"activeCount":101},[],{"trials":9398,"activeCount":101},[],{"trials":9400,"activeCount":101},[],{"trials":9402,"activeCount":101},[9403],{"nctId":8620,"briefTitle":8621,"status":113,"phases":9404,"primaryCompletion":8623,"completion":8624,"start":5999,"enrollment":8625,"conditions":9405,"interventions":9406},[93],[8627],[8597,8629,8630],{"intervention":8630,"totalTrials":140,"cells":9408},{"EARLY_PHASE1":9409,"PHASE1":9411,"PHASE2":9413,"PHASE3":9415,"PHASE4":9417,"NA":9419},{"trials":9410,"activeCount":101},[],{"trials":9412,"activeCount":101},[],{"trials":9414,"activeCount":101},[],{"trials":9416,"activeCount":101},[],{"trials":9418,"activeCount":101},[],{"trials":9420,"activeCount":101},[9421],{"nctId":8620,"briefTitle":8621,"status":113,"phases":9422,"primaryCompletion":8623,"completion":8624,"start":5999,"enrollment":8625,"conditions":9423,"interventions":9424},[93],[8627],[8597,8629,8630],{"intervention":9426,"totalTrials":140,"cells":9427},"hCG",{"EARLY_PHASE1":9428,"PHASE1":9430,"PHASE2":9432,"PHASE3":9434,"PHASE4":9436,"NA":9438},{"trials":9429,"activeCount":101},[],{"trials":9431,"activeCount":101},[],{"trials":9433,"activeCount":101},[],{"trials":9435,"activeCount":101},[],{"trials":9437,"activeCount":101},[],{"trials":9439,"activeCount":101},[9440],{"nctId":9441,"briefTitle":9442,"status":113,"phases":9443,"primaryCompletion":9444,"completion":5020,"start":9445,"enrollment":9,"conditions":9446,"interventions":9447},"NCT02145247","Ovarian Morphology and Theca Cell Androgen Production in Women With Polycystic Ovary Syndrome (PCOS)",[93],"2017-02","2014-05",[4366],[9426],{"intervention":9449,"totalTrials":140,"cells":9450},"Betaine",{"EARLY_PHASE1":9451,"PHASE1":9453,"PHASE2":9455,"PHASE3":9457,"PHASE4":9459,"NA":9461},{"trials":9452,"activeCount":101},[],{"trials":9454,"activeCount":101},[],{"trials":9456,"activeCount":101},[],{"trials":9458,"activeCount":101},[],{"trials":9460,"activeCount":101},[],{"trials":9462,"activeCount":101},[9463],{"nctId":9464,"briefTitle":9465,"status":113,"phases":9466,"primaryCompletion":5514,"completion":5514,"start":8711,"enrollment":974,"conditions":9467,"interventions":9470},"NCT00348933","Dietary Supplements for the Treatment of Angelman Syndrome",[93],[9468,9469],"Angelman Syndrome","Nervous System Diseases",[9449,9471,9472,9473],"Creatine","Metafolin","Vitamin B12",{"intervention":9471,"totalTrials":140,"cells":9475},{"EARLY_PHASE1":9476,"PHASE1":9478,"PHASE2":9480,"PHASE3":9482,"PHASE4":9484,"NA":9486},{"trials":9477,"activeCount":101},[],{"trials":9479,"activeCount":101},[],{"trials":9481,"activeCount":101},[],{"trials":9483,"activeCount":101},[],{"trials":9485,"activeCount":101},[],{"trials":9487,"activeCount":101},[9488],{"nctId":9464,"briefTitle":9465,"status":113,"phases":9489,"primaryCompletion":5514,"completion":5514,"start":8711,"enrollment":974,"conditions":9490,"interventions":9491},[93],[9468,9469],[9449,9471,9472,9473],{"intervention":9472,"totalTrials":140,"cells":9493},{"EARLY_PHASE1":9494,"PHASE1":9496,"PHASE2":9498,"PHASE3":9500,"PHASE4":9502,"NA":9504},{"trials":9495,"activeCount":101},[],{"trials":9497,"activeCount":101},[],{"trials":9499,"activeCount":101},[],{"trials":9501,"activeCount":101},[],{"trials":9503,"activeCount":101},[],{"trials":9505,"activeCount":101},[9506],{"nctId":9464,"briefTitle":9465,"status":113,"phases":9507,"primaryCompletion":5514,"completion":5514,"start":8711,"enrollment":974,"conditions":9508,"interventions":9509},[93],[9468,9469],[9449,9471,9472,9473],{"intervention":9473,"totalTrials":140,"cells":9511},{"EARLY_PHASE1":9512,"PHASE1":9514,"PHASE2":9516,"PHASE3":9518,"PHASE4":9520,"NA":9522},{"trials":9513,"activeCount":101},[],{"trials":9515,"activeCount":101},[],{"trials":9517,"activeCount":101},[],{"trials":9519,"activeCount":101},[],{"trials":9521,"activeCount":101},[],{"trials":9523,"activeCount":101},[9524],{"nctId":9464,"briefTitle":9465,"status":113,"phases":9525,"primaryCompletion":5514,"completion":5514,"start":8711,"enrollment":974,"conditions":9526,"interventions":9527},[93],[9468,9469],[9449,9471,9472,9473],{"intervention":9529,"totalTrials":140,"cells":9530},"Anti Obesity Drugs",{"EARLY_PHASE1":9531,"PHASE1":9533,"PHASE2":9535,"PHASE3":9537,"PHASE4":9539,"NA":9541},{"trials":9532,"activeCount":101},[],{"trials":9534,"activeCount":101},[],{"trials":9536,"activeCount":101},[],{"trials":9538,"activeCount":101},[],{"trials":9540,"activeCount":101},[],{"trials":9542,"activeCount":101},[9543],{"nctId":9544,"briefTitle":9545,"status":1066,"phases":9546,"primaryCompletion":9547,"completion":9547,"start":9548,"enrollment":875,"conditions":9549,"interventions":9551},"NCT03263390","Modeling the Neurological Basis and Characterizing the Neurological Phenotype of Obesity Using Human Neural Stem Cells",[],"2020-08-10","2017-10-05",[9550],"Obesity, Morbid",[9529],{"intervention":9553,"totalTrials":140,"cells":9554},"Ramelteon",{"EARLY_PHASE1":9555,"PHASE1":9557,"PHASE2":9559,"PHASE3":9561,"PHASE4":9563,"NA":9565},{"trials":9556,"activeCount":101},[],{"trials":9558,"activeCount":101},[],{"trials":9560,"activeCount":101},[],{"trials":9562,"activeCount":101},[],{"trials":9564,"activeCount":101},[],{"trials":9566,"activeCount":101},[9567],{"nctId":9568,"briefTitle":9569,"status":5377,"phases":9570,"primaryCompletion":4672,"completion":9571,"start":3349,"enrollment":163,"conditions":9572,"interventions":9575},"NCT02691013","The Impact of Ramelteon on Sleep and Delirium in Patients Who Undergo Pulmonary Thromboendarterectomy (PTE) Surgery",[93],"2022-12-01",[9573,9574],"Delirium","Sleep Deprivation",[9553],{"intervention":8774,"totalTrials":140,"cells":9577},{"EARLY_PHASE1":9578,"PHASE1":9580,"PHASE2":9582,"PHASE3":9584,"PHASE4":9586,"NA":9588},{"trials":9579,"activeCount":101},[],{"trials":9581,"activeCount":101},[],{"trials":9583,"activeCount":101},[],{"trials":9585,"activeCount":101},[],{"trials":9587,"activeCount":101},[],{"trials":9589,"activeCount":101},[9590],{"nctId":8767,"briefTitle":8768,"status":113,"phases":9591,"primaryCompletion":5224,"completion":8770,"start":3613,"enrollment":4391,"conditions":9592,"interventions":9593},[93],[8772],[8774,8775],{"intervention":9595,"totalTrials":140,"cells":9596},"Oxytocin: 24IU - 168 IU",{"EARLY_PHASE1":9597,"PHASE1":9599,"PHASE2":9601,"PHASE3":9603,"PHASE4":9605,"NA":9607},{"trials":9598,"activeCount":101},[],{"trials":9600,"activeCount":101},[],{"trials":9602,"activeCount":101},[],{"trials":9604,"activeCount":101},[],{"trials":9606,"activeCount":101},[],{"trials":9608,"activeCount":101},[9609],{"nctId":9610,"briefTitle":9611,"status":1066,"phases":9612,"primaryCompletion":3358,"completion":3358,"start":5268,"enrollment":4869,"conditions":9613,"interventions":9614},"NCT02144155","Open-label Study of the Efficacy of Intranasal Oxytocin in Schizophrenia",[93],[21],[9595],{"intervention":9616,"totalTrials":140,"cells":9617},"Raltegravir",{"EARLY_PHASE1":9618,"PHASE1":9620,"PHASE2":9622,"PHASE3":9624,"PHASE4":9626,"NA":9628},{"trials":9619,"activeCount":101},[],{"trials":9621,"activeCount":101},[],{"trials":9623,"activeCount":101},[],{"trials":9625,"activeCount":101},[],{"trials":9627,"activeCount":101},[],{"trials":9629,"activeCount":101},[9630],{"nctId":9631,"briefTitle":9632,"status":1066,"phases":9633,"primaryCompletion":3201,"completion":4166,"start":3177,"enrollment":97,"conditions":9634,"interventions":9635},"NCT01293123","Raltegravir Cerebrospinal Fluid Pharmacodynamic Study in HIV-Infected Individuals",[93],[29],[9616,9636],"Efavirenz",{"intervention":9636,"totalTrials":140,"cells":9638},{"EARLY_PHASE1":9639,"PHASE1":9641,"PHASE2":9643,"PHASE3":9645,"PHASE4":9647,"NA":9649},{"trials":9640,"activeCount":101},[],{"trials":9642,"activeCount":101},[],{"trials":9644,"activeCount":101},[],{"trials":9646,"activeCount":101},[],{"trials":9648,"activeCount":101},[],{"trials":9650,"activeCount":101},[9651],{"nctId":9631,"briefTitle":9632,"status":1066,"phases":9652,"primaryCompletion":3201,"completion":4166,"start":3177,"enrollment":97,"conditions":9653,"interventions":9654},[93],[29],[9616,9636],{"intervention":9656,"totalTrials":140,"cells":9657},"Cysteamine bitartrate",{"EARLY_PHASE1":9658,"PHASE1":9660,"PHASE2":9662,"PHASE3":9664,"PHASE4":9666,"NA":9668},{"trials":9659,"activeCount":101},[],{"trials":9661,"activeCount":101},[],{"trials":9663,"activeCount":101},[],{"trials":9665,"activeCount":101},[],{"trials":9667,"activeCount":101},[],{"trials":9669,"activeCount":101},[9670],{"nctId":9671,"briefTitle":9672,"status":113,"phases":9673,"primaryCompletion":3177,"completion":3177,"start":3087,"enrollment":2532,"conditions":9674,"interventions":9676},"NCT01432561","Study in Healthy Adults to Determine the Effect That Food Has on the Absorption and Delivery of the Drug Cystagon™",[93],[7504,9675],"Nephropathic Cystinosis",[9656],{"intervention":9678,"totalTrials":140,"cells":9679},"Buffered Lidocaine, vasopressin, sodium bicarbonate",{"EARLY_PHASE1":9680,"PHASE1":9682,"PHASE2":9684,"PHASE3":9686,"PHASE4":9688,"NA":9690},{"trials":9681,"activeCount":101},[],{"trials":9683,"activeCount":101},[],{"trials":9685,"activeCount":101},[],{"trials":9687,"activeCount":101},[],{"trials":9689,"activeCount":101},[],{"trials":9691,"activeCount":101},[9692],{"nctId":9693,"briefTitle":9694,"status":113,"phases":9695,"primaryCompletion":9696,"completion":9696,"start":7125,"enrollment":9697,"conditions":9698,"interventions":9700},"NCT00816751","Paracervical Versus Intracervical Lidocaine",[93],"2008-02",89,[9699,7548],"Abortion, Induced",[9678],{"intervention":8682,"totalTrials":140,"cells":9702},{"EARLY_PHASE1":9703,"PHASE1":9705,"PHASE2":9707,"PHASE3":9709,"PHASE4":9711,"NA":9713},{"trials":9704,"activeCount":101},[],{"trials":9706,"activeCount":101},[],{"trials":9708,"activeCount":101},[],{"trials":9710,"activeCount":101},[],{"trials":9712,"activeCount":101},[],{"trials":9714,"activeCount":101},[9715],{"nctId":8677,"briefTitle":8678,"status":113,"phases":9716,"primaryCompletion":5267,"completion":5267,"start":3089,"enrollment":3211,"conditions":9717,"interventions":9718},[93],[4366],[8663,8682,8671,7220,8683],{"intervention":8683,"totalTrials":140,"cells":9720},{"EARLY_PHASE1":9721,"PHASE1":9723,"PHASE2":9725,"PHASE3":9727,"PHASE4":9729,"NA":9731},{"trials":9722,"activeCount":101},[],{"trials":9724,"activeCount":101},[],{"trials":9726,"activeCount":101},[],{"trials":9728,"activeCount":101},[],{"trials":9730,"activeCount":101},[],{"trials":9732,"activeCount":101},[9733],{"nctId":8677,"briefTitle":8678,"status":113,"phases":9734,"primaryCompletion":5267,"completion":5267,"start":3089,"enrollment":3211,"conditions":9735,"interventions":9736},[93],[4366],[8663,8682,8671,7220,8683],{"intervention":9738,"totalTrials":140,"cells":9739},"losartan",{"EARLY_PHASE1":9740,"PHASE1":9742,"PHASE2":9744,"PHASE3":9746,"PHASE4":9748,"NA":9750},{"trials":9741,"activeCount":101},[],{"trials":9743,"activeCount":101},[],{"trials":9745,"activeCount":101},[],{"trials":9747,"activeCount":101},[],{"trials":9749,"activeCount":101},[],{"trials":9751,"activeCount":101},[9752],{"nctId":9753,"briefTitle":9754,"status":113,"phases":9755,"primaryCompletion":9756,"completion":9757,"start":9758,"enrollment":9759,"conditions":9760,"interventions":9762},"NCT02709018","A Controlled Trial of Losartan in Posttraumatic Stress Disorder",[93],"2020-02-29","2020-09-29","2016-07-16",149,[9761],"Posttraumatic Stress Disorder",[9738],{"intervention":8641,"totalTrials":140,"cells":9764},{"EARLY_PHASE1":9765,"PHASE1":9767,"PHASE2":9769,"PHASE3":9771,"PHASE4":9773,"NA":9775},{"trials":9766,"activeCount":101},[],{"trials":9768,"activeCount":101},[],{"trials":9770,"activeCount":101},[],{"trials":9772,"activeCount":101},[],{"trials":9774,"activeCount":101},[],{"trials":9776,"activeCount":101},[9777],{"nctId":8632,"briefTitle":8633,"status":1066,"phases":9778,"primaryCompletion":8635,"completion":8635,"start":5624,"enrollment":97,"conditions":9779,"interventions":9780},[93],[8637,8638,8639],[8641,8597],{"intervention":9782,"totalTrials":140,"cells":9783},"Pimecrolimus",{"EARLY_PHASE1":9784,"PHASE1":9786,"PHASE2":9788,"PHASE3":9790,"PHASE4":9792,"NA":9794},{"trials":9785,"activeCount":101},[],{"trials":9787,"activeCount":101},[],{"trials":9789,"activeCount":101},[],{"trials":9791,"activeCount":101},[],{"trials":9793,"activeCount":101},[],{"trials":9795,"activeCount":101},[9796],{"nctId":9797,"briefTitle":9798,"status":113,"phases":9799,"primaryCompletion":4845,"completion":2972,"start":3724,"enrollment":386,"conditions":9800,"interventions":9801},"NCT00946478","Effect of Pimecrolimus Cream on Cathelicidin Levels in Subjects With Eczema",[93],[2897],[9782],{"intervention":9803,"totalTrials":140,"cells":9804},"Latanoprostene bunod 0.024% QD",{"EARLY_PHASE1":9805,"PHASE1":9807,"PHASE2":9809,"PHASE3":9811,"PHASE4":9813,"NA":9815},{"trials":9806,"activeCount":101},[],{"trials":9808,"activeCount":101},[],{"trials":9810,"activeCount":101},[],{"trials":9812,"activeCount":101},[],{"trials":9814,"activeCount":101},[],{"trials":9816,"activeCount":101},[9817],{"nctId":9818,"briefTitle":9819,"status":113,"phases":9820,"primaryCompletion":9821,"completion":9822,"start":9823,"enrollment":430,"conditions":9824,"interventions":9827},"NCT03931317","Study Comparing the Effects of Latanoprostene Bunod and Timolol on Retinal Blood Vessel Density and Visual Acuity",[93],"2021-05-20","2023-03-01","2018-12-03",[9825,9826],"OAG - Open-Angle Glaucoma","OHT - Ocular Hypertension",[9803,9828],"Timolol maleate 0.5% BID",{"intervention":9828,"totalTrials":140,"cells":9830},{"EARLY_PHASE1":9831,"PHASE1":9833,"PHASE2":9835,"PHASE3":9837,"PHASE4":9839,"NA":9841},{"trials":9832,"activeCount":101},[],{"trials":9834,"activeCount":101},[],{"trials":9836,"activeCount":101},[],{"trials":9838,"activeCount":101},[],{"trials":9840,"activeCount":101},[],{"trials":9842,"activeCount":101},[9843],{"nctId":9818,"briefTitle":9819,"status":113,"phases":9844,"primaryCompletion":9821,"completion":9822,"start":9823,"enrollment":430,"conditions":9845,"interventions":9846},[93],[9825,9826],[9803,9828],{"intervention":9848,"totalTrials":140,"cells":9849},"Nocturnal oxygen",{"EARLY_PHASE1":9850,"PHASE1":9852,"PHASE2":9854,"PHASE3":9856,"PHASE4":9858,"NA":9860},{"trials":9851,"activeCount":101},[],{"trials":9853,"activeCount":101},[],{"trials":9855,"activeCount":101},[],{"trials":9857,"activeCount":101},[],{"trials":9859,"activeCount":101},[],{"trials":9861,"activeCount":101},[9862],{"nctId":9863,"briefTitle":9864,"status":113,"phases":9865,"primaryCompletion":9444,"completion":9866,"start":3076,"enrollment":4554,"conditions":9867,"interventions":9868},"NCT02244957","Right Ventricular Hemodynamics Using Cardiac MRI in Patients COPD and OSA",[93],"2020-02",[18,1717,1718],[9848],{"intervention":9870,"totalTrials":140,"cells":9871},"Guselkumab Prefilled Syringe [Tremfya]",{"EARLY_PHASE1":9872,"PHASE1":9874,"PHASE2":9876,"PHASE3":9878,"PHASE4":9880,"NA":9882},{"trials":9873,"activeCount":101},[],{"trials":9875,"activeCount":101},[],{"trials":9877,"activeCount":101},[],{"trials":9879,"activeCount":101},[],{"trials":9881,"activeCount":101},[],{"trials":9883,"activeCount":101},[9884],{"nctId":9885,"briefTitle":9886,"status":1160,"phases":9887,"primaryCompletion":9888,"completion":9888,"start":9888,"enrollment":101,"conditions":9889,"interventions":9893},"NCT07255781","Shared Pathways Between Non-Alcoholic Fatty Liver Disease and Psoriatic Disease With Guselekumab Therapy",[],"2025-11-30",[9890,9891,9892],"Psoriasis (PsO)","PsA (Psoriatic Arthritis)","NAFLD (Nonalcoholic Fatty Liver Disease)",[9870],{"intervention":9895,"totalTrials":140,"cells":9896},"Nitrofurantoin 100 MG, 7d",{"EARLY_PHASE1":9897,"PHASE1":9899,"PHASE2":9901,"PHASE3":9903,"PHASE4":9905,"NA":9907},{"trials":9898,"activeCount":101},[],{"trials":9900,"activeCount":101},[],{"trials":9902,"activeCount":101},[],{"trials":9904,"activeCount":101},[],{"trials":9906,"activeCount":101},[],{"trials":9908,"activeCount":101},[9909],{"nctId":9910,"briefTitle":9911,"status":113,"phases":9912,"primaryCompletion":341,"completion":6601,"start":5999,"enrollment":9913,"conditions":9914,"interventions":9917},"NCT02829060","Endourology Disease Group Excellence (EDGE) Consortium: Antibiotics (Abx) for Percutaneous Nephrolithotomy (PCNL) Part 2",[93],330,[120,9915,9916],"Urinary Tract Infection (UTI)","Sepsis",[9895,9918,9919,9920,9921,9922],"Gentamicin, 5mg\u002Fkg","Ampicillin 2g","Nitrofurantoin 100 mg, 48 hrs","Gentamicin, 80 mg, 7d","Gentamicin, 80 mg, 48hr",{"intervention":9918,"totalTrials":140,"cells":9924},{"EARLY_PHASE1":9925,"PHASE1":9927,"PHASE2":9929,"PHASE3":9931,"PHASE4":9933,"NA":9935},{"trials":9926,"activeCount":101},[],{"trials":9928,"activeCount":101},[],{"trials":9930,"activeCount":101},[],{"trials":9932,"activeCount":101},[],{"trials":9934,"activeCount":101},[],{"trials":9936,"activeCount":101},[9937],{"nctId":9910,"briefTitle":9911,"status":113,"phases":9938,"primaryCompletion":341,"completion":6601,"start":5999,"enrollment":9913,"conditions":9939,"interventions":9940},[93],[120,9915,9916],[9895,9918,9919,9920,9921,9922],{"intervention":9919,"totalTrials":140,"cells":9942},{"EARLY_PHASE1":9943,"PHASE1":9945,"PHASE2":9947,"PHASE3":9949,"PHASE4":9951,"NA":9953},{"trials":9944,"activeCount":101},[],{"trials":9946,"activeCount":101},[],{"trials":9948,"activeCount":101},[],{"trials":9950,"activeCount":101},[],{"trials":9952,"activeCount":101},[],{"trials":9954,"activeCount":101},[9955],{"nctId":9910,"briefTitle":9911,"status":113,"phases":9956,"primaryCompletion":341,"completion":6601,"start":5999,"enrollment":9913,"conditions":9957,"interventions":9958},[93],[120,9915,9916],[9895,9918,9919,9920,9921,9922],{"intervention":9920,"totalTrials":140,"cells":9960},{"EARLY_PHASE1":9961,"PHASE1":9963,"PHASE2":9965,"PHASE3":9967,"PHASE4":9969,"NA":9971},{"trials":9962,"activeCount":101},[],{"trials":9964,"activeCount":101},[],{"trials":9966,"activeCount":101},[],{"trials":9968,"activeCount":101},[],{"trials":9970,"activeCount":101},[],{"trials":9972,"activeCount":101},[9973],{"nctId":9910,"briefTitle":9911,"status":113,"phases":9974,"primaryCompletion":341,"completion":6601,"start":5999,"enrollment":9913,"conditions":9975,"interventions":9976},[93],[120,9915,9916],[9895,9918,9919,9920,9921,9922],{"intervention":9921,"totalTrials":140,"cells":9978},{"EARLY_PHASE1":9979,"PHASE1":9981,"PHASE2":9983,"PHASE3":9985,"PHASE4":9987,"NA":9989},{"trials":9980,"activeCount":101},[],{"trials":9982,"activeCount":101},[],{"trials":9984,"activeCount":101},[],{"trials":9986,"activeCount":101},[],{"trials":9988,"activeCount":101},[],{"trials":9990,"activeCount":101},[9991],{"nctId":9910,"briefTitle":9911,"status":113,"phases":9992,"primaryCompletion":341,"completion":6601,"start":5999,"enrollment":9913,"conditions":9993,"interventions":9994},[93],[120,9915,9916],[9895,9918,9919,9920,9921,9922],{"intervention":9922,"totalTrials":140,"cells":9996},{"EARLY_PHASE1":9997,"PHASE1":9999,"PHASE2":10001,"PHASE3":10003,"PHASE4":10005,"NA":10007},{"trials":9998,"activeCount":101},[],{"trials":10000,"activeCount":101},[],{"trials":10002,"activeCount":101},[],{"trials":10004,"activeCount":101},[],{"trials":10006,"activeCount":101},[],{"trials":10008,"activeCount":101},[10009],{"nctId":9910,"briefTitle":9911,"status":113,"phases":10010,"primaryCompletion":341,"completion":6601,"start":5999,"enrollment":9913,"conditions":10011,"interventions":10012},[93],[120,9915,9916],[9895,9918,9919,9920,9921,9922],{"intervention":10014,"totalTrials":140,"cells":10015},"Tilmanocept",{"EARLY_PHASE1":10016,"PHASE1":10018,"PHASE2":10020,"PHASE3":10022,"PHASE4":10024,"NA":10026},{"trials":10017,"activeCount":101},[],{"trials":10019,"activeCount":101},[],{"trials":10021,"activeCount":101},[],{"trials":10023,"activeCount":101},[],{"trials":10025,"activeCount":101},[],{"trials":10027,"activeCount":101},[10028],{"nctId":10029,"briefTitle":10030,"status":113,"phases":10031,"primaryCompletion":10032,"completion":10032,"start":3491,"enrollment":800,"conditions":10033,"interventions":10034},"NCT02065232","Sentinel Lymph Node Mapping Post-Injection Site Pain",[],"2015-02",[26],[10014,10035],"Sulfur Colloid",{"intervention":10035,"totalTrials":140,"cells":10037},{"EARLY_PHASE1":10038,"PHASE1":10040,"PHASE2":10042,"PHASE3":10044,"PHASE4":10046,"NA":10048},{"trials":10039,"activeCount":101},[],{"trials":10041,"activeCount":101},[],{"trials":10043,"activeCount":101},[],{"trials":10045,"activeCount":101},[],{"trials":10047,"activeCount":101},[],{"trials":10049,"activeCount":101},[10050],{"nctId":10029,"briefTitle":10030,"status":113,"phases":10051,"primaryCompletion":10032,"completion":10032,"start":3491,"enrollment":800,"conditions":10052,"interventions":10053},[],[26],[10014,10035],{"intervention":10055,"totalTrials":140,"cells":10056},"Magnevist",{"EARLY_PHASE1":10057,"PHASE1":10059,"PHASE2":10061,"PHASE3":10063,"PHASE4":10065,"NA":10067},{"trials":10058,"activeCount":101},[],{"trials":10060,"activeCount":101},[],{"trials":10062,"activeCount":101},[],{"trials":10064,"activeCount":101},[],{"trials":10066,"activeCount":101},[],{"trials":10068,"activeCount":101},[10069],{"nctId":10070,"briefTitle":10071,"status":113,"phases":10072,"primaryCompletion":4166,"completion":4166,"start":7123,"enrollment":875,"conditions":10073,"interventions":10075},"NCT02080312","Magnetic Resonance Imaging Evaluation of Inner Ear Pathology Using Intra-Tympanic Contrast Agent",[93],[10074],"Meniere's Disease",[10055],{"intervention":10077,"totalTrials":140,"cells":10078},"Simvastatin",{"EARLY_PHASE1":10079,"PHASE1":10081,"PHASE2":10083,"PHASE3":10085,"PHASE4":10087,"NA":10089},{"trials":10080,"activeCount":101},[],{"trials":10082,"activeCount":101},[],{"trials":10084,"activeCount":101},[],{"trials":10086,"activeCount":101},[],{"trials":10088,"activeCount":101},[],{"trials":10090,"activeCount":101},[10091],{"nctId":10092,"briefTitle":10093,"status":113,"phases":10094,"primaryCompletion":10095,"completion":10095,"start":10096,"enrollment":30,"conditions":10097,"interventions":10099},"NCT02490527","Effects of Epicatechin on Statins for Mitochondrial Dysfunction and Impaired Exercise Capacity",[93],"2021-07-28","2015-06",[10098],"Statin Intolerance",[10077],{"intervention":10101,"totalTrials":140,"cells":10102},"ibuprofen",{"EARLY_PHASE1":10103,"PHASE1":10105,"PHASE2":10107,"PHASE3":10109,"PHASE4":10111,"NA":10113},{"trials":10104,"activeCount":101},[],{"trials":10106,"activeCount":101},[],{"trials":10108,"activeCount":101},[],{"trials":10110,"activeCount":101},[],{"trials":10112,"activeCount":101},[],{"trials":10114,"activeCount":101},[10115],{"nctId":10116,"briefTitle":10117,"status":113,"phases":10118,"completion":10119,"start":10120,"enrollment":2609,"conditions":10121,"interventions":10122},"NCT00474721","Comparison of Acetaminophen With Codeine and Ibuprofen for Children With Injuries",[93],"2004-02","2002-11",[7548],[10101,10123],"acetaminophen with codeine",{"intervention":10123,"totalTrials":140,"cells":10125},{"EARLY_PHASE1":10126,"PHASE1":10128,"PHASE2":10130,"PHASE3":10132,"PHASE4":10134,"NA":10136},{"trials":10127,"activeCount":101},[],{"trials":10129,"activeCount":101},[],{"trials":10131,"activeCount":101},[],{"trials":10133,"activeCount":101},[],{"trials":10135,"activeCount":101},[],{"trials":10137,"activeCount":101},[10138],{"nctId":10116,"briefTitle":10117,"status":113,"phases":10139,"completion":10119,"start":10120,"enrollment":2609,"conditions":10140,"interventions":10141},[93],[7548],[10101,10123],{"intervention":10143,"totalTrials":140,"cells":10144},"Loteprednol etabonate ophthalmic ointment",{"EARLY_PHASE1":10145,"PHASE1":10147,"PHASE2":10149,"PHASE3":10151,"PHASE4":10153,"NA":10155},{"trials":10146,"activeCount":101},[],{"trials":10148,"activeCount":101},[],{"trials":10150,"activeCount":101},[],{"trials":10152,"activeCount":101},[],{"trials":10154,"activeCount":101},[],{"trials":10156,"activeCount":101},[10157],{"nctId":10158,"briefTitle":10159,"status":1160,"phases":10160,"primaryCompletion":4191,"completion":4191,"start":3088,"enrollment":101,"conditions":10161,"interventions":10163},"NCT01749241","Efficacy of Loteprednol Ointment Following Eyelid Surgery",[93],[10162],"Post-operative Healing Following Blepharoplasty and Ptosis Repair",[10143,10164],"Vehicle Ophthalmic Ointment",{"intervention":10164,"totalTrials":140,"cells":10166},{"EARLY_PHASE1":10167,"PHASE1":10169,"PHASE2":10171,"PHASE3":10173,"PHASE4":10175,"NA":10177},{"trials":10168,"activeCount":101},[],{"trials":10170,"activeCount":101},[],{"trials":10172,"activeCount":101},[],{"trials":10174,"activeCount":101},[],{"trials":10176,"activeCount":101},[],{"trials":10178,"activeCount":101},[10179],{"nctId":10158,"briefTitle":10159,"status":1160,"phases":10180,"primaryCompletion":4191,"completion":4191,"start":3088,"enrollment":101,"conditions":10181,"interventions":10182},[93],[10162],[10143,10164]]